<!DOCTYPE html>
 <!--[if lt IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8 lt-ie7"> <![endif]--> <!--[if IE 7]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9 lt-ie8"> <![endif]--> <!--[if IE 8]> <html dir="ltr" lang="en-US" class="aui ltr no-js lt-ie9"> <![endif]--> <!--[if gt IE 8]><!--> <html class="aui ltr" dir="ltr" lang="en-US" prefix="og: http://ogp.me/ns#"> <!--<![endif]--> <head> <title>Treating progressive disseminated histoplasmosis in people living with HIV - Murray, M - 2020 | Cochrane Library</title> <meta content="Treating progressive disseminated histoplasmosis in people living with HIV - Murray, M - 2020 | Cochrane Library" property="og:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013594/full" property="og:url"/> <meta content="article" property="og:type"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" property="og:image"/> <meta content="summary_large_image" name="twitter:card"/> <meta content="Treating progressive disseminated histoplasmosis in people living with HIV - Murray, M - 2020 | Cochrane Library" name="twitter:title"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013594/full" name="twitter:url"/> <meta content="https://www.cochranelibrary.com/cochrane-theme/images/cochrane_circulargraphic.png" name="twitter:image"/> <meta content="initial-scale=1.0, width=device-width" name="viewport"/> <meta content="10.1002/14651858.CD013594" name="dc.identifier" scheme="DOI"/> <meta content="Treating progressive disseminated histoplasmosis in people living with HIV" name="citation_title"/> <meta content="Marylou Murray" name="citation_author"/> <meta content="Liverpool School of Tropical Medicine" name="citation_author_institution"/> <meta content="Marylou.Murray@lstmed.ac.uk" name="citation_author_email"/> <meta content="Paul Hine" name="citation_author"/> <meta content="Liverpool School of Tropical Medicine" name="citation_author_institution"/> <meta content="Cochrane Database of Systematic Reviews" name="citation_journal_title"/> <meta content="John Wiley &amp; Sons, Ltd" name="citation_publisher"/> <meta content="4" name="citation_issue"/> <meta content="10.1002/14651858.CD013594" name="citation_doi"/> <meta content="2020" name="citation_date"/> <meta content="2020/04/28" name="citation_online_date"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013594/abstract" name="citation_abstract_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013594/full" name="citation_fulltext_html_url"/> <meta content="https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013594/pdf/full" name="citation_pdf_url"/> <meta content="1465-1858" name="citation_issn"/> <meta content="en" name="citation_language"/> <meta content="Amphotericin B [adverse effects, *therapeutic use]; Anti-HIV Agents [therapeutic use]; Antifungal Agents [adverse effects, *therapeutic use]; Cohort Studies; Deoxycholic Acid; Drug Administration Schedule; Fluconazole [therapeutic use]; Histoplasmosis [*drug therapy, mortality]; HIV Infections [*complications, drug therapy]; Induction Chemotherapy; Itraconazole [therapeutic use]; Kidney [drug effects]; Liposomes; Maintenance Chemotherapy; Randomized Controlled Trials as Topic" name="citation_keywords"/> <meta content="" name="citation_fulltext_world_readable"/> <link href="https://fonts.googleapis.com/css?family=Source+Sans+Pro:400,700,600,900" rel="stylesheet"/> <script src="https://cmp.osano.com/AzZdRbSORDOOzF9W/d594efc1-9663-477d-9528-6576640e64fd/osano.js"></script> <style> .osano-cm-widget{display: none;} </style> <script src="https://static.addtoany.com/menu/page.js"></script> <script async="" charset="utf-8" src="https://platform.twitter.com/widgets.js"></script> <script async="async" src="//script.crazyegg.com/pages/scripts/0056/6375.js" type="text/javascript"></script> <script type="text/javascript">window.dataLayer={};var xtend=function(){var a={};var b=false;var c=0;var d=arguments.length;if(Object.prototype.toString.call(arguments[0])==="[object Boolean]"){b=arguments[0];c++}var f=function(g){for(var h in g){if(Object.prototype.hasOwnProperty.call(g,h)){if(b&&Object.prototype.toString.call(g[h])==="[object Object]"){a[h]=xtend(true,a[h],g[h])}else{a[h]=g[h]}}}};for(;c<d;c++){var e=arguments[c];f(e)}return a};</script> <!-- Global site tag (gtag.js) - Google Analytics --> <script src="https://www.googletagmanager.com/gtag/js?id=UA-189672-63&amp;l=gDataLayer"></script> <script>window.gDataLayer=window.gDataLayer||[];function gtag(){gDataLayer.push(arguments)}gtag("js",new Date());gtag("config","UA-189672-63");</script> <script type="text/javascript">var o={auth:{customerIds:[],individualId:null,brandedCustomer:null,roles:["Guest"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <script type="text/javascript">var o={page:{siteSection:"Content",languageCode:"en",cms:{pageTitle:"Content"}}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <meta content="text/html; charset=utf-8" http-equiv="content-type"/> <link href="https://www.cochranelibrary.com/cochrane-theme/images/favicon.ico" rel="Shortcut Icon"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013594&amp;doi=10.1002/14651858.CD013594&amp;type=cdsr&amp;contentLanguage=" rel="canonical"/> <link href="https://www.cochranelibrary.com/zh/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013594&amp;doi=10.1002/14651858.CD013594&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANS" rel="alternate"/> <link href="https://www.cochranelibrary.com/zh_HANT/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013594&amp;doi=10.1002/14651858.CD013594&amp;type=cdsr&amp;contentLanguage=" hreflang="zh-HANT" rel="alternate"/> <link href="https://www.cochranelibrary.com/hr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013594&amp;doi=10.1002/14651858.CD013594&amp;type=cdsr&amp;contentLanguage=" hreflang="hr-HR" rel="alternate"/> <link href="https://www.cochranelibrary.com/nl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013594&amp;doi=10.1002/14651858.CD013594&amp;type=cdsr&amp;contentLanguage=" hreflang="nl-NL" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013594&amp;doi=10.1002/14651858.CD013594&amp;type=cdsr&amp;contentLanguage=" hreflang="x-default" rel="alternate"/> <link href="https://www.cochranelibrary.com/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013594&amp;doi=10.1002/14651858.CD013594&amp;type=cdsr&amp;contentLanguage=" hreflang="en-US" rel="alternate"/> <link href="https://www.cochranelibrary.com/fr/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013594&amp;doi=10.1002/14651858.CD013594&amp;type=cdsr&amp;contentLanguage=" hreflang="fr-FR" rel="alternate"/> <link href="https://www.cochranelibrary.com/de/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013594&amp;doi=10.1002/14651858.CD013594&amp;type=cdsr&amp;contentLanguage=" hreflang="de-DE" rel="alternate"/> <link href="https://www.cochranelibrary.com/hi/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013594&amp;doi=10.1002/14651858.CD013594&amp;type=cdsr&amp;contentLanguage=" hreflang="hi-HI" rel="alternate"/> <link href="https://www.cochranelibrary.com/hu/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013594&amp;doi=10.1002/14651858.CD013594&amp;type=cdsr&amp;contentLanguage=" hreflang="hu-HU" rel="alternate"/> <link href="https://www.cochranelibrary.com/in/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013594&amp;doi=10.1002/14651858.CD013594&amp;type=cdsr&amp;contentLanguage=" hreflang="in-ID" rel="alternate"/> <link href="https://www.cochranelibrary.com/ja/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013594&amp;doi=10.1002/14651858.CD013594&amp;type=cdsr&amp;contentLanguage=" hreflang="ja-JP" rel="alternate"/> <link href="https://www.cochranelibrary.com/ko/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013594&amp;doi=10.1002/14651858.CD013594&amp;type=cdsr&amp;contentLanguage=" hreflang="ko-KR" rel="alternate"/> <link href="https://www.cochranelibrary.com/ms/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013594&amp;doi=10.1002/14651858.CD013594&amp;type=cdsr&amp;contentLanguage=" hreflang="ms-MY" rel="alternate"/> <link href="https://www.cochranelibrary.com/fa/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013594&amp;doi=10.1002/14651858.CD013594&amp;type=cdsr&amp;contentLanguage=" hreflang="fa-IR" rel="alternate"/> <link href="https://www.cochranelibrary.com/pl/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013594&amp;doi=10.1002/14651858.CD013594&amp;type=cdsr&amp;contentLanguage=" hreflang="pl-PL" rel="alternate"/> <link href="https://www.cochranelibrary.com/pt/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013594&amp;doi=10.1002/14651858.CD013594&amp;type=cdsr&amp;contentLanguage=" hreflang="pt-PT" rel="alternate"/> <link href="https://www.cochranelibrary.com/ro/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013594&amp;doi=10.1002/14651858.CD013594&amp;type=cdsr&amp;contentLanguage=" hreflang="ro-RO" rel="alternate"/> <link href="https://www.cochranelibrary.com/ru/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013594&amp;doi=10.1002/14651858.CD013594&amp;type=cdsr&amp;contentLanguage=" hreflang="ru-RU" rel="alternate"/> <link href="https://www.cochranelibrary.com/es/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013594&amp;doi=10.1002/14651858.CD013594&amp;type=cdsr&amp;contentLanguage=" hreflang="es-ES" rel="alternate"/> <link href="https://www.cochranelibrary.com/ta/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013594&amp;doi=10.1002/14651858.CD013594&amp;type=cdsr&amp;contentLanguage=" hreflang="ta-IN" rel="alternate"/> <link href="https://www.cochranelibrary.com/th/web/cochrane/content?templateType=full&amp;urlTitle=/cdsr/doi/10.1002/14651858.CD013594&amp;doi=10.1002/14651858.CD013594&amp;type=cdsr&amp;contentLanguage=" hreflang="th-TH" rel="alternate"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/aui.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <link href="/html/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772874000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/scolaris-content-display/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/notifications-portlet/notifications/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" rel="stylesheet" type="text/css"/> <link href="https://www.cochranelibrary.com/html/portlet/login/css/main.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1739772901000" rel="stylesheet" type="text/css"/> <script type="text/javascript">var Liferay={Browser:{acceptsGzip:function(){return false},getMajorVersion:function(){return 80},getRevision:function(){return"537.36"},getVersion:function(){return"80.0"},isAir:function(){return false},isChrome:function(){return true},isFirefox:function(){return false},isGecko:function(){return true},isIe:function(){return false},isIphone:function(){return false},isLinux:function(){return true},isMac:function(){return false},isMobile:function(){return false},isMozilla:function(){return false},isOpera:function(){return false},isRtf:function(){return true},isSafari:function(){return true},isSun:function(){return false},isWap:function(){return false},isWapXhtml:function(){return false},isWebKit:function(){return true},isWindows:function(){return false},isWml:function(){return false}},Data:{NAV_SELECTOR:"#navigation",isCustomizationView:function(){return false},notices:[null]},ThemeDisplay:{getLayoutId:function(){return"7"},getLayoutURL:function(){return"https://www.cochranelibrary.com/en/content"},getParentLayoutId:function(){return"0"},isPrivateLayout:function(){return"false"},isVirtualLayout:function(){return false},getBCP47LanguageId:function(){return"en-US"},getCDNBaseURL:function(){return"https://www.cochranelibrary.com"},getCDNDynamicResourcesHost:function(){return""},getCDNHost:function(){return""},getCompanyId:function(){return"20155"},getCompanyGroupId:function(){return"20195"},getDefaultLanguageId:function(){return"en_US"},getDoAsUserIdEncoded:function(){return""},getLanguageId:function(){return"en_US"},getParentGroupId:function(){return"20182"},getPathContext:function(){return""},getPathImage:function(){return"/image"},getPathJavaScript:function(){return"/html/js"},getPathMain:function(){return"/en/c"},getPathThemeImages:function(){return"https://www.cochranelibrary.com/cochrane-theme/images"},getPathThemeRoot:function(){return"/cochrane-theme"},getPlid:function(){return"20757"},getPortalURL:function(){return"https://www.cochranelibrary.com"},getPortletSetupShowBordersDefault:function(){return true},getScopeGroupId:function(){return"20182"},getScopeGroupIdOrLiveGroupId:function(){return"20182"},getSessionId:function(){return""},getSiteGroupId:function(){return"20182"},getURLControlPanel:function(){return"/group/control_panel?refererPlid=20757"},getURLHome:function(){return"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane"},getUserId:function(){return"20159"},getUserName:function(){return""},isAddSessionIdToURL:function(){return false},isFreeformLayout:function(){return false},isImpersonated:function(){return false},isSignedIn:function(){return false},isStateExclusive:function(){return false},isStateMaximized:function(){return false},isStatePopUp:function(){return false}},PropsValues:{NTLM_AUTH_ENABLED:false}};var themeDisplay=Liferay.ThemeDisplay;Liferay.AUI={getAvailableLangPath:function(){return"available_languages.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getCombine:function(){return true},getComboPath:function(){return"/combo/?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000&"},getFilter:function(){return"min"},getJavaScriptRootPath:function(){return"/html/js"},getLangPath:function(){return"aui_lang.jsp?browserId=other&themeId=cochrane_WAR_cochranetheme&colorSchemeId=01&minifierType=js&languageId=en_US&b=6210&t=1513679709000"},getStaticResourceURLParams:function(){return"?browserId=other&minifierType=&languageId=en_US&b=6210&t=1513679709000"}};Liferay.authToken="9nGOjNGw";Liferay.currentURL="\x2fweb\x2fcochrane\x2fcontent\x3ftemplateType\x3dfull\x26urlTitle\x3d\x2fcdsr\x2fdoi\x2f10\x2e1002\x2f14651858\x2eCD013594\x26doi\x3d10\x2e1002\x2f14651858\x2eCD013594\x26type\x3dcdsr\x26contentLanguage\x3d";Liferay.currentURLEncoded="\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013594\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013594\x2526type\x253Dcdsr\x2526contentLanguage\x253D";</script> <script src="/html/js/barebone.jsp?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;colorSchemeId=01&amp;minifierType=js&amp;minifierBundleId=javascript.barebone.files&amp;languageId=en_US&amp;b=6210&amp;t=1513679709000" type="text/javascript"></script> <script type="text/javascript"></script> <script type="text/javascript">var o={database:"CDSR",page:{pageType:"Article Full Text HTML"},article:{availableLanguage:["en","es","fa","fr","ms"],languageCode:"en",accessStatus:"delayed-free",doi:"10.1002/14651858.CD013594",title:"Treating progressive disseminated histoplasmosis in people living with HIV",firstPublishedDate:"Apr 28, 2020 12:00:00 AM",isCurrentVersion:true,editorialGroup:"Cochrane Infectious Diseases Group",availableParts:["PDF Full","PDF Standard","PDF Abstract","HTML","Comments","Information","References","Stats","Related Content"]}};window.dataLayer=xtend(true,window.dataLayer,o);</script> <link class="lfr-css-file" href="https://www.cochranelibrary.com/cochrane-theme/css/custom.css?browserId=other&amp;themeId=cochrane_WAR_cochranetheme&amp;minifierType=css&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" rel="stylesheet" type="text/css"/> <style type="text/css"></style> <script async="" src="https://assets.adobedtm.com/59640f9fa510/7cad07cf7779/launch-a215d9c51521.min.js"></script> <!--[if lt IE 9]> <script src="/cochrane-theme/vendor/respond/dest/respond.min.js?t=1738734064000" type="text/javascript"></script> <![endif]--> </head> <body class="yui3-skin-sam controls-visible guest-site signed-out public-page site"> <div class="site-container"> <a href="#main-content" id="skip-to-content">Skip to Content</a> <div class="cookie-message cookie-message--hidden system-message-container" id="js-cookie-message"> <div class="container"> <a aria-label="Close cookies message" class="fa fa-times js-cookie-close pull-right" href="#"></a> <div class="system-message-wrapper container"> <i aria-hidden="true" class="fa fa-exclamation-triangle"></i> <div class="system-message-title">Cookies</div> <div class="system-message-description"> <p> Our site uses cookies to improve your experience. You can find out more about our use of cookies in About Cookies, including instructions on how to turn off cookies if you wish to do so. By continuing to browse this site you agree to us using cookies as described in <a href="http://olabout.wiley.com/WileyCDA/Section/id-813473.html">About Cookies</a>. </p> <a class="btn secondary js-cookie-close js-cookie-accept" href="#">I accept</a> </div> </div> </div> </div> <script>document.body.className=document.body.className+" js_enabled";</script><header> <div class="container"> <div class="branding"> <h1 class="brand-container"> <a href="https://www.cochranelibrary.com/en/"> <span class="brand-name">The Cochrane Library</span> <img alt="Cochrane Library logo" class="brand-logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_logo.png" title="Cochrane Library"/> </a> </h1> <span class="additional-branding"> <p class="brand-message"> <em>Trusted evidence.</em> <em>Informed decisions.</em> <em>Better health.</em> </p> </span> </div> <div class="desktop-search basic-search-container"> <div class="desktop-search-form"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="owel__null__null" src="/scolaris-search/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=9nGOjNGw&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"/> <input name="facetDisplayName" type="hidden" value=""/> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013594&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013594';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<div class="search-tools-nav">
<a class="btn secondary" href="/en/browse-by-topic">Browse</a>
<a class="btn primary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
</div>
<a class="toggle-menu-switch" href="#"><i aria-hidden="true" class="fa fa-bars"></i> <div class="toggle-menu-text">Open menu</div></a>
</div>
<div class="auxiliary-container">
<div class="container">
<div class="header-auxiliary-menu">
<div class="auxiliary-menu-item language-selector">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="bvrs__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> Review language : English </a> <a class="open-language-modal" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> Website language : English </a> </div> <div class="language-selector-modal-content" data-modal-title="Language selection" data-size="large" style="display: none;"> <div class="form-content language-selector-modal"> <div class="row-fluid"> <div> <table class="mytable" style="border: 1px solid #f0f0f0" width="90%"> <tbody> <tr class="row-box"> <td><i class="fa fa-file-text icon-size"></i></td> <td><h3>Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> </td> <td> <div> <select id="contentLanguageSelector" onchange="updateLang(this.value)"> <option class="content-language-option" data-languagecode="de" value="de"> Deutsch </option> <option class="content-language-option" data-languagecode="en" selected="" value="en"> English </option> <option class="content-language-option" data-languagecode="es" value="es"> Español </option> <option class="content-language-option" data-languagecode="fa" value="fa"> فارسی </option> <option class="content-language-option" data-languagecode="fr" value="fr"> Français </option> <option class="content-language-option" data-languagecode="hi" value="hi"> हिन्दी </option> <option class="content-language-option" data-languagecode="hr" value="hr"> Hrvatski </option> <option class="content-language-option" data-languagecode="id" value="id"> Bahasa Indonesia </option> <option class="content-language-option" data-languagecode="ja" value="ja"> 日本語 </option> <option class="content-language-option" data-languagecode="ko" value="ko"> 한국어 </option> <option class="content-language-option" data-languagecode="hu" value="hu"> Magyar </option> <option class="content-language-option" data-languagecode="ms" value="ms"> Bahasa Malaysia </option> <option class="content-language-option" data-languagecode="nl" value="nl"> Nederlands </option> <option class="content-language-option" data-languagecode="pl" value="pl"> Polski </option> <option class="content-language-option" data-languagecode="pt" value="pt"> Português </option> <option class="content-language-option" data-languagecode="ru" value="ru"> Русский </option> <option class="content-language-option" data-languagecode="ro" value="ro"> Română </option> <option class="content-language-option" data-languagecode="ta" value="ta"> தமிழ் </option> <option class="content-language-option" data-languagecode="th" value="th"> ภาษาไทย </option> <option class="content-language-option" data-languagecode="zh_HANT" value="zh_HANT"> 繁體中文 </option> <option class="content-language-option" data-languagecode="zh_HANS" value="zh_HANS"> 简体中文 </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> <tr class="row-box"> <td><i class="fa fa-globe icon-size"></i></td> <td> <div class="language-info"> <h3>Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> </div> </td> <td> <div class="language-dropdown"> <select id="portalLanguageSelector"> <option class="portal-language-selector" data-portallanguage="en" selected="" value="/en/cdsr/doi/10.1002/14651858.CD013594/full/en"> English </option> <option class="portal-language-selector" data-portallanguage="es" value="/es/cdsr/doi/10.1002/14651858.CD013594/full/es"> Español </option> </select> </div> </td> </tr> <tr> <td colspan="1" style="height: 10px"></td> </tr> </tbody> </table> </div> </div> <div style="text-align: right;"> <button class="btn primary btn-cancel" style="margin-left: 10px;" type="button">Cancel</button> <a class="btn secondary ok-btn" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
<a class="auxiliary-menu-item signin last" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013594%2Ffull" rel="nofollow">
<i class="icon fa fa-user"></i> Sign In
    </a>
<span class="auxiliary-container-extended"></span>
</div>
</div>
</div>
</header>
<div class="main-nav-wrapper">
<span class="main-nav-left-extended"></span>
<nav class="main container">
<ul>
<li class="nav-root-item parent">
<a href="#">Cochrane reviews<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_14" role="presentation">
<a aria-labelledby="layout_14" href="https://www.cochranelibrary.com/en/cdsr/reviews" role="menuitem">
            Search reviews (CDSR)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_15" role="presentation">
<a aria-labelledby="layout_15" href="https://www.cochranelibrary.com/en/cdsr/reviews/topics" role="menuitem">
            Browse reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_18" role="presentation">
<a aria-labelledby="layout_18" href="https://www.cochranelibrary.com/en/cdsr/table-of-contents" role="menuitem">
            Issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_17" role="presentation">
<a aria-labelledby="layout_17" href="https://www.cochranelibrary.com/en/cdsr/editorials" role="menuitem">
            Editorials
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_19" role="presentation">
<a aria-labelledby="layout_19" href="https://www.cochranelibrary.com/en/special-collections" role="menuitem">
            Special Collections
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_20" role="presentation">
<a aria-labelledby="layout_20" href="https://www.cochranelibrary.com/en/cdsr/supplements" role="menuitem">
            Supplements
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_121" role="presentation">
<a aria-labelledby="layout_121" href="https://www.cochranelibrary.com/en/about/about-cochrane-reviews" role="menuitem">
            About Cochrane reviews
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Searching for trials<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_254" role="presentation">
<a aria-labelledby="layout_254" href="https://www.cochranelibrary.com/en/search/releases" role="menuitem">
            What's new (search and CENTRAL)
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_266" role="presentation">
<a aria-labelledby="layout_266" href="https://www.cochranelibrary.com/en/search-help" role="menuitem">
            Search help
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_252" role="presentation">
<a aria-labelledby="layout_252" href="https://www.cochranelibrary.com/en/search-help-quick-guides" role="menuitem">
            Search help quick guides
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_251" role="presentation">
<a aria-labelledby="layout_251" href="https://www.cochranelibrary.com/en/search-faqs" role="menuitem">
            Search FAQs
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_114" role="presentation">
<a aria-labelledby="layout_114" href="https://www.cochranelibrary.com/en/central/about-central" role="menuitem">
            About CENTRAL
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_115" role="presentation">
<a aria-labelledby="layout_115" href="https://www.cochranelibrary.com/en/central/central-creation" role="menuitem">
            How CENTRAL is created
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_241" role="presentation">
<a aria-labelledby="layout_241" href="https://www.cochranelibrary.com/en/retracted-trials" role="menuitem">
            Retracted publications in CENTRAL
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Clinical Answers<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_29" role="presentation">
<a aria-labelledby="layout_29" href="https://www.cochranelibrary.com/en/cca" role="menuitem">
            Browse Clinical Answers
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_91" role="presentation">
<a aria-labelledby="layout_91" href="https://www.cochranelibrary.com/en/cca/about" role="menuitem">
            About Clinical Answers
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">About<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_116" role="presentation">
<a aria-labelledby="layout_116" href="https://www.cochranelibrary.com/en/about/about-cochrane-library" role="menuitem">
            About the Cochrane Library
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_13" role="presentation">
<a aria-labelledby="layout_13" href="https://www.cochranelibrary.com/en/cdsr/about-cdsr" role="menuitem">
            Cochrane Database of Systematic reviews
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_198" role="presentation">
<a aria-labelledby="layout_198" href="https://www.cochranelibrary.com/en/cdsr/editorial-policies" role="menuitem">
            Editorial policies
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_92" role="presentation">
<a aria-labelledby="layout_92" href="https://www.cochranelibrary.com/en/about/author-information" role="menuitem">
            Information for authors
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_212" role="presentation">
<a aria-labelledby="layout_212" href="https://www.cochranelibrary.com/en/about-pico" role="menuitem">
            About PICO
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_207" role="presentation">
<a aria-labelledby="layout_207" href="https://www.cochranelibrary.com/en/about/about-translations" role="menuitem">
            About translations
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_188" role="presentation">
<a aria-labelledby="layout_188" href="https://www.cochranelibrary.com/en/about/releases" role="menuitem">
            What's new
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_216" role="presentation">
<a aria-labelledby="layout_216" href="https://www.cochranelibrary.com/en/data" role="menuitem">
            Data reuse
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_235" role="presentation">
<a aria-labelledby="layout_235" href="https://www.cochranelibrary.com/en/about/about-cochrane-library/editorial-board" role="menuitem">
            Cochrane Library Editorial Board
        </a>
</li>
</ul>
</li>
<li class="nav-root-item parent">
<a href="#">Help<span class="icon fa fa-caret-down"></span></a>
<ul class="child">
<li class="child-nav-item" id="layout_nav_child_attr_259" role="presentation">
<a aria-labelledby="layout_259" href="https://m.info.wiley.com/webApp/cochranenewsletter?id=0" role="menuitem">
            Newsletter
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_177" role="presentation">
<a aria-labelledby="layout_177" href="https://www.wiley.com/en-us/customer-success/cochrane-library-training-hub" role="menuitem">
            Cochrane Library Training
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_44" role="presentation">
<a aria-labelledby="layout_44" href="https://www.cochranelibrary.com/en/help/access" role="menuitem">
            Access
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_150" role="presentation">
<a aria-labelledby="layout_150" href="https://www.cochranelibrary.com/en/help/permissions" role="menuitem">
            Permissions and reprints
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_93" role="presentation">
<a aria-labelledby="layout_93" href="https://www.cochranelibrary.com/en/help/media" role="menuitem">
            Media information
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_97" role="presentation">
<a aria-labelledby="layout_97" href="https://www.cochranelibrary.com/en/help/contact-us" role="menuitem">
            Contact us
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_125" role="presentation">
<a aria-labelledby="layout_125" href="https://www.cochranelibrary.com/en/about/terms-and-conditions" role="menuitem">
            Terms and conditions
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_176" role="presentation">
<a aria-labelledby="layout_176" href="https://cochranesupport.wiley.com/s/article/cochrane-library-known-issues" role="menuitem">
            Known issues
        </a>
</li>
<li class="child-nav-item" id="layout_nav_child_attr_270" role="presentation">
<a aria-labelledby="layout_270" href="https://www.cochranelibrary.com/search-help" role="menuitem">
            Search help
        </a>
</li>
</ul>
</li>
<li class="about-link"><a href="https://www.cochrane.org/about-us" target="_blank"><span>About Cochrane</span><i class="fa fa-caret-right"></i></a></li>
</ul>
</nav>
</div>
<div class="portlet-boundary portlet-boundary_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_">
<span id="p_scolariscontentlanguagebanner_WAR_scolarislanguageportlet"></span>
<section class="portlet" id="portlet_scolariscontentlanguagebanner_WAR_scolarislanguageportlet">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Language\x20Banner\x20Portlet')">
<img alt="" id="etlj__null__null" src="/scolaris-language-portlet/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Language Banner Portlet</span> </span> <span class="portlet-title-text">Scolaris Content Language Banner Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentlanguagebanner_WAR_scolarislanguageportlet" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="" id="content">
<div class="columns-1" id="main-content" role="main">
<div class="portlet-layout row-fluid">
<div class="portlet-column portlet-column-only span12" id="column-1">
<div class="portlet-dropzone portlet-column-content portlet-column-content-only" id="layout-column_column-1">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="rjus__column1__0" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="publication cdsr container"> <div class="article-navigation-container" id="cdsr-nav"> <nav class="article-navigation"> <ul class="tools-row"> <li> <li class="tools pdf pulldown-menu readcube-menu closed en_US"> <a class="pulldown-menu-trigger" href="#0"> <span class="pdf-icon"> <i class="icon fa fa-file-pdf-o"></i> <span>Download PDF</span> </span> <i aria-hidden="true" class="fa fa-caret-down"></i> </a> <ul class="pulldown-menu-items"> <li class=""> <a class="download media pdf-link-full pdf-link" href="/cdsr/doi/10.1002/14651858.CD013594/pdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> <a class="download media pdf-link-full readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013594/epdf/full/en" title="Article in PDF format"> <span class="readcube-label"> Full </span> <span class="readcube-description"> All content </span> </a> </li> <li class=""> <a class="download media pdf-link-abstract pdf-link" href="/cdsr/doi/10.1002/14651858.CD013594/pdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> <a class="download media pdf-link-abstract readcube-epdf-link" href="/cdsr/doi/10.1002/14651858.CD013594/epdf/abstract/en" title="Article in PDF format"> <span class="readcube-label"> Summary </span> <span class="readcube-description"> Abstract and plain language summary only </span> </a> </li> </ul> </li> <li class="tools cite cite-article-link" data-article-id="CD013594" data-modal-title="Cite this review"> <span><i aria-hidden="true" class="icon fa fa-share"></i></span> <span>Cite this review</span> </li> </li> </ul> <ul class="tools-row tools-secondary"> <li> <li class="tools print print-cdsr-link" data-content-language="en" data-indicator-tooltip="scolaris.print.modal.language.tooltip.en" data-print-options="[{&quot;param&quot;: &quot;abstract&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Abstract&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;چکیده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé scientifique&quot;}]},{&quot;param&quot;: &quot;pls&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Plain language summary&quot;},{&quot;language&quot;:&quot;es&quot;,&quot;title&quot;:&quot;Resumen en términos sencillos&quot;},{&quot;language&quot;:&quot;fa&quot;,&quot;title&quot;:&quot;خلاصه به زبان ساده&quot;},{&quot;language&quot;:&quot;fr&quot;,&quot;title&quot;:&quot;Résumé simplifié&quot;},{&quot;language&quot;:&quot;ms&quot;,&quot;title&quot;:&quot;Ringkasan bahasa mudah&quot;}]},{&quot;param&quot;: &quot;conclusions&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors' conclusions&quot;}]},{&quot;param&quot;: &quot;summaryOfFindings&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Summary of findings&quot;}]},{&quot;param&quot;: &quot;background&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Background&quot;}]},{&quot;param&quot;: &quot;objectives&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Objectives&quot;}]},{&quot;param&quot;: &quot;methods&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Methods&quot;}]},{&quot;param&quot;: &quot;results&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Results&quot;}]},{&quot;param&quot;: &quot;discussion&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Discussion&quot;}]},{&quot;param&quot;: &quot;references&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;References&quot;}]},{&quot;param&quot;: &quot;appendices&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Appendices&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Search strategies&quot;}]},{&quot;param&quot;: &quot;characteristics&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Characteristics of studies&quot;}]},{&quot;param&quot;: &quot;data&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Analyses&quot;}]},{&quot;param&quot;: &quot;information&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Information&quot;}]},{&quot;param&quot;: &quot;authors&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;Authors&quot;}]},{&quot;param&quot;: &quot;history&quot;,&quot;titles&quot;:[{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;},{&quot;language&quot;:&quot;en&quot;,&quot;title&quot;:&quot;History&quot;}]}]" data-print-urlbase="/cdsr/doi/10.1002/14651858.CD013594/print"> <span><i class="icon fa fa-print"></i></span> <span>Print</span> </li> <li class="js-old-version-modal-trigger tools comments comment-on-review" data-article-id="CD013594" data-english-only-message="Please note, that commenting is available in English only. Apologies for any inconvenience." data-href="/cdsr/doi/10.1002/14651858.CD013594/read-comments" data-new-version="" id="comment-on-review"> <span class="comment-icon"><i class="icon fa fa-comment"></i></span> <span class="comments-count">0</span> <span>Comment</span> </li> <li class="tools share-cdsr-link" data-share-url="/cdsr/doi/10.1002/14651858.CD013594/full"> <span><i class="icon fa fa-share-alt"></i></span> <span>Share</span> </li> <li class="tools follow"> <span class="article-not-followed cochrane-link signin follow-wrapper"> <span> <i class="icon fa fa-plus"></i> </span> <span> Follow </span> </span> </li> </li> </ul> <div class="metrics-wrapper"> <div class="metrics-count"> <span>Full text views: </span> <span>3169 <i class="icon fa fa-info-circle custom-tooltip" style="padding-left: 2px;color: #962d91;" title="Usage represents full text views on Cochrane Library since January 2022 or 2023. For articles published after this date, the usage represents views since the article was first published on Cochrane Library."> </i> </span> </div> </div> <div class="metrics-wrapper nav-link-section"> <div class="altmetric-embed" data-badge-type="1" data-condensed="true" data-doi="10.1002/14651858.CD013594" data-link-target="_blank"></div> <div class="inline-status-wrapper guidelines-count" data-count-plural="Cited in $1 guidelines" data-count-single="Cited in 1 guideline"> <a href="related-content#guidelines_data" title="Guidelines"></a> </div> </div> <ul class="nav-section-header"> <li> <h3>Contents</h3> </li> </ul> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013594/full"> Abstract </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013594/full#pico"> PICOs </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013594/full#CD013594-abs-0002"> Plain language summary </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013594/full#CD013594-sec-0066"> Authors' conclusions </a> </li> <li class="cdsr-nav-link bold-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013594/full#CD013594-sec-0008"> Summary of findings </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013594/full#CD013594-sec-0009"> Background </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013594/full#CD013594-sec-0014"> Objectives </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013594/full#CD013594-sec-0015"> Methods </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013594/full#CD013594-sec-0033"> Results </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013594/full#CD013594-sec-0060"> Discussion </a> </li> <li class="cdsr-nav-link"> <a class="figures-and-tables-link" href="/cdsr/doi/10.1002/14651858.CD013594/#"> Figures and tables </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013594/references"> References </a> </li> </ul> <div class="nav-section-header"> <h3>Supplementary materials</h3> </div> <ul class="nav-long-form nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013594/appendices#CD013594-sec-0071"> Search strategies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013594/references#characteristicStudies"> Characteristics of studies </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013594/references#dataAndAnalyses"> Analyses </a> </li> <li class="cdsr-nav-link download-stats-data-link" data-download-href="/cdsr/doi/10.1002/14651858.CD013594/media/CDSR/CD013594/table_n/CD013594StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> <a href="/cdsr/doi/10.1002/14651858.CD013594/media/CDSR/CD013594/table_n/CD013594StatsDataOnly.rm5?content-disposition=attachment&amp;mime-type=application/octet-stream"> Download data </a> </li> </ul> <ul class="tools-row"> <li> </li> </ul> <ul class="nav-section-header"> <li><h3>Related</h3></li> </ul> <ul class="linked-content linked-content-dropdown" id="linked-content-articles" tabindex="0"> <li class="linked-cca" data-type="cca"> <div class="linked-content-section"> <span class="linked-type">Cochrane Clinical Answers<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-editorials" data-type="editorial"> <div class="linked-content-section"> <span class="linked-type">Editorials<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-podcasts" data-type="podcast"> <div class="linked-content-section"> <span class="linked-type">Podcasts<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> <li class="linked-sc" data-type="sc"> <div class="linked-content-section"> <span class="linked-type">Special Collections<span class="count"></span></span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="articles"></div> </li> </ul> <div class="nav-section-header"> <h3>About this review</h3> </div> <ul class="nav-long-form nav-info nav-link-section"> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013594/information"> <i> <svg viewbox="0 0 24 24"> <path d="M11,9H13V7H11M12,20C7.59,20 4,16.41 4,12C4,7.59 7.59,4 12,4C16.41,4 20,7.59 20,12C20,16.41 16.41,20 12,20M12,2A10,10 0 0,0 2,12A10,10 0 0,0 12,22A10,10 0 0,0 22,12A10,10 0 0,0 12,2M11,17H13V11H11V17Z"></path> </svg> </i> Information </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013594/information#authors"> <i> <svg viewbox="0 0 24 24"> <path d="M12,5.5A3.5,3.5 0 0,1 15.5,9A3.5,3.5 0 0,1 12,12.5A3.5,3.5 0 0,1 8.5,9A3.5,3.5 0 0,1 12,5.5M5,8C5.56,8 6.08,8.15 6.53,8.42C6.38,9.85 6.8,11.27 7.66,12.38C7.16,13.34 6.16,14 5,14A3,3 0 0,1 2,11A3,3 0 0,1 5,8M19,8A3,3 0 0,1 22,11A3,3 0 0,1 19,14C17.84,14 16.84,13.34 16.34,12.38C17.2,11.27 17.62,9.85 17.47,8.42C17.92,8.15 18.44,8 19,8M5.5,18.25C5.5,16.18 8.41,14.5 12,14.5C15.59,14.5 18.5,16.18 18.5,18.25V20H5.5V18.25M0,20V18.5C0,17.11 1.89,15.94 4.45,15.6C3.86,16.28 3.5,17.22 3.5,18.25V20H0M24,20H20.5V18.25C20.5,17.22 20.14,16.28 19.55,15.6C22.11,15.94 24,17.11 24,18.5V20Z"></path> </svg> </i> Authors </a> </li> <li class="cdsr-nav-link" lang="en"> <a href="/cdsr/doi/10.1002/14651858.CD013594/information#history"> <i> <svg viewbox="0 0 24 24"> <path d="M13.5,8H12V13L16.28,15.54L17,14.33L13.5,12.25V8M13,3A9,9 0 0,0 4,12H1L4.96,16.03L9,12H6A7,7 0 0,1 13,5A7,7 0 0,1 20,12A7,7 0 0,1 13,19C11.07,19 9.32,18.21 8.06,16.94L6.64,18.36C8.27,20 10.5,21 13,21A9,9 0 0,0 22,12A9,9 0 0,0 13,3"></path> </svg> </i> Version history </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013594/information#keywords"> <i> <svg viewbox="0 0 24 24"> <path d="M11 3C10.18 3 9.44 3.5 9.14 4.27L3.64 18.27C3.12 19.58 4.09 21 5.5 21H7.75C8.59 21 9.33 20.5 9.62 19.7L10.26 18H13.74L14.38 19.7C14.67 20.5 15.42 21 16.25 21H18.5C19.91 21 20.88 19.58 20.36 18.27L14.86 4.27C14.56 3.5 13.82 3 13 3M11 5H13L18.5 19H16.25L15.12 16H8.87L7.75 19H5.5M12 7.67L9.62 14H14.37Z"></path> </svg> </i> Keywords (MeSH, PICOs) </a> </li> <li class="cdsr-nav-link"> <a href="/cdsr/doi/10.1002/14651858.CD013594/related-content"> <i class="icon fa fa-sitemap fa-rotate-270"></i> Related content </a> </li> <li class="cdsr-nav-link translation-notes-link"> <a href="/cdsr/doi/10.1002/14651858.CD013594/#"> <i> <svg viewbox="0 0 24 24"> <path d="M12.87,15.07L10.33,12.56L10.36,12.53C12.1,10.59 13.34,8.36 14.07,6H17V4H10V2H8V4H1V6H12.17C11.5,7.92 10.44,9.75 9,11.35C8.07,10.32 7.3,9.19 6.69,8H4.69C5.42,9.63 6.42,11.17 7.67,12.56L2.58,17.58L4,19L9,14L12.11,17.11L12.87,15.07M18.5,10H16.5L12,22H14L15.12,19H19.87L21,22H23L18.5,10M15.88,17L17.5,12.67L19.12,17H15.88Z"></path> </svg> </i> Translation notes </a> </li> <li class="cdsr-nav-link"> <a class="request-permissions" data-copyright="Copyright © 2020 The Authors. Cochrane Database of Systematic Reviews published by John Wiley &amp; Sons, Ltd. on behalf of The Cochrane Collaboration." data-creative-commons="true" href="/cdsr/doi/10.1002/14651858.CD013594/#"> <span class="request-permissions-icon"></span> Request permissions </a> </li> <li class="cdsr-nav-link"> <a href="/data"> <i class="icon fa fa-database"></i> Request data reuse </a> </li> </ul> </nav> </div> <article> <div class="cdsr-header-top"> <div class="cdsr-header-left"> <a class="publish-database" href="/">Cochrane Database of Systematic reviews</a> <span class="publish-type">Review - Intervention</span> </div> <div class="cdsr-header-right"> </div> </div> <header class="publication-header"> <h1 class="publication-title" lang="en">Treating progressive disseminated histoplasmosis in people living with HIV</h1> <div class="publication-metadata-block"> <div class="publication-authors"> <div class="publish-meta-wrapper"> <ul class="authors"> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013594/information#CD013594-cr-0004"><i class="icon corresponding-author fa fa-envelope"></i>Marylou Murray</a></li> <li class="author"><a href="/cdsr/doi/10.1002/14651858.CD013594/information#CD013594-cr-0005">Paul Hine</a></li> </ul> <span class="author declaration"> <a class="declarationsOfInterestLink" href="/cdsr/doi/10.1002/14651858.CD013594/information/en#CD013594-sec-0089">Authors' declarations of interest</a> </span> </div> </div> </div> <div class="publication-metadata-block"> <p> <span class="publish-date">Version published: 28 April 2020 </span> <a class="whatsNewLink" href="/cdsr/doi/10.1002/14651858.CD013594/information/en#versionTable">Version history</a> </p> <div class="doi-header"> <a href="https://doi.org/10.1002/14651858.CD013594">https://doi.org/10.1002/14651858.CD013594</a> </div> </div> </header> <div class="publication-control-bar"> <span class="publication-control-button publication-control-collapse"> Collapse all </span> <span class="publication-control-button publication-control-expand"> Expand all </span> </div> <section class="abstract"> <div class="section-header section-collapse-header" id="CD013594-abs-0001" lang="en"> <h2 class="title section-collapse-title"> Abstract <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013594-abs-0001">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD013594-abs-0008">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013594-abs-0003">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD013594-abs-0005">Français</a> </li> </nav> </div> </div> <div class="abstract full_abstract" id="CD013594-abs-0001" lang="en"> <section id="CD013594-sec-0001"> <h3 class="title" id="CD013594-sec-0001">Background</h3> <p>Progressive disseminated histoplasmosis (PDH) is a serious fungal infection that affects people living with HIV. The best way to treat the condition is unclear. </p> </section> <section id="CD013594-sec-0002"> <h3 class="title" id="CD013594-sec-0002">Objectives</h3> <p>We assessed evidence in three areas of equipoise.</p> <p><b>1. Induction.</b> To compare efficacy and safety of initial therapy with liposomal amphotericin B versus initial therapy with alternative antifungals. </p> <p><b>2. Maintenance.</b> To compare efficacy and safety of maintenance therapy with 12 months of oral antifungal treatment with shorter durations of maintenance therapy. </p> <p><b>3. Antiretroviral therapy (ART).</b> To compare the outcomes of early initiation versus delayed initiation of ART. </p> </section> <section id="CD013594-sec-0003"> <h3 class="title" id="CD013594-sec-0003">Search methods</h3> <p>We searched the Cochrane Infectious Diseases Group Specialized Register; Cochrane CENTRAL; MEDLINE (PubMed); Embase (Ovid); Science Citation Index Expanded, Conference Proceedings Citation Index‐Science, and BIOSIS Previews (all three in the Web of Science); the WHO International Clinical Trials Registry Platform, ClinicalTrials.gov, and the ISRCTN registry, all up to 20 March 2020. </p> </section> <section id="CD013594-sec-0004"> <h3 class="title" id="CD013594-sec-0004">Selection criteria</h3> <p>We evaluated studies assessing the use of liposomal amphotericin B and alternative antifungals for induction therapy; studies assessing the duration of antifungals for maintenance therapy; and studies assessing the timing of ART. We included randomized controlled trials (RCT), single‐arm trials, prospective cohort studies, and single‐arm cohort studies. </p> </section> <section id="CD013594-sec-0005"> <h3 class="title" id="CD013594-sec-0005">Data collection and analysis</h3> <p>Two review authors assessed eligibility and risk of bias, extracted data, and assessed certainty of evidence. We used the Cochrane 'Risk of bias' tool to assess risk of bias in randomized studies, and ROBINS‐I tool to assess risk of bias in non‐randomized studies. We summarized dichotomous outcomes using risk ratios (RRs), with 95% confidence intervals (CI). </p> </section> <section id="CD013594-sec-0006"> <h3 class="title" id="CD013594-sec-0006">Main results</h3> <p>We identified 17 individual studies. We judged eight studies to be at critical risk of bias, and removed these from the analysis. </p> <p><b>1. Induction</b> </p> <p>We found one RCT which compared liposomal amphotericin B to deoxycholate amphotericin B. Compared to deoxycholate amphotericin B, liposomal amphotericin B may have higher clinical success rates (RR 1.46, 95% CI 1.01 to 2.11; 1 study, 80 participants; low‐certainty evidence). Compared to deoxycholate amphotericin B, liposomal amphotericin B has lower rates of nephrotoxicity (RR 0.25, 95% CI 0.09 to 0.67; 1 study, 77 participants; high‐certainty evidence). We found very low‐certainty evidence to inform comparisons between amphotericin B formulations and azoles for induction therapy. </p> <p><b>2. Maintenance</b> </p> <p>We found no eligible study that compared less than 12 months of oral antifungal treatment to 12 months or greater for maintenance therapy. </p> <p>For both induction and maintenance, fluconazole performed poorly in comparison to other azoles. </p> <p><b>3. ART</b> </p> <p>We found one study, in which one out of seven participants in the 'early' arm and none of the three participants in the 'late' arm died. </p> </section> <section id="CD013594-sec-0007"> <h3 class="title" id="CD013594-sec-0007">Authors' conclusions</h3> <p>Liposomal amphotericin B appears to be a better choice compared to deoxycholate amphotericin B for treating PDH in people with HIV; and fluconazole performed poorly compared to other azoles. Other treatment choices for induction, maintenance, and when to start ART have no evidence, or very low certainty evidence. PDH needs prospective comparative trials to help inform clinical decisions. </p> </section> </div> </section> <section class="pico-section" id="pico"> <h2 class="title section-collapse-title">PICOs <i class="icon fa fa-info-circle" title="The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome."></i> <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-content" style="display: block;"> <h3 class="keyword-heading">PICOs</h3> <div class="pico-table"> <div class="pico-column Population"> <h6>Population<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Intervention"> <h6>Intervention<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Comparison"> <h6>Comparison<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> <div class="pico-column Outcome"> <h6>Outcome<span class="pico-count"></span></h6> <ul class="pico-terms"> </ul> </div> </div> <div class="pico-information"> <p><i class="icon fa fa-info-circle"></i> The PICO model is widely used and taught in evidence-based health care as a strategy for formulating questions and search strategies and for characterizing clinical studies or meta-analyses. PICO stands for four different potential components of a clinical question: Patient, Population or Problem; Intervention; Comparison; Outcome.</p> <p>See more on using PICO in the <a href="https://training.cochrane.org/handbook/current/chapter-02#section-2-3">Cochrane Handbook</a>.</p> </div> </div> </section> <section class="pls"> <div class="section-header section-collapse-header" id="CD013594-abs-0002" lang="en"> <h2 class="title section-collapse-title"> Plain language summary <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> <div class="section-language-toggles"> <span class="section-languages-legend">available in</span> <nav class="section-languages"> <li class="section-language"> <a class="is-active" href="full/en#CD013594-abs-0002">English</a> </li> <li class="section-language"> <a class="" href="full/es#CD013594-abs-0009">Español</a> </li> <li class="section-language"> <a class="" href="full/fa#CD013594-abs-0004">فارسی</a> </li> <li class="section-language"> <a class="" href="full/fr#CD013594-abs-0006">Français</a> </li> <li class="section-language"> <a class="" href="full/ms#CD013594-abs-0007">Bahasa Malaysia</a> </li> </nav> </div> </div> <div class="abstract abstract_plainLanguageSummary" id="CD013594-abs-0002" lang="en"> <h3>How best to treat progressive disseminated histoplasmosis in people with HIV</h3> <p><b>What was the aim of this review?</b> </p> <p>The aim of this Cochrane Review was to investigate some treatment dilemmas with progressive disseminated histoplasmosis in people living with HIV. We collected and analysed all relevant studies to answer this question and found 17 studies. </p> <p><b>Key messages</b> </p> <p>Liposomal amphotericin B may improve clinical success compared to deoxycholate amphotericin B when starting treatment. </p> <p>Liposomal amphotericin B results in less kidney damage compared to deoxycholate amphotericin B when starting treatment. </p> <p>We are unsure how long people should stay on treatment after they have successfully completed the starting stage. We are unsure at what time during treatment of the fungal infection it is best to start treatment to fight the HIV virus. </p> <p><b>What was studied in this review?</b> </p> <p>Histoplasmosis is an infection caused by inhaling a fungus called <i>Histoplasma</i>. The most severe form of histoplasmosis is called progressive disseminated histoplasmosis, in which the infection spreads from the lungs to other organs. It is life‐threatening for people with advanced HIV. </p> <p>The treatment of progressive disseminated histoplasmosis starts with 'induction', in which medicines are started to rapidly attack the fungus. The next phase is called 'maintenance', in which medicines are used to prevent the fungus taking hold again. During treatment of the fungus, antiretroviral medicines are started to fight the HIV virus. </p> <p>We wanted to find out the best induction treatment, if maintenance could be for less than one year, and when was the best time to start antiretroviral medicines. </p> <p><b>What are the main results of the review?</b> </p> <p>We found 17 studies. We removed eight from the review as they did not include important measurements that might change results. These included how severe the HIV infection was, or if the patients had other infections at the same time. </p> <p>One study compared two forms of the same medicine for starting treatment of histoplasmosis, liposomal amphotericin B and deoxycholate amphotericin B. It found that the more expensive liposomal form is less likely to cause kidney damage and may have higher clinical success rates than the deoxycholate form. </p> <p>None of the studies looked at whether maintenance could be less than one year. Two studies looked a antiretroviral medicines, but we do not know when it is best to start them. </p> <p><b>How up to date is the review?</b> </p> <p>We searched for studies that had been published up to 20 March 2020.</p> </div> </section> <section id="vls" style="display: none"> <div class="section-header section-collapse-header"> <h2 class="title section-collapse-title">Visual summary<i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i></h2> </div> <a href="" target="_blank"><img alt="visual summary" src=""/></a> </section> <section class="conclusions"> <div class="section-header section-collapse-header" id="CD013594-sec-0066" lang="en"> <h2 class="title section-collapse-title"> Authors' conclusions <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="authorsConclusions" lang="en"> <div class="section-header" id="CD013594-sec-0066"></div> <h3 class="title" id="CD013594-sec-0067">Implications for practice</h3> <section id="CD013594-sec-0067"> <p>Liposomal amphotericin B appears to be a better choice compared to deoxycholate amphotericin B for treating progressive disseminated histoplasmosis in people with HIV. Fluconazole appears unsuitable for induction or maintenance. </p> </section> <h3 class="title" id="CD013594-sec-0068">Implications for research</h3> <section id="CD013594-sec-0068"> <p>As there is very low‐certainty evidence to inform other treatment choices, we recommend further prospective research. A priority question is whether in people with a clinical and immunological response to therapy, maintenance antifungal therapy can be safely discontinued earlier than 12 months. A further question is when is the optimal time to start ART, and in what circumstances the risk of IRIS may be higher? The high and varying costs of appropriate oral antifungal agents make these questions more pertinent. </p> </section> </section> </section> <section class="summaryOfFindings"> <div class="section-header section-collapse-header" id="CD013594-sec-0008" lang="en"> <h2 class="title section-collapse-title"> Summary of findings <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="summaryOfFindings" lang="en"> <div class="section-header" id="CD013594-sec-0008"></div> <div class="table" id="CD013594-tbl-0001"> <table class="summary-of-findings framed"><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Induction: liposomal amphotericin compared with amphotericin deoxycholate</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Liposomal amphotericin compared with amphotericin deoxycholate for induction therapy of progressive disseminated histoplasmosis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with HIV and progressive disseminated histoplasmosis </p> <p><b>Settings:</b> endemic areas </p> <p><b>Intervention:</b> induction therapy with liposomal amphotericin B </p> <p><b>Comparison:</b> amphotericin B deoxycholate </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Number of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>dAmB</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>lAmB</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical success</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>560 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>818 per 1000</b><br/>(566 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.46</b><br/>(1.01 to 2.11) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Compared to dAmB, lAmB may have higher clinical success rates.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Death</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>125 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>19 per 1000</b><br/>(3 to 173) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.15</b><br/>(0.02 to 1.38) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Treatment with lAmB may result in lower mortality than treatment with dAmB.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Safety outcomes:</b> nephrotoxicity </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>375 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>94 per 1000</b><br/>(34 to 251) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.25</b><br/>(0.09 to 0.67) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕</p> <p><b>High</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Treatment with lAmB resulted in lower rates of nephrotoxicity compared to treatment with dAmB; this was supported by findings of a Cochrane Review which reported moderate‐certainty evidence (<a href="./references#CD013594-bbs2-0064" title="Botero AguirreJP , Restrepo HamidAM . Amphotericin B deoxycholate versus liposomal amphotericin B: effects on kidney function. Cochrane Database of Systematic Reviews2015, Issue 11. [DOI: 10.1002/14651858.CD010481]">Botero Aguirre 2015</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Safety outcomes:</b> drug discontinuation </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>83 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>19 per 1000</b><br/>(2 to 198) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.23</b><br/>(0.02 to 2.38) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know if treatment with lAmB leads to fewer treatment discontinuations than dAmB. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>dAmB:</b> deoxycholate amphotericin B; <b>lAmB:</b> liposomal amphotericin B; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE</b> Working Group grades of evidence<br/><b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded two levels for very serious imprecision: the CI met the line of no effect and was based on very few events (73 participants, 1 randomized controlled trial).<br/><sup>b</sup>Downgraded two levels for very serious imprecision: the CIs were wide and crossed the line of no effect.<br/><sup>c</sup>Downgraded one level for serious risk of bias (due to unclear reporting criteria) and two levels for very serious imprecision (the CIs were wide and crossed the line of no effect). </p> </div> </td> </tr> </tfoot> </table> </div> </section> </section> <section class="background"> <div class="section-header section-collapse-header" id="CD013594-sec-0009" lang="en"> <h2 class="title section-collapse-title"> Background <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="background" lang="en"> <div class="section-header" id="CD013594-sec-0009"></div> <section id="CD013594-sec-0010"> <h3 class="title" id="CD013594-sec-0010">Description of the condition</h3> <p>Progressive disseminated histoplasmosis (PDH) is an important infectious disease among people living with HIV. PDH is one of the endemic mycoses, meaning a fungal infection localized to a specific region. It is caused by two human pathogens, <i>Histoplasma capsulatum</i> var. <i>capsulatum</i> (in the Americas) and <i>Histoplasma capsulatum</i> var. <i>duboisii</i> (in Africa). It causes severe morbidity and carries a risk of mortality of over 60% (<a href="./references#CD013594-bbs2-0056" title="AdenisA , NacherM , HanfM , VantilckeV , BoukhariR , BlachetD , et al. HIV-associated histoplasmosis early mortality and incidence trends: from neglect to priority. PLoS Neglected Tropical Diseases2014;8(8):e3100.">Adenis 2014</a>; <a href="./references#CD013594-bbs2-0066" title="Cano-TorresJO , Olmedo-ReneaumA , Esquivel-SanchezJM , Camiro-ZunigaA , Perez-CarrisozaA , Madrigal-IberriC , et al. Progressive disseminated histoplasmosis in Latin America and the Caribbean in people receiving highly active antiretroviral therapy for HIV infection: a systematic review. Medical Mycology2019;18:18.">Cano‐Torres 2019</a>). <i>H capsulatum</i> var. <i>capsulatum</i> has historically been thought of as predominantly effecting the Americas, but there is evidence of a wider global distribution (<a href="./references#CD013594-bbs2-0059" title="BakerJ , SetianingrumF , WahyuningsihR , DenningD . Mapping histoplasmosis in South East Asia – implications for diagnosis in AIDS. Emerging Microbes and Infections2019;8(1):1139-1145.">Baker 2019</a>). </p> <p>The diagnosis of PDH in people living with HIV is usually made based on:</p> <p> <ul id="CD013594-list-0001"> <li> <p>risk factors for the disease (advanced HIV);</p> </li> <li> <p>clinical manifestations consistent with disseminated histoplasmosis, such as fever, fatigue, weight loss, and hepatosplenomegaly; </p> </li> <li> <p>histoplasma antigen assays;</p> </li> <li> <p>microscopic demonstration or isolation of <i>Histoplasma</i> from extrapulmonary sites; due to slow growth, isolation is likely to be too slow to allow diagnosis. </p> </li> </ul> </p> </section> <section id="CD013594-sec-0011"> <h3 class="title" id="CD013594-sec-0011">Description of the intervention</h3> <p>The current standard of care for PDH is typically based on Infectious Diseases Society of America 2007 guidelines (<a href="./references#CD013594-bbs2-0116" title="WheatLJ , FreifeldAG , KleimanMB , BaddleyJW , McKinseyDS , LoydJE , et al. Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. Clinical Infectious Diseases2007;45(7):807-25.">Wheat 2007</a>). This guideline recommends: </p> <p> <ul id="CD013594-list-0002"> <li> <p>for moderately severe to severe disease, liposomal amphotericin B (3.0 mg/kg daily for 1 to 2 weeks), followed by oral itraconazole (200 mg 3 times daily for 3 days and then 200 mg twice daily for a total of at least 12 months); </p> </li> <li> <p>for mild‐to‐moderate disease, itraconazole (200 mg 3 times daily for 3 days), and then twice daily for at least 12 months. </p> </li> </ul> </p> <p>Alongside treatment of PDH, HIV is treated with antiretroviral therapy (ART). Commencing ART might rapidly restore immune function. This may cause an excessive inflammatory response known as immune reconstitution inflammatory syndrome (IRIS) (<a href="./references#CD013594-bbs2-0011" title="MelzaniA , deReynal de Saint MichelR , NtabB , DjossouF , EpelboinL , NacherM , et al. Incidence and trends in immune reconstitution inflammatory syndrome associated with Histoplasma capsulatum among people living with HIV: a 20-year case series and literature review. Clinical Infectious Diseases2020;70(4):643-52. ">Melzani 2020</a>). </p> </section> <section id="CD013594-sec-0012"> <h3 class="title" id="CD013594-sec-0012">How the intervention might work</h3> <p>Azoles inhibit biosynthesis of ergosterol, which is essential in fungal cell membranes. Itraconazole, voriconazole, and posiconazole are thought to be fungicidal for histoplasma, but fluconazole is thought to have fungistatic activity only. Polyenes, such as amphotericin B, bind to fungal membrane sterols and disrupt cell membranes. They are thought to have fungicidal activity. Non‐randomized trial data from animal studies suggest that near maximal antifungal activity with amphotericin B occurs within three days, which has led to interest in shorter courses in treatment of other mycoses, such as cryptococcal meningitis (<a href="./references#CD013594-bbs2-0112" title="TenfordeMW , ShapiroAE , RouseB , JarvisJN , LiT , Eshun-WilsonI , et al. Treatment for HIV-associated cryptococcal meningitis. Cochrane Database of Systematic Reviews2018, Issue 7. [DOI: 10.1002/14651858.CD005647]">Tenforde 2018</a>). </p> </section> <section id="CD013594-sec-0013"> <h3 class="title" id="CD013594-sec-0013">Why it is important to do this review</h3> <p>Currently available guidelines for management of PDH date from 2007. These were designed for use by clinicians in the USA, a high‐resource country. The advent of widespread availability of ART internationally has changed treatment paradigms for HIV. In resource‐limited settings, there is interest in revisiting the optimal treatment options for PDH. This review summarizes available evidence, and in particular we aimed to understand if new evidence could inform updated international guidelines on PDH. </p> </section> </section> </section> <section class="objectives"> <div class="section-header section-collapse-header" id="CD013594-sec-0014" lang="en"> <h2 class="title section-collapse-title"> Objectives <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="objectives" lang="en"> <div class="section-header" id="CD013594-sec-0014"></div> <p><b>1. Induction.</b> To compare efficacy and safety of initial therapy with liposomal amphotericin B versus initial therapy with alternative antifungals. </p> <p><b>2. Maintenance.</b> To compare efficacy and safety of maintenance therapy with 12 months of oral antifungal treatment with shorter durations of maintenance therapy. (Please note, itraconazole is a preferred oral antifungal agent, see results.) </p> <p><b>3. Antiretroviral therapy (ART).</b> To compare the outcomes of early initiation of ART versus delayed initiation of ART. </p> </section> </section> <section class="methods"> <div class="section-header section-collapse-header" id="CD013594-sec-0015" lang="en"> <h2 class="title section-collapse-title"> Methods <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="methods" lang="en"> <div class="section-header" id="CD013594-sec-0015"></div> <section id="CD013594-sec-0016"> <h3 class="title">Criteria for considering studies for this review</h3> <section id="CD013594-sec-0017"> <h4 class="title">Types of studies</h4> <p>We planned to synthesize the study types in order of priority. At each stage, if we found a sufficient number of studies to allow a high‐certainty synthesis, we did not intend to progress further. As we did not find sufficient evidence to allow high‐certainty synthesis, our review includes the following study types: </p> <p> <ul id="CD013594-list-0003"> <li> <p>randomized controlled trials (RCTs);</p> </li> <li> <p>quasi‐RCTs/non‐RCTs;</p> </li> <li> <p>prospective cohort studies;</p> </li> <li> <p>retrospective cohort studies;</p> </li> <li> <p>single arm cohort studies.</p> </li> </ul> </p> <p>We excluded case reports and case series.</p> </section> <section id="CD013594-sec-0018"> <h4 class="title">Types of participants</h4> <p>HIV‐positive children, adolescents, and adults with a clinical diagnosis of PDH.</p> </section> <section id="CD013594-sec-0019"> <h4 class="title">Types of interventions</h4> <p>We aimed to make the following comparisons.</p> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Objective</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Intervention</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Comparisons</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1. Induction</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Liposomal amphotericin B (3.0 mg/kg daily) for 1–2 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Lipid complex amphotericin B<br/>Deoxycholate amphotericin B<br/>Other antifungal agents </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>2. Maintenance</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral antifungal treatment for &lt; 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Oral antifungal treatment for ≥ 12 months</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>3. ART</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Early initiation (within 4 weeks of commencing antifungal therapy)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Delayed initiation (&gt; 4 weeks after starting antifungal treatment)</p> </td> </tr> </tbody> </table> </div> </p> </section> <section id="CD013594-sec-0020"> <h4 class="title">Types of outcome measures</h4> <p>We collected data on key outcomes, as summarized in the table below.</p> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Objective</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Efficacy outcomes of interest</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Safety outcomes of interest</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>1. Induction</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical failure at or before study end</p> <p>Laboratory failure at or before study end</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Toxicity</p> <p>Early discontinuation</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>2. Maintenance</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relapse of histoplasmosis at 12 months, or other clinically important time points</p> <p>All‐cause mortality at 12 months</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Toxicity</p> <p>Early discontinuation</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>3. ART</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Incidence of immune reconstitution inflammatory syndrome</p> <p>Viral failure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Toxicity</p> <p>Early discontinuation</p> </td> </tr> </tbody> </table> </div> </p> <p>Where possible, we collected dichotomous and time‐to‐event data for relevant outcomes. We also collected data on mortality, and severe adverse events, including type and frequency. </p> </section> </section> <section id="CD013594-sec-0021"> <h3 class="title">Search methods for identification of studies</h3> <section id="CD013594-sec-0022"> <h4 class="title">Electronic searches</h4> <p>We developed our search strategy with the assistance of the Information Specialist, Vittoria Lutje. We searched the following databases on 20 March 2020 using the search terms and strategy described in <a href="./appendices#CD013594-sec-0072">Appendix 1</a>: Cochrane Infectious Diseases Group Specialized Register; Central Register of Controlled Trials (CENTRAL; 2020, Issue 3, published in the Cochrane Library); MEDLINE (PubMed, from 1966); Embase (Ovid, from 1947); Science Citation Index Expanded (SCI‐EXPANDED, from 1900), Conference Proceedings Citation Index‐Science (CPCI‐S, from 1900), and BIOSIS Previews (from 1926) (all three using the Web of Science platform). We also searched the World Health Organization International Clinical Trials Registry Platform (<a href="http://www.who.int/ictrp/search/en/" target="_blank">www.who.int/ictrp/search/en/</a>), ClinicalTrials.gov (<a href="http://clinicaltrials.gov/" target="_blank">clinicaltrials.gov/</a>), and the ISRCTN registry (<a href="http://www.isrctn.com/" target="_blank">www.isrctn.com/</a>) to identify ongoing studies. </p> </section> <section id="CD013594-sec-0023"> <h4 class="title">Searching other resources</h4> <p>We examined reference lists of relevant studies and reviews.</p> </section> </section> <section id="CD013594-sec-0024"> <h3 class="title" id="CD013594-sec-0024">Data collection and analysis</h3> <section id="CD013594-sec-0025"> <h4 class="title">Selection of studies</h4> <p>Two review authors (MM and PH) screened the titles and abstracts of the search results to determine eligibility using Covidence (<a href="https://www.covidence.org/" target="_blank">www.covidence.org/</a>). We did not perform double screening as we prepared the review rapidly to inform a guidelines meeting. We each assessed a random sample of the other author's screening. There were no disagreements. Both review authors screened the full texts of potentially eligible studies, and resolved any disagreement by discussion. At the time of full‐text screening, we categorized the studies by study design. </p> </section> <section id="CD013594-sec-0026"> <h4 class="title">Data extraction and management</h4> <p>One review author (PH) extracted data, and one review author (MM) reviewed all data extraction to ensure accuracy. </p> </section> <section id="CD013594-sec-0027"> <h4 class="title">Assessment of risk of bias in included studies</h4> <p>For each included study, both review authors performed a risk of bias assessment resolving any disagreements through discussion. We used the Cochrane 'Risk of bias' tool for RCTs. For non‐randomized studies, we used the Risk of Bias In Non‐Randomized Studies of Interventions (ROBINS‐I) tool. We developed a theoretical target study and assessed each non‐randomized study across up to seven domains. Each assessment was discontinued if a domain was deemed to be at critical risk of bias. Each outcome was assessed. We identified relevant confounding factors through investigation of the literature and in discussion with expert clinicians. These a priori factors included severity of disease (histoplasmosis and CD4 count); time to treatment; and, for objectives 2 and 3, adherence to ART/maintenance therapy for histoplasmosis. </p> </section> <section id="CD013594-sec-0028"> <h4 class="title">Data synthesis</h4> <section id="CD013594-sec-0029"> <h5 class="title">Narrative synthesis</h5> <p>We followed narrative synthesis methodology (<a href="./references#CD013594-bbs2-0104" title="PopayJ , RobertsH , SowdenA , et al. Guidance on the Conduct of Narrative Synthesis in Systematic Reviews. A Product from the ESRC Methods Programme2006.">Popay 2006</a>). Within this synthesis, we organized findings from included studies to describe patterns across the studies in terms of the: </p> <p> <ul id="CD013594-list-0004"> <li> <p>direction of effects;</p> </li> <li> <p>size of effects.</p> </li> </ul> </p> <p>We calculated 95% confidence intervals (CI) for binomial proportions. We calculated 95% CIs for risk ratios (RR) using Review Manager 5 (<a href="./references#CD013594-bbs2-0106" title="Nordic Cochrane Centre, The Cochrane CollaborationReview Manager 5 (RevMan 5). Version 5.3. Copenhagen: Nordic Cochrane Centre, The Cochrane Collaboration, 2014.">Review Manager 2014</a>). Studies assessed as at critical risk of bias were excluded from narrative synthesis. </p> </section> <section id="CD013594-sec-0030"> <h5 class="title">Quantitative synthesis</h5> <p>We did not identify trials that were sufficiently similar in design or outcomes to allow a meaningful meta‐analysis of outcome data. Therefore, we have not performed quantitative synthesis. </p> </section> </section> <section id="CD013594-sec-0031"> <h4 class="title">Exploring relationships in the data</h4> <p>We planned to explore relationships to consider the factors that might explain any differences in direction and size of effect across the included studies. For data included in narrative synthesis, we explored relationships using textual descriptions of key study elements (see <a href="./references#CD013594-sec-0095" title="">Characteristics of included studies</a> table), groupings and clusters of similar studies, and presentation of findings in tabulated form. </p> </section> <section id="CD013594-sec-0032"> <h4 class="title">Assessing the certainty of our conclusions</h4> <p>We planned to present adapted GRADE tables to summarize the certainty of our findings for each outcome. As we did not find good evidence to answer all objectives, we presented a GRADE table for outcomes relevant to 'Objective 1. Induction' detailing certainty of findings. We could not include any studies to answer 'Objective 2. Maintenance', so presented a narrative summary of indirect evidence in the body of the review only. We presented an additional summary table for 'Objective 3. ART'. </p> </section> </section> </section> </section> <section class="results"> <div class="section-header section-collapse-header" id="CD013594-sec-0033" lang="en"> <h2 class="title section-collapse-title"> Results <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="results" lang="en"> <div class="section-header" id="CD013594-sec-0033"></div> <section id="CD013594-sec-0034"> <h3 class="title">Description of studies</h3> <section id="CD013594-sec-0035"> <h4 class="title">Results of the search</h4> <p>We retrieved 1259 results from our electronic search. After title and abstract screening, we identified 206 reports for full‐text screening. Following full‐text screening, we identified 16 individual studies which were relevant to the review. These included: </p> <p> <ul id="CD013594-list-0005"> <li> <p>two RCTs (<a href="./references#CD013594-bbs2-0004" title="GrantPM , KomarowL , AndersenJ , SeretiI , PahwaS , LedermanMM , et al. Risk factor analyses for immune reconstitution inflammatory syndrome in a randomized study of early vs. deferred ART during an opportunistic infection. PloS One2010;5(7):e11416. ZolopaA , AndersenJ , PowderlyW , SanchezA , SanneI , SuckowC , et al. Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. PloS One2009;4(5):e5575. ">ACTG‐A5164, 2009</a>; <a href="./references#CD013594-bbs2-0008" title="JohnsonPC , WheatLJ , CloudGA , GoldmanM , LancasterD , BambergerDM , et al. Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS. Annals of Internal Medicine2002;137(2):105-9. WheatLJ , CloudG , JohnsonPC , ConnollyP , GoldmanM , Le MonteA , et al. Clearance of fungal burden during treatment of disseminated histoplasmosis with liposomal amphotericin B versus itraconazole. Antimicrobials Agents and Chemotherapy2001;45(8):2354-7. ">Johnson 2002</a>); </p> </li> <li> <p>four single arm trials (<a href="./references#CD013594-bbs2-0001" title="NCT00000992. A study of itraconazole in preventing the return of histoplasmosis, a fungal infection, in patients with AIDS [Pilot study to determine the feasibility of itraconazole for suppression of relapse of disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome]. clinicaltrials.gov/show/NCT00000992 (first received 1 August 2001). WheatJ , HafnerR , WulfsohnM , SpencerP , SquiresK , PowderlyW , et al. Prevention of relapse of histoplasmosis with itraconazole in patients with the acquired immunodeficiency syndrome. Annals of Internal Medicine1993;118(8):610-6. ">ACTG084, 1992</a>; <a href="./references#CD013594-bbs2-0002" title="HechtF , KorzunA , WheatJ , HafnerR . Itraconazole maintenance treatment for histoplasmosis in AIDS: prospective multi-center trial. Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy1995;35:241. HechtFM , WheatJ , KorzunAH , HafnerR , SkahanKJ , LarsenR , et al. Itraconazole maintenance treatment for histoplasmosis in AIDS: a prospective, multicenter trial. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology1997;16(2):100-7. NCT00000975. A study of itraconazole in the treatment and prevention of histoplasmosis, a fungal infection, in patients with AIDS [Pilot study to determine the feasibility of itraconazole for primary treatment and suppression of relapse of disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome]. clinicaltrials.gov/show/NCT00000975 (first received 31 August 2001). WheatJ , HafnerR , KorzunAH , LimjocoMT , SpencerP , LarsenRA , et al. Itraconazole treatment of disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome. AIDS Clinical Trial Group. American Journal of Medicine1995;98(4):336-42. WheatLJ , ConnollyP , HaddadN , Le MonteA , BrizendineE , HafnerR . Antigen clearance during treatment of disseminated histoplasmosis with itraconazole versus fluconazole in patients with AIDS. Antimicrobial Agents and Chemotherapy2002;46(1):248-50. ">ACTG120, 1992</a>; <a href="./references#CD013594-bbs2-0003" title="NCT00000627. Pilot study to determine the feasibility of fluconazole for induction treatment and suppression of relapse of histoplasmosis in patients with the acquired immunodeficiency syndrome. clinicaltrials.gov/show/NCT00000627 (first received 31 August 2001). WheatJ , MaWhinneyS , HafnerR , McKinseyD , ChenD , KorzunA , et al. Treatment of histoplasmosis with fluconazole in patients with acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Acquired Immunodeficiency Syndrome Clinical Trials Group and Mycoses Study Group. American Journal of Medicine1997;103(3):223-32. WheatLJ , ConnollyP , HaddadN , Le MonteA , BrizendineE , HafnerR . Antigen clearance during treatment of disseminated histoplasmosis with itraconazole versus fluconazole in patients with AIDS. Antimicrobial Agents and Chemotherapy2002;46(1):248-50. WheatLJ , ConnollyP , SmedemaM , BrizendineE , HafnerR . Emergence of resistance to fluconazole as a cause of failure during treatment of histoplasmosis in patients with acquired immunodeficiency disease syndrome. Clinical Infectious Diseases2001;33(11):1910-3. ">ACTG174, 1994</a>; <a href="./references#CD013594-bbs2-0010" title="McKinseyDS , GuptaMR , RiddlerSA , DriksMR , SmithDL , KurtinPJ . Long-term amphotericin B therapy for disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome (AIDS). Annals of Internal Medicine1989;111(8):655-9. ">McKinsey 1989</a>); </p> </li> <li> <p>four prospective cohort studies (<a href="./references#CD013594-bbs2-0005" title="BaddleyJW , SankaraIR , RodriquezJM , PappasPG , Many WJ Jr. Histoplasmosis in HIV-infected patients in a southern regional medical center: poor prognosis in the era of highly active antiretroviral therapy. Diagnostic Microbiology and Infectious Disease2008;62(2):151-6. ">Baddley 2008</a>; <a href="./references#CD013594-bbs2-0006" title="CouppiéP , SobeskyM , AznarC , BichatS , ClytiE , BissuelF , et al. Histoplasmosis and acquired immunodeficiency syndrome: a study of prognostic factors. Clinical Infectious Diseases2004;38(1):134-8. ">Couppié 2004</a>; <a href="./references#CD013594-bbs2-0007" title="GoldmanM , ZackinR , FichtenbaumCJ , SkiestDJ , KoletarSL , HafnerR , et al. Safety of discontinuation of maintenance therapy for disseminated histoplasmosis after immunologic response to antiretroviral therapy. Clinical Infectious Diseases2004;38(10):1485-9. NCT00006316. Withdrawal of antifungal treatment for histoplasmosis in patients after improved immune response to anti-HIV drugs [Discontinuation of antifungal therapy for histoplasmosis following immunologic response to antiretroviral therapy]. clinicaltrials.gov/show/NCT00006316 (first received 31 August 2001). ">Goldman 2004</a>; <a href="./references#CD013594-bbs2-0017" title="RamdialPK , MosamA , DlovaNC , SatarNB , AboobakerJ , SinghSM . Disseminated cutaneous histoplasmosis in patients infected with human immunodeficiency virus. Journal of Cutaneous Pathology2002;29(4):215-25. ">Ramdial 2002</a>); </p> </li> <li> <p>six retrospective cohort studies (<a href="./references#CD013594-bbs2-0009" title="LuckettK , DummerJS , MillerG , HesterS , ThomasL . Histoplasmosis in patients with cell-mediated immunodeficiency: human immunodeficiency virus infection, organ transplantation, and tumor necrosis factor-alpha inhibition. Open Forum Infectious Diseases2015;2(1):ofu116. ">Luckett 2015</a>; <a href="./references#CD013594-bbs2-0012" title="MootsikapunP , SrikulbutrS . Histoplasmosis and penicilliosis: comparison of clinical features, laboratory findings and outcome. International Journal of Infectious Diseases2006;10(1):66-71. ">Mootsikapun 2006</a>; <a href="./references#CD013594-bbs2-0013" title="MyintT , AndersonAM , SanchezA , FarabiA , HageC , BaddleyJW , et al. Histoplasmosis in patients with human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS): multicenter study of outcomes and factors associated with relapse. Medicine (Baltimore)2014;93(1):11-8. ">Myint 2014</a>; <a href="./references#CD013594-bbs2-0014" title="NegroniR , MessinaF , ArechavalaA , SantisoG , BianchiM . Efficacy of the treatment and secondary antifungal prophylaxis in AIDS-related histoplasmosis. Experience at the Francisco J. Muñiz Infectious Diseases Hospital in Buenos Aires. Revista Iberoamericana de Micologia2017;34(2):94-8. ">Negroni 2017</a>; <a href="./references#CD013594-bbs2-0015" title="NorrisS , WheatJ , McKinseyD , LancasterD , KatzB , BlackJ , et al. Prevention of relapse of histoplasmosis with fluconazole in patients with the acquired immunodeficiency syndrome. American Journal of Medicine1994;96(6):504-8. ">Norris 1994</a>; <a href="./references#CD013594-bbs2-0016" title="PietrobonD , Negro-MarquínezL , KilsteinJ , GalíndezJ , GrecaA , BattagliottiC . Disseminated histoplasmosis and AIDS in an Argentine hospital: clinical manifestations, diagnosis and treatment. Enfermedades Infecciosas y Microbiologia Clinica2004;22(3):156-9. ">Pietrobon 2004</a>). </p> </li> </ul> </p> <p>We have shown the results of our search in <a href="#CD013594-fig-0001">Figure 1</a>. </p> <div class="figure" id="CD013594-fig-0001"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 1</div> </div> <hr class="top"/><img alt="Review flow diagram." data-id="CD013594-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013594/media/CDSR/CD013594/image_n/nCD013594-FIG-01.png"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Review flow diagram.</p> </div> </div> </div> <p>We found one additional unpublished retrospective cohort study via correspondence with authors (<a href="./references#CD013594-bbs2-0011" title="MelzaniA , deReynal de Saint MichelR , NtabB , DjossouF , EpelboinL , NacherM , et al. Incidence and trends in immune reconstitution inflammatory syndrome associated with Histoplasma capsulatum among people living with HIV: a 20-year case series and literature review. Clinical Infectious Diseases2020;70(4):643-52. ">Melzani 2020</a>). </p> <p>Therefore, there were 17 individual studies. We excluded eight of these studies from analysis as we assessed them to be at critical risk of bias using ROBINS‐I methodology (<a href="#CD013594-tbl-0002">Table 1</a>). We listed these below. </p> <div class="table" id="CD013594-tbl-0002"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Table of studies at critical risk of bias overall (ROBINS‐I): disease‐related outcomes</span></div> <tbody> <tr> <th align="" class="headercell" colspan="4" rowspan="1" scope="col" valign=""> <p><b>Studies at critical risk of bias outcomes: death, relapse of histoplasmosis</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Review objective</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Domain</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comment</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013594-bbs2-0010" title="McKinseyDS , GuptaMR , RiddlerSA , DriksMR , SmithDL , KurtinPJ . Long-term amphotericin B therapy for disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome (AIDS). Annals of Internal Medicine1989;111(8):655-9. ">McKinsey 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 and 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Confounding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Confounding domains were not controlled for. No report of ART use, CD4 counts, or clinical condition of participants. Rationale for selection of treatment regimen not described. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013594-bbs2-0006" title="CouppiéP , SobeskyM , AznarC , BichatS , ClytiE , BissuelF , et al. Histoplasmosis and acquired immunodeficiency syndrome: a study of prognostic factors. Clinical Infectious Diseases2004;38(1):134-8. ">Couppié 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participant selection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Selection of intervention was made by the treating physician. As more severely ill participants were more likely to get AmB than ITRA selection was strongly related to the outcome. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013594-bbs2-0017" title="RamdialPK , MosamA , DlovaNC , SatarNB , AboobakerJ , SinghSM . Disseminated cutaneous histoplasmosis in patients infected with human immunodeficiency virus. Journal of Cutaneous Pathology2002;29(4):215-25. ">Ramdial 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Confounding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Confounders not addressed with respect to treatment regimens. Descriptive account provided of management of participants without detail on severity of conditions, comedications, or comorbidities. No information provided on time to treatment or duration of treatment. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013594-bbs2-0005" title="BaddleyJW , SankaraIR , RodriquezJM , PappasPG , Many WJ Jr. Histoplasmosis in HIV-infected patients in a southern regional medical center: poor prognosis in the era of highly active antiretroviral therapy. Diagnostic Microbiology and Infectious Disease2008;62(2):151-6. ">Baddley 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Confounding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Logistic regression used to determine association of variables with mortality including potential confounders, age, and race. Antifungal treatment data were not included in regression or reported in detail per participant. Authors reported 32/41 participants received ITRA, 22/41 dAmB, and 7/41 lAmB. Switches between medications were not reported. Authors reported 29 participants received ITRA after AmB. Denominator not reported. 8/13 participants who died were receiving an AmB preparation and 5/13 receiving ITRA. Time of transition from AmB to azole not reported. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013594-bbs2-0013" title="MyintT , AndersonAM , SanchezA , FarabiA , HageC , BaddleyJW , et al. Histoplasmosis in patients with human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS): multicenter study of outcomes and factors associated with relapse. Medicine (Baltimore)2014;93(1):11-8. ">Myint 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Confounding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Physician determined discontinuation of maintenance therapy may have been influenced by prognostic factors that were not controlled for. Multiple logistic regression used to determine variables associated with relapse; however, assignment to treatment arms were based on clinical assessment and viral load. 'Adherence to therapy' not defined. Unclear if this referred to ART, ITRA, or both. No evidence of adjustment for time‐varying confounding. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013594-bbs2-0014" title="NegroniR , MessinaF , ArechavalaA , SantisoG , BianchiM . Efficacy of the treatment and secondary antifungal prophylaxis in AIDS-related histoplasmosis. Experience at the Francisco J. Muñiz Infectious Diseases Hospital in Buenos Aires. Revista Iberoamericana de Micologia2017;34(2):94-8. ">Negroni 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Confounding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Comorbidity and comedications were not reported or controlled for. Outcome data were not linked to disease severity. Outcomes not reported by drug regimen. Treatment regimens varied by drug and duration. There were drug switches. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013594-bbs2-0015" title="NorrisS , WheatJ , McKinseyD , LancasterD , KatzB , BlackJ , et al. Prevention of relapse of histoplasmosis with fluconazole in patients with the acquired immunodeficiency syndrome. American Journal of Medicine1994;96(6):504-8. ">Norris 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Confounding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Authors reported no specific criteria to select participants for intervention. Criteria included unavailability of ITRA and preference for oral therapy. Intervention group determined by treating physicians who also evaluated clinical evidence of relapse and side effects. Severity of HIV, comorbidities and comedication were not reported. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013594-bbs2-0016" title="PietrobonD , Negro-MarquínezL , KilsteinJ , GalíndezJ , GrecaA , BattagliottiC . Disseminated histoplasmosis and AIDS in an Argentine hospital: clinical manifestations, diagnosis and treatment. Enfermedades Infecciosas y Microbiologia Clinica2004;22(3):156-9. ">Pietrobon 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Confounding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>For outcome 'relapse of histoplasmosis'</b>: follow‐up periods not reported. Duration of ITRA or FCN not reported. Switches between regimens not reported. Concurrent medication not reported. No statistical methods to control for confounding reported. </p> <p><b>For outcome 'death'</b>: this study can be considered to be at 'serious risk of bias'. No use of ART during treatment period. Comorbidities mentioned but unclear whether all relevant co morbidities studied. Severity of PDH not reported. No report of statistical methods to control for confounders. ≥ 1 known important domain was not appropriately measured or controlled for. Given the very small numbers, we have not reported further details in synthesis. </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>For details of risk of bias assessments see <a href="./appendices#CD013594-sec-0084">Appendix 3</a>. </p> <p>AmB: amphotericin B; ART: antiretroviral therapy; dAmB: deoxycholate amphotericin B; FCN: fluconazole; ITRA: itraconazole; lAmB: liposomal amphotericin B. </p> </div> </div> </section> <section id="CD013594-sec-0036"> <h4 class="title">Included studies</h4> <section id="CD013594-sec-0037"> <h5 class="title">1. Induction</h5> <p>From our search, the studies that gave information about relevant outcomes for induction therapies included: </p> <p> <ul id="CD013594-list-0006"> <li> <p>one RCT (<a href="./references#CD013594-bbs2-0008" title="JohnsonPC , WheatLJ , CloudGA , GoldmanM , LancasterD , BambergerDM , et al. Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS. Annals of Internal Medicine2002;137(2):105-9. WheatLJ , CloudG , JohnsonPC , ConnollyP , GoldmanM , Le MonteA , et al. Clearance of fungal burden during treatment of disseminated histoplasmosis with liposomal amphotericin B versus itraconazole. Antimicrobials Agents and Chemotherapy2001;45(8):2354-7. ">Johnson 2002</a>); </p> </li> <li> <p>two single arm trials (<a href="./references#CD013594-bbs2-0002" title="HechtF , KorzunA , WheatJ , HafnerR . Itraconazole maintenance treatment for histoplasmosis in AIDS: prospective multi-center trial. Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy1995;35:241. HechtFM , WheatJ , KorzunAH , HafnerR , SkahanKJ , LarsenR , et al. Itraconazole maintenance treatment for histoplasmosis in AIDS: a prospective, multicenter trial. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology1997;16(2):100-7. NCT00000975. A study of itraconazole in the treatment and prevention of histoplasmosis, a fungal infection, in patients with AIDS [Pilot study to determine the feasibility of itraconazole for primary treatment and suppression of relapse of disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome]. clinicaltrials.gov/show/NCT00000975 (first received 31 August 2001). WheatJ , HafnerR , KorzunAH , LimjocoMT , SpencerP , LarsenRA , et al. Itraconazole treatment of disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome. AIDS Clinical Trial Group. American Journal of Medicine1995;98(4):336-42. WheatLJ , ConnollyP , HaddadN , Le MonteA , BrizendineE , HafnerR . Antigen clearance during treatment of disseminated histoplasmosis with itraconazole versus fluconazole in patients with AIDS. Antimicrobial Agents and Chemotherapy2002;46(1):248-50. ">ACTG120, 1992</a>; <a href="./references#CD013594-bbs2-0003" title="NCT00000627. Pilot study to determine the feasibility of fluconazole for induction treatment and suppression of relapse of histoplasmosis in patients with the acquired immunodeficiency syndrome. clinicaltrials.gov/show/NCT00000627 (first received 31 August 2001). WheatJ , MaWhinneyS , HafnerR , McKinseyD , ChenD , KorzunA , et al. Treatment of histoplasmosis with fluconazole in patients with acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Acquired Immunodeficiency Syndrome Clinical Trials Group and Mycoses Study Group. American Journal of Medicine1997;103(3):223-32. WheatLJ , ConnollyP , HaddadN , Le MonteA , BrizendineE , HafnerR . Antigen clearance during treatment of disseminated histoplasmosis with itraconazole versus fluconazole in patients with AIDS. Antimicrobial Agents and Chemotherapy2002;46(1):248-50. WheatLJ , ConnollyP , SmedemaM , BrizendineE , HafnerR . Emergence of resistance to fluconazole as a cause of failure during treatment of histoplasmosis in patients with acquired immunodeficiency disease syndrome. Clinical Infectious Diseases2001;33(11):1910-3. ">ACTG174, 1994</a>); </p> </li> <li> <p>one retrospective cohort study (<a href="./references#CD013594-bbs2-0009" title="LuckettK , DummerJS , MillerG , HesterS , ThomasL . Histoplasmosis in patients with cell-mediated immunodeficiency: human immunodeficiency virus infection, organ transplantation, and tumor necrosis factor-alpha inhibition. Open Forum Infectious Diseases2015;2(1):ofu116. ">Luckett 2015</a>). </p> </li> </ul> </p> <p>The following studies were excluded from narrative synthesis as they were at critical risk of bias using ROBINS‐I methodology. </p> <p> <ul id="CD013594-list-0007"> <li> <p>one single arm trial (<a href="./references#CD013594-bbs2-0010" title="McKinseyDS , GuptaMR , RiddlerSA , DriksMR , SmithDL , KurtinPJ . Long-term amphotericin B therapy for disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome (AIDS). Annals of Internal Medicine1989;111(8):655-9. ">McKinsey 1989</a>); </p> </li> <li> <p>two prospective cohort studies (<a href="./references#CD013594-bbs2-0006" title="CouppiéP , SobeskyM , AznarC , BichatS , ClytiE , BissuelF , et al. Histoplasmosis and acquired immunodeficiency syndrome: a study of prognostic factors. Clinical Infectious Diseases2004;38(1):134-8. ">Couppié 2004</a>; <a href="./references#CD013594-bbs2-0017" title="RamdialPK , MosamA , DlovaNC , SatarNB , AboobakerJ , SinghSM . Disseminated cutaneous histoplasmosis in patients infected with human immunodeficiency virus. Journal of Cutaneous Pathology2002;29(4):215-25. ">Ramdial 2002</a>). </p> </li> </ul> </p> </section> <section id="CD013594-sec-0038"> <h5 class="title">2. Maintenance</h5> <p>From our search, the studies that gave information about relevant outcomes for maintenance therapies included: </p> <p> <ul id="CD013594-list-0008"> <li> <p>three single arm trials (<a href="./references#CD013594-bbs2-0001" title="NCT00000992. A study of itraconazole in preventing the return of histoplasmosis, a fungal infection, in patients with AIDS [Pilot study to determine the feasibility of itraconazole for suppression of relapse of disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome]. clinicaltrials.gov/show/NCT00000992 (first received 1 August 2001). WheatJ , HafnerR , WulfsohnM , SpencerP , SquiresK , PowderlyW , et al. Prevention of relapse of histoplasmosis with itraconazole in patients with the acquired immunodeficiency syndrome. Annals of Internal Medicine1993;118(8):610-6. ">ACTG084, 1992</a>; <a href="./references#CD013594-bbs2-0002" title="HechtF , KorzunA , WheatJ , HafnerR . Itraconazole maintenance treatment for histoplasmosis in AIDS: prospective multi-center trial. Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy1995;35:241. HechtFM , WheatJ , KorzunAH , HafnerR , SkahanKJ , LarsenR , et al. Itraconazole maintenance treatment for histoplasmosis in AIDS: a prospective, multicenter trial. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology1997;16(2):100-7. NCT00000975. A study of itraconazole in the treatment and prevention of histoplasmosis, a fungal infection, in patients with AIDS [Pilot study to determine the feasibility of itraconazole for primary treatment and suppression of relapse of disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome]. clinicaltrials.gov/show/NCT00000975 (first received 31 August 2001). WheatJ , HafnerR , KorzunAH , LimjocoMT , SpencerP , LarsenRA , et al. Itraconazole treatment of disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome. AIDS Clinical Trial Group. American Journal of Medicine1995;98(4):336-42. WheatLJ , ConnollyP , HaddadN , Le MonteA , BrizendineE , HafnerR . Antigen clearance during treatment of disseminated histoplasmosis with itraconazole versus fluconazole in patients with AIDS. Antimicrobial Agents and Chemotherapy2002;46(1):248-50. ">ACTG120, 1992</a>; <a href="./references#CD013594-bbs2-0003" title="NCT00000627. Pilot study to determine the feasibility of fluconazole for induction treatment and suppression of relapse of histoplasmosis in patients with the acquired immunodeficiency syndrome. clinicaltrials.gov/show/NCT00000627 (first received 31 August 2001). WheatJ , MaWhinneyS , HafnerR , McKinseyD , ChenD , KorzunA , et al. Treatment of histoplasmosis with fluconazole in patients with acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Acquired Immunodeficiency Syndrome Clinical Trials Group and Mycoses Study Group. American Journal of Medicine1997;103(3):223-32. WheatLJ , ConnollyP , HaddadN , Le MonteA , BrizendineE , HafnerR . Antigen clearance during treatment of disseminated histoplasmosis with itraconazole versus fluconazole in patients with AIDS. Antimicrobial Agents and Chemotherapy2002;46(1):248-50. WheatLJ , ConnollyP , SmedemaM , BrizendineE , HafnerR . Emergence of resistance to fluconazole as a cause of failure during treatment of histoplasmosis in patients with acquired immunodeficiency disease syndrome. Clinical Infectious Diseases2001;33(11):1910-3. ">ACTG174, 1994</a>); </p> </li> <li> <p>one prospective cohort study (<a href="./references#CD013594-bbs2-0007" title="GoldmanM , ZackinR , FichtenbaumCJ , SkiestDJ , KoletarSL , HafnerR , et al. Safety of discontinuation of maintenance therapy for disseminated histoplasmosis after immunologic response to antiretroviral therapy. Clinical Infectious Diseases2004;38(10):1485-9. NCT00006316. Withdrawal of antifungal treatment for histoplasmosis in patients after improved immune response to anti-HIV drugs [Discontinuation of antifungal therapy for histoplasmosis following immunologic response to antiretroviral therapy]. clinicaltrials.gov/show/NCT00006316 (first received 31 August 2001). ">Goldman 2004</a>); </p> </li> <li> <p>one retrospective cohort study (<a href="./references#CD013594-bbs2-0012" title="MootsikapunP , SrikulbutrS . Histoplasmosis and penicilliosis: comparison of clinical features, laboratory findings and outcome. International Journal of Infectious Diseases2006;10(1):66-71. ">Mootsikapun 2006</a>). </p> </li> </ul> </p> <p>The following studies were excluded from narrative synthesis as they were at critical risk of bias using ROBINS‐I methodology: </p> <p> <ul id="CD013594-list-0009"> <li> <p>one single arm trial (<a href="./references#CD013594-bbs2-0010" title="McKinseyDS , GuptaMR , RiddlerSA , DriksMR , SmithDL , KurtinPJ . Long-term amphotericin B therapy for disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome (AIDS). Annals of Internal Medicine1989;111(8):655-9. ">McKinsey 1989</a>); </p> </li> <li> <p>one prospective cohort study (<a href="./references#CD013594-bbs2-0005" title="BaddleyJW , SankaraIR , RodriquezJM , PappasPG , Many WJ Jr. Histoplasmosis in HIV-infected patients in a southern regional medical center: poor prognosis in the era of highly active antiretroviral therapy. Diagnostic Microbiology and Infectious Disease2008;62(2):151-6. ">Baddley 2008</a>); </p> </li> <li> <p>four retrospective cohort studies (<a href="./references#CD013594-bbs2-0013" title="MyintT , AndersonAM , SanchezA , FarabiA , HageC , BaddleyJW , et al. Histoplasmosis in patients with human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS): multicenter study of outcomes and factors associated with relapse. Medicine (Baltimore)2014;93(1):11-8. ">Myint 2014</a>; <a href="./references#CD013594-bbs2-0014" title="NegroniR , MessinaF , ArechavalaA , SantisoG , BianchiM . Efficacy of the treatment and secondary antifungal prophylaxis in AIDS-related histoplasmosis. Experience at the Francisco J. Muñiz Infectious Diseases Hospital in Buenos Aires. Revista Iberoamericana de Micologia2017;34(2):94-8. ">Negroni 2017</a>; <a href="./references#CD013594-bbs2-0015" title="NorrisS , WheatJ , McKinseyD , LancasterD , KatzB , BlackJ , et al. Prevention of relapse of histoplasmosis with fluconazole in patients with the acquired immunodeficiency syndrome. American Journal of Medicine1994;96(6):504-8. ">Norris 1994</a>; <a href="./references#CD013594-bbs2-0016" title="PietrobonD , Negro-MarquínezL , KilsteinJ , GalíndezJ , GrecaA , BattagliottiC . Disseminated histoplasmosis and AIDS in an Argentine hospital: clinical manifestations, diagnosis and treatment. Enfermedades Infecciosas y Microbiologia Clinica2004;22(3):156-9. ">Pietrobon 2004</a>). </p> </li> </ul> </p> </section> <section id="CD013594-sec-0039"> <h5 class="title">3. ART</h5> <p>We found one RCT which helped inform decisions regarding ART (<a href="./references#CD013594-bbs2-0004" title="GrantPM , KomarowL , AndersenJ , SeretiI , PahwaS , LedermanMM , et al. Risk factor analyses for immune reconstitution inflammatory syndrome in a randomized study of early vs. deferred ART during an opportunistic infection. PloS One2010;5(7):e11416. ZolopaA , AndersenJ , PowderlyW , SanchezA , SanneI , SuckowC , et al. Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. PloS One2009;4(5):e5575. ">ACTG‐A5164, 2009</a>). We included <a href="./references#CD013594-bbs2-0011" title="MelzaniA , deReynal de Saint MichelR , NtabB , DjossouF , EpelboinL , NacherM , et al. Incidence and trends in immune reconstitution inflammatory syndrome associated with Histoplasma capsulatum among people living with HIV: a 20-year case series and literature review. Clinical Infectious Diseases2020;70(4):643-52. ">Melzani 2020</a> in a narrative synthesis as it provided evidence of baseline risk, but could not directly inform the objective. </p> </section> </section> <section id="CD013594-sec-0040"> <h4 class="title">Excluded studies</h4> <p>We excluded 186 studies (including an RCT, single arm trials, prospective cohort studies, and retrospective cohort studies) after full‐text review. In the majority of cases, we were unable to extract relevant data from the study reports. We reported reasons for exclusion for a sample of 34 references in the <a href="./references#CD013594-sec-0096" title="">Characteristics of excluded studies</a> table. </p> </section> </section> <section id="CD013594-sec-0041"> <h3 class="title">Risk of bias in included studies</h3> <p>For the two randomized studies, risk of bias was low (<a href="./references#CD013594-bbs2-0008" title="JohnsonPC , WheatLJ , CloudGA , GoldmanM , LancasterD , BambergerDM , et al. Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS. Annals of Internal Medicine2002;137(2):105-9. WheatLJ , CloudG , JohnsonPC , ConnollyP , GoldmanM , Le MonteA , et al. Clearance of fungal burden during treatment of disseminated histoplasmosis with liposomal amphotericin B versus itraconazole. Antimicrobials Agents and Chemotherapy2001;45(8):2354-7. ">Johnson 2002</a> shown in <a href="#CD013594-tbl-0003">Table 2</a>; <a href="./references#CD013594-bbs2-0004" title="GrantPM , KomarowL , AndersenJ , SeretiI , PahwaS , LedermanMM , et al. Risk factor analyses for immune reconstitution inflammatory syndrome in a randomized study of early vs. deferred ART during an opportunistic infection. PloS One2010;5(7):e11416. ZolopaA , AndersenJ , PowderlyW , SanchezA , SanneI , SuckowC , et al. Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. PloS One2009;4(5):e5575. ">ACTG‐A5164, 2009</a> shown in <a href="#CD013594-tbl-0004">Table 3</a>). These are summarized in <a href="#CD013594-fig-0002">Figure 2</a>. </p> <div class="table" id="CD013594-tbl-0003"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Risk of bias Johnson 2002</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Bias</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Authors' judgement</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Support for judgement</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Random sequence generation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Authors reported randomizations in blocks. Details of method of randomization not provided </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Allocation concealment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Closed envelopes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blinding of participants and personnel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Authors reported that participants received the intervention and comparator by intravenous infusion "in a blinded fashion". It is possible that both participants and personnel were blinded. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blinding of outcome assessment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical and mycological outcomes were predetermined. These included objective components including temperature and laboratory findings. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Incomplete outcome data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reasons reported for missing data. Proportion of data missing from each group was similar. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Selective reporting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No protocol cited; however, reported outcomes are consistent with trial aims.</p> </td> </tr> </tbody> </table> </div> <div class="table" id="CD013594-tbl-0004"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Risk of bias ACTG‐A5164, 2009</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bias</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Authors' judgement</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Support for judgement</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Random sequence generation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Random sequence was generated by central computer using permuted blocks within strata. Neither block size nor treatment assignments to other sites were public. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Allocation concealment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No details provided in protocol or included study.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blinding of participants and personnel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Protocol stated that for arm B (deferred ART), no study‐provided drugs were to be provided initially hence blinding of participants and personnel was not possible. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blinding of outcome assessment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Primary outcome was a composite endpoint of survival and viral load. Detection bias was unlikely. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Incomplete outcome data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Equal numbers withdrew without primary endpoint data in each study arm. Details provided for these participants. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Selective reporting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported outcomes were consistent with protocol.</p> </td> </tr> </tbody> </table> </div> <div class="figure" id="CD013594-fig-0002"> <div class="figure-caption-wrapper-top"> <nav class="inline-nav-list has-dividers"> <ul> <li><a class="open-in-figure-viewer" href="#0">Open in figure viewer</a></li> </ul> </nav> <div class="figure-label">Figure 2</div> </div> <hr class="top"/><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included randomized study." data-id="CD013594-fig-0002" src="/cdsr/doi/10.1002/14651858.CD013594/media/CDSR/CD013594/image_n/nCD013594-FIG-02.svg"/><hr class="bottom"/> <div class="figure-caption-wrapper-bottom"> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included randomized study. </p> </div> </div> </div> <p>For the remaining 15 non‐randomized studies, we assessed eight to be at critical risk of bias using ROBINS‐I, and excluded these from synthesis as described above (<a href="#CD013594-tbl-0002">Table 1</a>). The remaining seven non‐randomized studies were at serious risk of bias using ROBINS‐I (<a href="#CD013594-tbl-0005">Table 4</a>). One study was at critical risk of bias for the relapse outcome, and serious risk of bias for the mortality outcome (<a href="./references#CD013594-bbs2-0016" title="PietrobonD , Negro-MarquínezL , KilsteinJ , GalíndezJ , GrecaA , BattagliottiC . Disseminated histoplasmosis and AIDS in an Argentine hospital: clinical manifestations, diagnosis and treatment. Enfermedades Infecciosas y Microbiologia Clinica2004;22(3):156-9. ">Pietrobon 2004</a>). We excluded this study from synthesis as the mortality outcome did not sufficiently inform the objective. </p> <div class="table" id="CD013594-tbl-0005"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Table of studies at serious risk of bias overall (ROBINS‐I): disease‐related outcomes</span></div> <tbody> <tr> <th align="" class="headercell" colspan="4" rowspan="1" scope="col" valign=""> <p><b>Studies at serious risk of bias outcomes: death, relapse of histoplasmosis</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Review objective</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Domain(s)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comment</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013594-bbs2-0002" title="HechtF , KorzunA , WheatJ , HafnerR . Itraconazole maintenance treatment for histoplasmosis in AIDS: prospective multi-center trial. Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy1995;35:241. HechtFM , WheatJ , KorzunAH , HafnerR , SkahanKJ , LarsenR , et al. Itraconazole maintenance treatment for histoplasmosis in AIDS: a prospective, multicenter trial. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology1997;16(2):100-7. NCT00000975. A study of itraconazole in the treatment and prevention of histoplasmosis, a fungal infection, in patients with AIDS [Pilot study to determine the feasibility of itraconazole for primary treatment and suppression of relapse of disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome]. clinicaltrials.gov/show/NCT00000975 (first received 31 August 2001). WheatJ , HafnerR , KorzunAH , LimjocoMT , SpencerP , LarsenRA , et al. Itraconazole treatment of disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome. AIDS Clinical Trial Group. American Journal of Medicine1995;98(4):336-42. WheatLJ , ConnollyP , HaddadN , Le MonteA , BrizendineE , HafnerR . Antigen clearance during treatment of disseminated histoplasmosis with itraconazole versus fluconazole in patients with AIDS. Antimicrobial Agents and Chemotherapy2002;46(1):248-50. ">ACTG120, 1992</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 and 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Confounding; participant selection; intervention classification</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severity of HIV; severity of PDH and comorbidities were not controlled for using appropriate statistical methodology. ART use at baseline of an earlier phase of the trial reported: those who responded to the intervention (ITRA) in the induction phase were selected for the intervention in the maintenance phase: participants started intervention at various doses and had reductions in dose made at variable intervals. While this was likely to have been informed by ITRA blood levels that were being monitored, detailed data were not provided per participant. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013594-bbs2-0003" title="NCT00000627. Pilot study to determine the feasibility of fluconazole for induction treatment and suppression of relapse of histoplasmosis in patients with the acquired immunodeficiency syndrome. clinicaltrials.gov/show/NCT00000627 (first received 31 August 2001). WheatJ , MaWhinneyS , HafnerR , McKinseyD , ChenD , KorzunA , et al. Treatment of histoplasmosis with fluconazole in patients with acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Acquired Immunodeficiency Syndrome Clinical Trials Group and Mycoses Study Group. American Journal of Medicine1997;103(3):223-32. WheatLJ , ConnollyP , HaddadN , Le MonteA , BrizendineE , HafnerR . Antigen clearance during treatment of disseminated histoplasmosis with itraconazole versus fluconazole in patients with AIDS. Antimicrobial Agents and Chemotherapy2002;46(1):248-50. WheatLJ , ConnollyP , SmedemaM , BrizendineE , HafnerR . Emergence of resistance to fluconazole as a cause of failure during treatment of histoplasmosis in patients with acquired immunodeficiency disease syndrome. Clinical Infectious Diseases2001;33(11):1910-3. ">ACTG174, 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 and 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Confounding; participant selection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At 3 months, protocol was revised and treatment regimen amended. Analyses were performed on participants who received the revised protocol (higher doses of FCN). Severity and management of HIV was not reported or controlled with appropriate statistical methods: selection into the maintenance arm of the study was related to the effect of the intervention in the induction phase. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013594-bbs2-0009" title="LuckettK , DummerJS , MillerG , HesterS , ThomasL . Histoplasmosis in patients with cell-mediated immunodeficiency: human immunodeficiency virus infection, organ transplantation, and tumor necrosis factor-alpha inhibition. Open Forum Infectious Diseases2015;2(1):ofu116. ">Luckett 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention classification; outcome measurement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No information about dose, frequency, and timing of interventions. Information was collected retrospectively. Treatment failure outcome was based on clinician judgement only. This was likely to favour switch from azole to amphotericin. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013594-bbs2-0001" title="NCT00000992. A study of itraconazole in preventing the return of histoplasmosis, a fungal infection, in patients with AIDS [Pilot study to determine the feasibility of itraconazole for suppression of relapse of disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome]. clinicaltrials.gov/show/NCT00000992 (first received 1 August 2001). WheatJ , HafnerR , WulfsohnM , SpencerP , SquiresK , PowderlyW , et al. Prevention of relapse of histoplasmosis with itraconazole in patients with the acquired immunodeficiency syndrome. Annals of Internal Medicine1993;118(8):610-6. ">ACTG084, 1992</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Confounding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severity of HIV infection and ART use were not controlled for with appropriate statistical methods. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013594-bbs2-0007" title="GoldmanM , ZackinR , FichtenbaumCJ , SkiestDJ , KoletarSL , HafnerR , et al. Safety of discontinuation of maintenance therapy for disseminated histoplasmosis after immunologic response to antiretroviral therapy. Clinical Infectious Diseases2004;38(10):1485-9. NCT00006316. Withdrawal of antifungal treatment for histoplasmosis in patients after improved immune response to anti-HIV drugs [Discontinuation of antifungal therapy for histoplasmosis following immunologic response to antiretroviral therapy]. clinicaltrials.gov/show/NCT00006316 (first received 31 August 2001). ">Goldman 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participant selection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Start of intervention varied – participants enrolled after a range of 14–81 months of antifungal therapy. Unclear how many eligible people were not enrolled. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013594-bbs2-0012" title="MootsikapunP , SrikulbutrS . Histoplasmosis and penicilliosis: comparison of clinical features, laboratory findings and outcome. International Journal of Infectious Diseases2006;10(1):66-71. ">Mootsikapun 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Confounding; participant selection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≥ 1 known important domain was not appropriately measured or controlled for: details of disease severity, comedications and comorbidities not provided for 27 participants discharged from hospital: maintenance therapy was commenced in those who responded to initial treatment on amphotericin B. Timing of start of maintenance therapy was not reported. Selection into this part of the study was related to the intervention. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013594-bbs2-0011" title="MelzaniA , deReynal de Saint MichelR , NtabB , DjossouF , EpelboinL , NacherM , et al. Incidence and trends in immune reconstitution inflammatory syndrome associated with Histoplasma capsulatum among people living with HIV: a 20-year case series and literature review. Clinical Infectious Diseases2020;70(4):643-52. ">Melzani 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Confounding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ART was discontinued in 2/22 participants at the physician's decision; 2/22 due to patient choice. In unmasking group (14 participants), 10/14 received lAmB and 4/14 received ITRA. Paradoxical group (8 participants) physicians continued ART and ITRA for 6/8. Rationale for treatment choices not reported. Appropriate statistical measures to control for confounding were not reported. ≥ 1 known important domain was not appropriately measured or controlled for. </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p>For details of risk of bias assessment see <a href="./appendices#CD013594-sec-0084">Appendix 3</a>. </p> <p>ART: antiretroviral therapy; FCN: fluconazole; ITRA: itraconazole; lAmB: liposomal amphotericin B; PDH: progressive disseminated histoplasmosis. </p> </div> </div> <p>Risk of bias was low in both included randomized studies (<a href="#CD013594-tbl-0003">Table 2</a>; <a href="#CD013594-tbl-0004">Table 3</a>; <a href="#CD013594-fig-0002">Figure 2</a>). Eight non‐randomized studies were at critical risk of bias and eight at serious risk of bias overall using ROBINS‐I. Details on assessment by outcome are provided in <a href="#CD013594-tbl-0002">Table 1</a> and <a href="#CD013594-tbl-0005">Table 4</a>. Detailed domain assessments are available in <a href="./appendices#CD013594-sec-0078">Appendix 2</a>. </p> </section> <section id="CD013594-sec-0042"> <h3 class="title" id="CD013594-sec-0042">Effects of interventions</h3> <p>See: <a href="./full#CD013594-tbl-0001"><b>Summary of findings 1</b> Induction: liposomal amphotericin compared with amphotericin deoxycholate</a> </p> <section id="CD013594-sec-0043"> <h4 class="title">1. Induction therapy for progressive disseminated histoplasmosis</h4> <section id="CD013594-sec-0044"> <h5 class="title">Liposomal amphotericin B compared to deoxycholate amphotericin B</h5> <p>One RCT compared liposomal amphotericin B and deoxycholate amphotericin B (<a href="./references#CD013594-bbs2-0008" title="JohnsonPC , WheatLJ , CloudGA , GoldmanM , LancasterD , BambergerDM , et al. Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS. Annals of Internal Medicine2002;137(2):105-9. WheatLJ , CloudG , JohnsonPC , ConnollyP , GoldmanM , Le MonteA , et al. Clearance of fungal burden during treatment of disseminated histoplasmosis with liposomal amphotericin B versus itraconazole. Antimicrobials Agents and Chemotherapy2001;45(8):2354-7. ">Johnson 2002</a>). There was greater treatment success with liposomal amphotericin B compared to deoxycholate amphotericin B (RR 1.46, 95% CI 1.01 to 2.11; 1 trial, 80 participants; <a href="./references#CD013594-fig-0003" title="">Analysis 1.1</a>). There were three deaths in the deoxycholate amphotericin B arm and one death in the liposomal amphotericin B arm (RR 0.15, 95% CI 0.02 to 1.38; 1 trial, 77 participants; <a href="./references#CD013594-fig-0004" title="">Analysis 1.2</a>). There were lower rates of nephrotoxicity (defined as creatinine greater than twice the upper limit of normal) with liposomal amphotericin B than with deoxycholate amphotericin B (RR 0.25, 95% CI 0.09 to 0.67; 1 trial, 77 participants; <a href="./references#CD013594-fig-0005" title="">Analysis 1.3</a>). The authors did not report other safety data, including frequencies of commonly reported toxicities such as anaemia. </p> </section> <section id="CD013594-sec-0045"> <h5 class="title">Liposomal amphotericin B compared to other antifungals</h5> <p>No RCTs compared liposomal amphotericin B to other antifungals.</p> <p>One retrospective cohort study compared all forms of amphotericin B to triazole therapy (including itraconazole, posaconazole, and voriconazole) (<a href="./references#CD013594-bbs2-0009" title="LuckettK , DummerJS , MillerG , HesterS , ThomasL . Histoplasmosis in patients with cell-mediated immunodeficiency: human immunodeficiency virus infection, organ transplantation, and tumor necrosis factor-alpha inhibition. Open Forum Infectious Diseases2015;2(1):ofu116. ">Luckett 2015</a>). Treatment success for triazoles was 83% (95% CI 62% to 95%). The report did not disaggregate data by disease severity, but reported that across the study (which included people who were immunocompromised for reasons other than HIV infection), frequency of triazole failure was similar among people with severe infection compared with those with mild‐to‐moderate infection. </p> </section> <section id="CD013594-sec-0046"> <h5 class="title">Deoxycholate amphotericin B compared to other antifungals</h5> <p>No study compared deoxycholate amphotericin B to other antifungals.</p> </section> <section id="CD013594-sec-0047"> <h5 class="title">Treatment success rates for other antifungals</h5> <p>In the absence of comparative studies, we reported treatment success rates for antifungal agents (see 'Narrative results table 1'). </p> <section id="CD013594-sec-0048"> <h6 class="title">Itraconazole</h6> <p>One single arm trial of itraconazole in mild‐to‐moderate PDH reported a treatment success rate of 85% (95% CI 73% to 93%; 1 study, 50/59 participants) at a dose of 300 mg twice daily for three days then 200 mg twice daily for 12 weeks (<a href="./references#CD013594-bbs2-0002" title="HechtF , KorzunA , WheatJ , HafnerR . Itraconazole maintenance treatment for histoplasmosis in AIDS: prospective multi-center trial. Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy1995;35:241. HechtFM , WheatJ , KorzunAH , HafnerR , SkahanKJ , LarsenR , et al. Itraconazole maintenance treatment for histoplasmosis in AIDS: a prospective, multicenter trial. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology1997;16(2):100-7. NCT00000975. A study of itraconazole in the treatment and prevention of histoplasmosis, a fungal infection, in patients with AIDS [Pilot study to determine the feasibility of itraconazole for primary treatment and suppression of relapse of disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome]. clinicaltrials.gov/show/NCT00000975 (first received 31 August 2001). WheatJ , HafnerR , KorzunAH , LimjocoMT , SpencerP , LarsenRA , et al. Itraconazole treatment of disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome. AIDS Clinical Trial Group. American Journal of Medicine1995;98(4):336-42. WheatLJ , ConnollyP , HaddadN , Le MonteA , BrizendineE , HafnerR . Antigen clearance during treatment of disseminated histoplasmosis with itraconazole versus fluconazole in patients with AIDS. Antimicrobial Agents and Chemotherapy2002;46(1):248-50. ">ACTG120, 1992</a>). </p> </section> <section id="CD013594-sec-0049"> <h6 class="title">Fluconazole</h6> <p>One single arm trial of fluconazole reported a treatment success rate of 74% (95% CI 59% to 85%; 1 study, 36 successes of 49 participants), at a dose of 1600 mg on day one, then 800 mg once daily for 12 weeks (<a href="./references#CD013594-bbs2-0003" title="NCT00000627. Pilot study to determine the feasibility of fluconazole for induction treatment and suppression of relapse of histoplasmosis in patients with the acquired immunodeficiency syndrome. clinicaltrials.gov/show/NCT00000627 (first received 31 August 2001). WheatJ , MaWhinneyS , HafnerR , McKinseyD , ChenD , KorzunA , et al. Treatment of histoplasmosis with fluconazole in patients with acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Acquired Immunodeficiency Syndrome Clinical Trials Group and Mycoses Study Group. American Journal of Medicine1997;103(3):223-32. WheatLJ , ConnollyP , HaddadN , Le MonteA , BrizendineE , HafnerR . Antigen clearance during treatment of disseminated histoplasmosis with itraconazole versus fluconazole in patients with AIDS. Antimicrobial Agents and Chemotherapy2002;46(1):248-50. WheatLJ , ConnollyP , SmedemaM , BrizendineE , HafnerR . Emergence of resistance to fluconazole as a cause of failure during treatment of histoplasmosis in patients with acquired immunodeficiency disease syndrome. Clinical Infectious Diseases2001;33(11):1910-3. ">ACTG174, 1994</a>). This study initially reported a treatment success rate of 80% (95% CI 56% to 94%; 16 successes of 20 participants) for fluconazole 1600 mg on day one followed by 600 mg once daily for eight weeks. However, the protocol was intensified when relapse was subsequently observed in 6/16 participants (37.5%, 95% CI 15% to 64%). </p> </section> </section> <section id="CD013594-sec-0050"> <h5 class="title">Narrative results: table 1: induction therapy</h5> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Method</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Participants</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Interventions</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Primary outcome(s)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Setting</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Disease severity</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Overall risk of bias</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Narrative of efficacy findings (95% CIs)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Narrative of safety findings</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013594-bbs2-0002" title="HechtF , KorzunA , WheatJ , HafnerR . Itraconazole maintenance treatment for histoplasmosis in AIDS: prospective multi-center trial. Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy1995;35:241. HechtFM , WheatJ , KorzunAH , HafnerR , SkahanKJ , LarsenR , et al. Itraconazole maintenance treatment for histoplasmosis in AIDS: a prospective, multicenter trial. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology1997;16(2):100-7. NCT00000975. A study of itraconazole in the treatment and prevention of histoplasmosis, a fungal infection, in patients with AIDS [Pilot study to determine the feasibility of itraconazole for primary treatment and suppression of relapse of disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome]. clinicaltrials.gov/show/NCT00000975 (first received 31 August 2001). WheatJ , HafnerR , KorzunAH , LimjocoMT , SpencerP , LarsenRA , et al. Itraconazole treatment of disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome. AIDS Clinical Trial Group. American Journal of Medicine1995;98(4):336-42. WheatLJ , ConnollyP , HaddadN , Le MonteA , BrizendineE , HafnerR . Antigen clearance during treatment of disseminated histoplasmosis with itraconazole versus fluconazole in patients with AIDS. Antimicrobial Agents and Chemotherapy2002;46(1):248-50. ">ACTG120, 1992</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single arm trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>59 with PDH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ITRA 300 mg BD for 3 days then 200 mg BD for 12 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Response to therapy"</p> <p>Death</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mild to moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical success:</b> </p> <p>50/59 participants</p> <p>85% (73% to 93%)</p> <p><b>Death:</b> </p> <p>1/59</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2/59 participants withdrew due to adverse events, and responded to AmB.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013594-bbs2-0003" title="NCT00000627. Pilot study to determine the feasibility of fluconazole for induction treatment and suppression of relapse of histoplasmosis in patients with the acquired immunodeficiency syndrome. clinicaltrials.gov/show/NCT00000627 (first received 31 August 2001). WheatJ , MaWhinneyS , HafnerR , McKinseyD , ChenD , KorzunA , et al. Treatment of histoplasmosis with fluconazole in patients with acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Acquired Immunodeficiency Syndrome Clinical Trials Group and Mycoses Study Group. American Journal of Medicine1997;103(3):223-32. WheatLJ , ConnollyP , HaddadN , Le MonteA , BrizendineE , HafnerR . Antigen clearance during treatment of disseminated histoplasmosis with itraconazole versus fluconazole in patients with AIDS. Antimicrobial Agents and Chemotherapy2002;46(1):248-50. WheatLJ , ConnollyP , SmedemaM , BrizendineE , HafnerR . Emergence of resistance to fluconazole as a cause of failure during treatment of histoplasmosis in patients with acquired immunodeficiency disease syndrome. Clinical Infectious Diseases2001;33(11):1910-3. ">ACTG174, 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single arm trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49 with PDH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><i><b>Initial protocol</b> </i> </p> <p>FCN 1200 mg, then 600 mg OD for 8 weeks</p> <p><i><b>Revised protocol</b> </i> </p> <p>FCN 1200 mg, then 80 mg OD for 8 weeks</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>"Treatment response"</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mild to moderate</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical success:</b> </p> <p>36/49 participants.</p> <p>74% (59% to 85%)</p> <p><i>Revised protocol</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 discontinuations due to toxicity, unclear if induction or maintenance.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013594-bbs2-0008" title="JohnsonPC , WheatLJ , CloudGA , GoldmanM , LancasterD , BambergerDM , et al. Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS. Annals of Internal Medicine2002;137(2):105-9. WheatLJ , CloudG , JohnsonPC , ConnollyP , GoldmanM , Le MonteA , et al. Clearance of fungal burden during treatment of disseminated histoplasmosis with liposomal amphotericin B versus itraconazole. Antimicrobials Agents and Chemotherapy2001;45(8):2354-7. ">Johnson 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>81 with PDH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>lAmB (55 participants)</p> <p>dAmB (26 participants)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Efficacy: "Clinical success"</p> <p>Safety: early discontinuation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Moderate to severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical success:</b> </p> <p>lAmB: 82% (69% to 91%)</p> <p>45/55 participants.</p> <p>dAmB: 56% (37% to 76%)</p> <p>14/25 participants.</p> <p>RR 1.46</p> <p>(1.01 to 2.11)</p> <p><b>Death:</b> </p> <p>lAmB: 1/53 (2%)</p> <p>dAmB: 3/24 (13%)</p> <p>RR 0.15</p> <p>(0.02 to 1.38)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Early discontinuation:</b> 1/53 (2%) with lAmB vs 2/24 (8%) with dAmB </p> <p>RR 0.23</p> <p>(95% CI 0.02 to 2.38)</p> <p><b>Nephrotoxicity:</b> 5/53 (9%) with lAmB vs 9/24 (37%) with dAmB </p> <p>RR 0.25</p> <p>(95% CI 0.09 to 0.67)</p> <p>Of note, authors did not report specific data in relation to other commonly recognized adverse effects, including anaemia. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013594-bbs2-0009" title="LuckettK , DummerJS , MillerG , HesterS , ThomasL . Histoplasmosis in patients with cell-mediated immunodeficiency: human immunodeficiency virus infection, organ transplantation, and tumor necrosis factor-alpha inhibition. Open Forum Infectious Diseases2015;2(1):ofu116. ">Luckett 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Retrospective cohort study</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>56 with HIV and PDH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ITRA/VORI/POSA</p> <p>AmB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Death</p> <p>(90‐day histoplasmosis‐related)</p> <p>Triazole failure</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Mild to severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Death</b> </p> <p>5/56 participants.</p> <p>Not reported by treatment regimen.</p> <p><b>Clinical success:</b> </p> <p>triazole induction successful in 20/24 participants</p> <p>83% (62% to 95%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No safety issues reported.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="10" rowspan="1" valign=""> <p>AmB: amphotericin B; BD: twice daily; CI: confidence interval; dAmB: deoxycholate amphotericin B; FCN: fluconazole; ITRA: itraconazole; IAmB: liposomal amphotericin B; n: number of participants; OD: once daily; PDH: progressive disseminated histoplasmosis; POSA: posaconazole; RCT: randomized controlled trial; RR: risk ratio; VORI: voriconazole. </p> </td> </tr> </tbody> </table> </div> </p> </section> </section> <section id="CD013594-sec-0051"> <h4 class="title">2. Maintenance therapy</h4> <section id="CD013594-sec-0052"> <h5 class="title">Less than 12 months of oral itraconazole compared to 12 months or greater of oral itraconazole </h5> <p>No included study compared less than 12 months of oral itraconazole and 12 months or greater of oral itraconazole. </p> </section> <section id="CD013594-sec-0053"> <h5 class="title">Continuation of antifungals versus discontinuation of antifungals</h5> <p>This result is summarized in <a href="#CD013594-tbl-0006">Table 5</a>. </p> <div class="table" id="CD013594-tbl-0006"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Additional summary 1: amphotericin B formulations versus azoles</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>Early ART compared with deferred ART for PDH in HIV</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with HIV and progressive disseminated histoplasmosis </p> <p><b>Settings:</b> endemic areas </p> <p><b>Intervention:</b> induction therapy with triazoles </p> <p><b>Comparison:</b> induction therapy with amphotericin B formulations </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Narrative summary</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Treatment success</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No RCTs make direct comparisons of amphotericin B and triazoles. Treatment success of triazoles (other than fluconazole) were 83% and 85% in the 2 studies which reported them. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p>ART: antiretroviral therapy; PDH: progressive disseminated histoplasmosis; RCT: randomized controlled trial. </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>Downgraded two levels for serious imprecision. The CIs are wide due to small numbers of participants.<br/><sup>b</sup>Downgraded one level for serious indirectness. No studies report direct comparisons. </p> </div> </div> <p>One prospective single‐arm cohort study followed a cohort of participants who discontinued antifungal therapy after at least 12 months, providing the participant had received at least six months of ART and had achieved a CD4 count of 150 cells/μL or greater (<a href="./references#CD013594-bbs2-0007" title="GoldmanM , ZackinR , FichtenbaumCJ , SkiestDJ , KoletarSL , HafnerR , et al. Safety of discontinuation of maintenance therapy for disseminated histoplasmosis after immunologic response to antiretroviral therapy. Clinical Infectious Diseases2004;38(10):1485-9. NCT00006316. Withdrawal of antifungal treatment for histoplasmosis in patients after improved immune response to anti-HIV drugs [Discontinuation of antifungal therapy for histoplasmosis following immunologic response to antiretroviral therapy]. clinicaltrials.gov/show/NCT00006316 (first received 31 August 2001). ">Goldman 2004</a>). There were no relapses in 32 participants who discontinued therapy after 12 months. </p> </section> <section id="CD013594-sec-0054"> <h5 class="title">Treatment success rates for modalities of maintenance therapies</h5> <p>'Narrative results table 2' indicates crude treatment success rates for different maintenance therapies used in studies. </p> <section id="CD013594-sec-0055"> <h6 class="title">Itraconazole</h6> <p>Two single arm trials reported low relapse rates of approximately 0.5% with itraconazole (<a href="./references#CD013594-bbs2-0001" title="NCT00000992. A study of itraconazole in preventing the return of histoplasmosis, a fungal infection, in patients with AIDS [Pilot study to determine the feasibility of itraconazole for suppression of relapse of disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome]. clinicaltrials.gov/show/NCT00000992 (first received 1 August 2001). WheatJ , HafnerR , WulfsohnM , SpencerP , SquiresK , PowderlyW , et al. Prevention of relapse of histoplasmosis with itraconazole in patients with the acquired immunodeficiency syndrome. Annals of Internal Medicine1993;118(8):610-6. ">ACTG084, 1992</a>; <a href="./references#CD013594-bbs2-0002" title="HechtF , KorzunA , WheatJ , HafnerR . Itraconazole maintenance treatment for histoplasmosis in AIDS: prospective multi-center trial. Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy1995;35:241. HechtFM , WheatJ , KorzunAH , HafnerR , SkahanKJ , LarsenR , et al. Itraconazole maintenance treatment for histoplasmosis in AIDS: a prospective, multicenter trial. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology1997;16(2):100-7. NCT00000975. A study of itraconazole in the treatment and prevention of histoplasmosis, a fungal infection, in patients with AIDS [Pilot study to determine the feasibility of itraconazole for primary treatment and suppression of relapse of disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome]. clinicaltrials.gov/show/NCT00000975 (first received 31 August 2001). WheatJ , HafnerR , KorzunAH , LimjocoMT , SpencerP , LarsenRA , et al. Itraconazole treatment of disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome. AIDS Clinical Trial Group. American Journal of Medicine1995;98(4):336-42. WheatLJ , ConnollyP , HaddadN , Le MonteA , BrizendineE , HafnerR . Antigen clearance during treatment of disseminated histoplasmosis with itraconazole versus fluconazole in patients with AIDS. Antimicrobial Agents and Chemotherapy2002;46(1):248-50. ">ACTG120, 1992</a>). </p> </section> <section id="CD013594-sec-0056"> <h6 class="title">Fluconazole</h6> <p>One single arm trial was discontinued early due to higher relapse rates (11/36 participants; 30%, 95% CI 16% to 48%) (<a href="./references#CD013594-bbs2-0003" title="NCT00000627. Pilot study to determine the feasibility of fluconazole for induction treatment and suppression of relapse of histoplasmosis in patients with the acquired immunodeficiency syndrome. clinicaltrials.gov/show/NCT00000627 (first received 31 August 2001). WheatJ , MaWhinneyS , HafnerR , McKinseyD , ChenD , KorzunA , et al. Treatment of histoplasmosis with fluconazole in patients with acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Acquired Immunodeficiency Syndrome Clinical Trials Group and Mycoses Study Group. American Journal of Medicine1997;103(3):223-32. WheatLJ , ConnollyP , HaddadN , Le MonteA , BrizendineE , HafnerR . Antigen clearance during treatment of disseminated histoplasmosis with itraconazole versus fluconazole in patients with AIDS. Antimicrobial Agents and Chemotherapy2002;46(1):248-50. WheatLJ , ConnollyP , SmedemaM , BrizendineE , HafnerR . Emergence of resistance to fluconazole as a cause of failure during treatment of histoplasmosis in patients with acquired immunodeficiency disease syndrome. Clinical Infectious Diseases2001;33(11):1910-3. ">ACTG174, 1994</a>). This trial used 400 mg doses of fluconazole after induction with fluconazole. </p> </section> </section> <section id="CD013594-sec-0057"> <h5 class="title">Narrative results table 2: maintenance therapy</h5> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Method</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Participants</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Interventions</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Primary outcomes</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Setting</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Disease severity</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Overall risk of bias</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Narrative of efficacy findings</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Narrative of safety findings</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="10" rowspan="1" valign="top"> <p><b>Studies assessing discontinuation of oral antifungals</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013594-bbs2-0007" title="GoldmanM , ZackinR , FichtenbaumCJ , SkiestDJ , KoletarSL , HafnerR , et al. Safety of discontinuation of maintenance therapy for disseminated histoplasmosis after immunologic response to antiretroviral therapy. Clinical Infectious Diseases2004;38(10):1485-9. NCT00006316. Withdrawal of antifungal treatment for histoplasmosis in patients after improved immune response to anti-HIV drugs [Discontinuation of antifungal therapy for histoplasmosis following immunologic response to antiretroviral therapy]. clinicaltrials.gov/show/NCT00006316 (first received 31 August 2001). ">Goldman 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Prospective cohort study (single arm)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>32</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Discontinuation after &gt; 12 months of ITRA/FCN/AmB</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relapse after 1 year</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≥ 6 months of ART.</p> <p>CD4 count &lt; 150 cells/μL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No relapses after 12 months of discontinuation of antifungal therapy.</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No safety issues reported.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="10" rowspan="1" valign="top"> <p><b>Studies reporting outcomes of maintenance therapy regimens</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013594-bbs2-0001" title="NCT00000992. A study of itraconazole in preventing the return of histoplasmosis, a fungal infection, in patients with AIDS [Pilot study to determine the feasibility of itraconazole for suppression of relapse of disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome]. clinicaltrials.gov/show/NCT00000992 (first received 1 August 2001). WheatJ , HafnerR , WulfsohnM , SpencerP , SquiresK , PowderlyW , et al. Prevention of relapse of histoplasmosis with itraconazole in patients with the acquired immunodeficiency syndrome. Annals of Internal Medicine1993;118(8):610-6. ">ACTG084, 1992</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single arm trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>42 (after dAmB induction)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ITRA 200 mg BD; continuous</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relapse</p> <p>Death</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No ART</p> <p>Median CD4 count 47 cells/μL</p> <p>(35 participants)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Relapse:</b> </p> <p>2/42 participants (0.5%, 95% CI 0.05% to 16%)</p> <p>Median follow‐up 98 weeks</p> <p><b>Death:</b> </p> <p>1/42 deaths attributed to PDH</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Treatment discontinuation in 1/42 participants</p> <p>Severe or life‐threatening adverse events in 37/42 participants, attributed mainly to HIV infection, opportunistic infections, and adverse effects of other medications. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013594-bbs2-0002" title="HechtF , KorzunA , WheatJ , HafnerR . Itraconazole maintenance treatment for histoplasmosis in AIDS: prospective multi-center trial. Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy1995;35:241. HechtFM , WheatJ , KorzunAH , HafnerR , SkahanKJ , LarsenR , et al. Itraconazole maintenance treatment for histoplasmosis in AIDS: a prospective, multicenter trial. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology1997;16(2):100-7. NCT00000975. A study of itraconazole in the treatment and prevention of histoplasmosis, a fungal infection, in patients with AIDS [Pilot study to determine the feasibility of itraconazole for primary treatment and suppression of relapse of disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome]. clinicaltrials.gov/show/NCT00000975 (first received 31 August 2001). WheatJ , HafnerR , KorzunAH , LimjocoMT , SpencerP , LarsenRA , et al. Itraconazole treatment of disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome. AIDS Clinical Trial Group. American Journal of Medicine1995;98(4):336-42. WheatLJ , ConnollyP , HaddadN , Le MonteA , BrizendineE , HafnerR . Antigen clearance during treatment of disseminated histoplasmosis with itraconazole versus fluconazole in patients with AIDS. Antimicrobial Agents and Chemotherapy2002;46(1):248-50. ">ACTG120, 1992</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single arm trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>46 (of 59 enrolled)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ITRA 200 mg (26 participants)</p> <p>ITRA 400 mg (18 participants)</p> <p>ITRA 600 mg (2 participants)</p> <p>4 participants remained on doses &gt; 200 mg.</p> <p>Median duration 64 weeks (range 7–120 weeks)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relapse</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No ART</p> <p>Median CD4 29 cells/µL</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Relapse:</b> </p> <p>2/46 participants</p> <p>(0.4%, 95% CI 0.05% to 14%)</p> <p>Median follow‐up 87 weeks</p> <p><b>Death:</b> </p> <p>1/46 deaths due to relapse</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Treatment discontinuation in 8/46 participants.</p> <p>24/46 participants enrolled known to have died, including discontinuations; pre‐ART.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013594-bbs2-0003" title="NCT00000627. Pilot study to determine the feasibility of fluconazole for induction treatment and suppression of relapse of histoplasmosis in patients with the acquired immunodeficiency syndrome. clinicaltrials.gov/show/NCT00000627 (first received 31 August 2001). WheatJ , MaWhinneyS , HafnerR , McKinseyD , ChenD , KorzunA , et al. Treatment of histoplasmosis with fluconazole in patients with acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Acquired Immunodeficiency Syndrome Clinical Trials Group and Mycoses Study Group. American Journal of Medicine1997;103(3):223-32. WheatLJ , ConnollyP , HaddadN , Le MonteA , BrizendineE , HafnerR . Antigen clearance during treatment of disseminated histoplasmosis with itraconazole versus fluconazole in patients with AIDS. Antimicrobial Agents and Chemotherapy2002;46(1):248-50. WheatLJ , ConnollyP , SmedemaM , BrizendineE , HafnerR . Emergence of resistance to fluconazole as a cause of failure during treatment of histoplasmosis in patients with acquired immunodeficiency disease syndrome. Clinical Infectious Diseases2001;33(11):1910-3. ">ACTG174, 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Single arm trial</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>49 with PDH, 36 entered maintenance therapy</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>FCN 400 mg Continuous</p> <p>Median duration 30 weeks <i>(early termination of study)</i> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Relapse</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No ART</p> <p>Mild to severe</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Serious</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Relapse:</b> </p> <p>11/36 participants (30%, 95% CI 16% to 48%)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2 discontinuations due to toxicity, unclear if induction or maintenance.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="10" rowspan="1" valign=""> <p>AmB: amphotericin B; ART: antiretroviral therapy; BD: twice daily; dAmB: deoxycholate amphotericin B; FCN: fluconazole; ITRA: itraconazole; n: number of participants; PDH: progressive disseminated histoplasmosis. </p> </td> </tr> </tbody> </table> </div> </p> </section> </section> <section id="CD013594-sec-0058"> <h4 class="title">3. ART initiation</h4> <p>One trial compared early ART initiation to late ART initiation in people with coexisting opportunistic infections (<a href="./references#CD013594-bbs2-0004" title="GrantPM , KomarowL , AndersenJ , SeretiI , PahwaS , LedermanMM , et al. Risk factor analyses for immune reconstitution inflammatory syndrome in a randomized study of early vs. deferred ART during an opportunistic infection. PloS One2010;5(7):e11416. ZolopaA , AndersenJ , PowderlyW , SanchezA , SanneI , SuckowC , et al. Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. PloS One2009;4(5):e5575. ">ACTG‐A5164, 2009</a>). There were 10/282 participants with a presumptive or confirmed diagnosis of histoplasmosis. No diagnostic criteria were given for histoplasmosis. One participant with histoplasmosis in each trial arm developed IRIS. Both survived. One out of seven participants in the early ART died by day 30. None of the three participants with histoplasmosis in the delayed group died by day 30. This result is summarized in 'Narrative results table 3' and <a href="#CD013594-tbl-0007">Table 6</a>. </p> <div class="table" id="CD013594-tbl-0007"> <table><a class="open-table-viewer open-in-figure-viewer" href="#0">Open in table viewer</a><div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Additional summary 2: early versus deferred ART</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Early ART compared with deferred ART for PDH in HIV</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with HIV and progressive disseminated histoplasmosis </p> <p><b>Settings:</b> endemic areas </p> <p><b>Intervention:</b> early ART (&lt; 14 days) </p> <p><b>Comparison:</b> late ART (&gt; 14 days) </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative risks</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IRIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/3 participants<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/7 participants<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.43</b> </p> <p>(0.04 to 4.82)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know if early ART increases the risk of IRIS in people with HIV and PDH.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>ART: antiretroviral therapy; IRIS: immune reconstitution inflammatory syndrome; PDH: progressive disseminated histoplasmosis; RCT: randomized controlled trial; RR: risk ratio. </p> </td> </tr> </tbody> </table> <div class="table-footnote"> <p><sup>a</sup>1/3 people with histoplasmosis in deferred ART arm developed histoplasma IRIS (day 47). 1/7 people with histoplasmosis in early ART arm developed hepatitis C IRIS (day 14).<br/><sup>b</sup>Downgraded two levels for serious imprecision. The CI was wide.<br/><sup>c</sup>Downgraded one level for serious indirectness. The trial only included 10 participants with histoplasmosis and the case definitions were not stated. </p> </div> </div> <p>One additional study reported crude incidence rates of histoplasma IRIS including paradoxical IRIS (flare‐up of a previously treated histoplasmosis) (<a href="./references#CD013594-bbs2-0011" title="MelzaniA , deReynal de Saint MichelR , NtabB , DjossouF , EpelboinL , NacherM , et al. Incidence and trends in immune reconstitution inflammatory syndrome associated with Histoplasma capsulatum among people living with HIV: a 20-year case series and literature review. Clinical Infectious Diseases2020;70(4):643-52. ">Melzani 2020</a>). This indicated an overall incidence rate of 0.74 cases per 1000 person‐years. This study does not directly answer the objective of early versus deferred ART, but provides an indication of baseline risk. </p> <section id="CD013594-sec-0059"> <h5 class="title">Narrative results table 3: antiretroviral initiation</h5> <p> <div class="table" id=""> <table> <div class="table-heading"><span class="table-title"></span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Method</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Participants</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Interventions</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Setting</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Disease severity</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Overall risk of bias</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Narrative of findings</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013594-bbs2-0004" title="GrantPM , KomarowL , AndersenJ , SeretiI , PahwaS , LedermanMM , et al. Risk factor analyses for immune reconstitution inflammatory syndrome in a randomized study of early vs. deferred ART during an opportunistic infection. PloS One2010;5(7):e11416. ZolopaA , AndersenJ , PowderlyW , SanchezA , SanneI , SuckowC , et al. Early antiretroviral therapy reduces AIDS progression/death in individuals with acute opportunistic infections: a multicenter randomized strategy trial. PloS One2009;4(5):e5575. ">ACTG‐A5164, 2009</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>RCT</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>282, AIDS‐related opportunist infections</p> <p>10 people with histoplasmosis</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Early ART (n 7)</p> <p>Deferred ART (n 3)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Primary</b>: composite endpoint of death and HIV viral load. </p> <p><b>Safety</b>: IRIS; lab adverse events Grades 2–4; clinical adverse events Grades 2‐4. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>USA, South Africa</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Baseline<br/>median CD4 count<br/>29 (IQR 10–55) cells/μL </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/7 participants with histoplasmosis dies in the early ART group.</p> <p>0/3 participants with histoplasmosis died in the deferred ART group.</p> <p>1/3 people with histoplasmosis in deferred ART arm developed histoplasma IRIS (day 47). IRIS aetiology: hepatitis C. Survived. </p> <p>1/7 people with histoplasmosis in early ART arm developed hepatitis C IRIS (day 14). IRIS aetiology: histoplasmosis. Survived. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="9" rowspan="1" valign=""> <p>ART: antiretroviral therapy; IQR: interquartile range; IRIS: immune reconstitution inflammatory syndrome. </p> </td> </tr> </tbody> </table> </div> </p> </section> </section> </section> </section> </section> <section class="discussion"> <div class="section-header section-collapse-header" id="CD013594-sec-0060" lang="en"> <h2 class="title section-collapse-title"> Discussion <i aria-hidden="true" class="fa fa-caret-up section-collapse-icon"></i> </h2> </div> <section class="discussion" lang="en"> <div class="section-header" id="CD013594-sec-0060"></div> <section id="CD013594-sec-0061"> <h3 class="title" id="CD013594-sec-0061">Summary of main results</h3> <p>For 'Objective 1. Induction' comparing liposomal amphotericin B to other antifungals, four studies met the inclusion criteria: one RCT with 81 participants and three non‐randomized studies with 164 participants. We judged all three non‐randomized studies at serious risk of bias. Compared to deoxycholate amphotericin B, liposomal amphotericin B may have higher clinical success rates (low‐certainty evidence), and has lower rates of nephrotoxicity (high‐certainty evidence). We do not know if all amphotericin B formulations are more effective than azoles for the induction phase of management (very low‐certainty evidence). </p> <p>For 'Objective 2. Maintenance', comparing less than 12 months of oral antifungal treatment to greater than 12 months, no studies met the inclusion criteria. </p> <p>For both objectives 1 and 2, fluconazole performed poorly in comparison to other azoles in the single‐arm trial which studied this (<a href="./references#CD013594-bbs2-0003" title="NCT00000627. Pilot study to determine the feasibility of fluconazole for induction treatment and suppression of relapse of histoplasmosis in patients with the acquired immunodeficiency syndrome. clinicaltrials.gov/show/NCT00000627 (first received 31 August 2001). WheatJ , MaWhinneyS , HafnerR , McKinseyD , ChenD , KorzunA , et al. Treatment of histoplasmosis with fluconazole in patients with acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Acquired Immunodeficiency Syndrome Clinical Trials Group and Mycoses Study Group. American Journal of Medicine1997;103(3):223-32. WheatLJ , ConnollyP , HaddadN , Le MonteA , BrizendineE , HafnerR . Antigen clearance during treatment of disseminated histoplasmosis with itraconazole versus fluconazole in patients with AIDS. Antimicrobial Agents and Chemotherapy2002;46(1):248-50. WheatLJ , ConnollyP , SmedemaM , BrizendineE , HafnerR . Emergence of resistance to fluconazole as a cause of failure during treatment of histoplasmosis in patients with acquired immunodeficiency disease syndrome. Clinical Infectious Diseases2001;33(11):1910-3. ">ACTG174, 1994</a>). No further trials were done as there was no longer sufficient equipoise to justify this. </p> <p>'Objective 3: ART' sought to compare early and delayed initiation of ART. One RCT with 282 participants met the inclusion criteria. Only 10 participants had coexisting HIV and a presumptive or confirmed diagnosis of PDH. By day 30, one of seven participants in the 'early' arm and none of the three participants in the 'late' arm died. We do not know the efficacy and safety outcomes of early versus late initiation of ART (very low‐certainty evidence). </p> </section> <section id="CD013594-sec-0062"> <h3 class="title" id="CD013594-sec-0062">Overall completeness and applicability of evidence</h3> <p>The overall evidence was limited; therefore, we were unable to address all the objectives of our review. Most studies were in the USA and such findings may not be generalizable to low‐resource settings as availability of liposomal amphotericin B and management of HIV may differ. This affects the external validity of our review. There is insufficient evidence to be confident that azoles and other formulations of amphotericin are as effective and safe as liposomal amphotericin B in the induction phase of the management of PDH in people living with HIV. Clinical practice may be governed by availability. Current clinical practice would indicate that shorter courses of maintenance therapy may be acceptable; however, there is insufficient evidence available to corroborate or refute this practice. There is insufficient evidence to be confident of the safety of discontinuation of maintenance therapy before 12 months or the timing of ART. Overall, clinical practice tends to favour early ART in most situations. The low rates of IRIS in the single RCT do not present a signal that this practice is unsafe; however, there is insufficient evidence to confirm this. It seems that people in resource‐limited settings are doing what they are able to do. </p> </section> <section id="CD013594-sec-0063"> <h3 class="title" id="CD013594-sec-0063">Certainty of the evidence</h3> <p>Overall, the certainty of the evidence for most outcomes was low or very low. Non‐randomized study designs predominate in this area of research, many of which were critically compromised by uncontrolled confounding. For the comparison of liposomal amphotericin B to deoxycholate amphotericin B for induction therapy, there was high‐certainty evidence of lower rates of nephrotoxicity (RR 0.25, 95% CI 0.09 to 0.67; 1 study, 77 participants). Evidence for clinical success for this comparison was of low certainty due to very serious imprecision indicating that further research is very likely to have an important impact on our confidence in the estimate of effect (RR 1.46, 95% CI 1.01 to 2.11; 1 study, 80 participants). For maintenance regimens, all six studies were of a non‐randomized design, at serious risk of bias, and they could only provide low‐certainty evidence. </p> </section> <section id="CD013594-sec-0064"> <h3 class="title" id="CD013594-sec-0064">Potential biases in the review process</h3> <p>To minimize the effect of all domains of bias in the non‐randomized studies we presented only those at serious risk of bias. There is little evidence available from populations outside the USA. </p> </section> <section id="CD013594-sec-0065"> <h3 class="title" id="CD013594-sec-0065">Agreements and disagreements with other studies or reviews</h3> <p>Liposomal amphotericin B has previously been found to be significantly safer than conventional amphotericin B with respect to renal toxicity in PDH. One systematic review published in 2015 studying any invasive fungal infections reported an effect size of RR 0.49 (95% CI 0.40 to 0.59; 12 studies, 2298 participants; <a href="./references#CD013594-bbs2-0064" title="Botero AguirreJP , Restrepo HamidAM . Amphotericin B deoxycholate versus liposomal amphotericin B: effects on kidney function. Cochrane Database of Systematic Reviews2015, Issue 11. [DOI: 10.1002/14651858.CD010481]">Botero Aguirre 2015</a>). </p> <p>There is insufficient evidence to confidently challenge or concur with current clinical guidelines on duration of maintenance therapy (<a href="./references#CD013594-bbs2-0116" title="WheatLJ , FreifeldAG , KleimanMB , BaddleyJW , McKinseyDS , LoydJE , et al. Clinical practice guidelines for the management of patients with histoplasmosis: 2007 update by the Infectious Diseases Society of America. Clinical Infectious Diseases2007;45(7):807-25.">Wheat 2007</a>). </p> <p>One systematic review that investigated the effects of early versus late ART in participants with coexisting HIV and cryptococcal meningitis found the RR for development of IRIS to be 3.56 (95% CI 0.51 to 25.02, 2 RCTs). The authors graded this evidence as very‐low certainty due to imprecision, risk of bias, and indirectness indicating that they had little confidence in the effect estimate. This is consistent with the certainty of our findings for this outcome although the effect size of our included study was considerably smaller (RR 0.43, 95% CI 0.04 to 4.82; 1 study, 10 participants). This study also concluded that the risk of death appeared to be higher with early ART, leading to World Health Organization recommendations that treatment should be deferred for four to six weeks (<a href="./references#CD013594-bbs2-0071" title="Eshun-WilsonI , OkwenMP , RichardsonM , BicanicT . Early versus delayed antiretroviral treatment in HIV-positive people with cryptococcal meningitis. Cochrane Database of Systematic Reviews2018, Issue 7. [DOI: 10.1002/14651858.CD009012.pub3]">Eshun‐Wilson 2018</a>). </p> </section> </section> </section> <div class="figures-list"> <div class="figure" id="CD013594-fig-0001"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013594/media/CDSR/CD013594/urn:x-wiley:14651858:media:CD013594:CD013594-FIG-01" target="_blank"><b></b></a></p> </div><img alt="Review flow diagram." data-id="CD013594-fig-0001" src="/cdsr/doi/10.1002/14651858.CD013594/media/CDSR/CD013594/image_n/nCD013594-FIG-01.png"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013594/media/CDSR/CD013594/image_t/tCD013594-FIG-01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 1</div> <div class="figure-caption"> <p>Review flow diagram.</p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013594/full#CD013594-fig-0001">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013594/media/CDSR/CD013594/image_n/nCD013594-FIG-01.png" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013594-fig-0002"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013594/media/CDSR/CD013594/urn:x-wiley:14651858:media:CD013594:CD013594-FIG-02" target="_blank"><b></b></a></p> </div><img alt="Risk of bias summary: review authors' judgements about each risk of bias item for each included randomized study." data-id="CD013594-fig-0002" src="/cdsr/doi/10.1002/14651858.CD013594/media/CDSR/CD013594/image_n/nCD013594-FIG-02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013594/media/CDSR/CD013594/image_t/tCD013594-FIG-02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Figure 2</div> <div class="figure-caption"> <p>Risk of bias summary: review authors' judgements about each risk of bias item for each included randomized study. </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013594/full#CD013594-fig-0002">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013594/media/CDSR/CD013594/image_n/nCD013594-FIG-02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013594-fig-0003"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013594/media/CDSR/CD013594/urn:x-wiley:14651858:media:CD013594:CD013594-CMP-001.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Liposomal amphotericin B (lAmB) versus deoxycholate amphotericin B (dAmB), Outcome 1: Clinical success" data-id="CD013594-fig-0003" src="/cdsr/doi/10.1002/14651858.CD013594/media/CDSR/CD013594/image_n/nCD013594-CMP-001.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013594/media/CDSR/CD013594/image_t/tCD013594-CMP-001.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.1</div> <div class="figure-caption"> <p>Comparison 1: Liposomal amphotericin B (lAmB) versus deoxycholate amphotericin B (dAmB), Outcome 1: Clinical success </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013594/references#CD013594-fig-0003">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013594/media/CDSR/CD013594/image_n/nCD013594-CMP-001.01.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013594-fig-0004"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013594/media/CDSR/CD013594/urn:x-wiley:14651858:media:CD013594:CD013594-CMP-001.02" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Liposomal amphotericin B (lAmB) versus deoxycholate amphotericin B (dAmB), Outcome 2: Death" data-id="CD013594-fig-0004" src="/cdsr/doi/10.1002/14651858.CD013594/media/CDSR/CD013594/image_n/nCD013594-CMP-001.02.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013594/media/CDSR/CD013594/image_t/tCD013594-CMP-001.02.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.2</div> <div class="figure-caption"> <p>Comparison 1: Liposomal amphotericin B (lAmB) versus deoxycholate amphotericin B (dAmB), Outcome 2: Death </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013594/references#CD013594-fig-0004">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013594/media/CDSR/CD013594/image_n/nCD013594-CMP-001.02.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013594-fig-0005"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013594/media/CDSR/CD013594/urn:x-wiley:14651858:media:CD013594:CD013594-CMP-001.03" target="_blank"><b></b></a></p> </div><img alt="Comparison 1: Liposomal amphotericin B (lAmB) versus deoxycholate amphotericin B (dAmB), Outcome 3: Safety outcomes" data-id="CD013594-fig-0005" src="/cdsr/doi/10.1002/14651858.CD013594/media/CDSR/CD013594/image_n/nCD013594-CMP-001.03.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013594/media/CDSR/CD013594/image_t/tCD013594-CMP-001.03.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 1.3</div> <div class="figure-caption"> <p>Comparison 1: Liposomal amphotericin B (lAmB) versus deoxycholate amphotericin B (dAmB), Outcome 3: Safety outcomes </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013594/references#CD013594-fig-0005">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013594/media/CDSR/CD013594/image_n/nCD013594-CMP-001.03.svg" target="_blank">Open in new tab</a></div> </div> <div class="figure" id="CD013594-fig-0006"> <div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013594/media/CDSR/CD013594/urn:x-wiley:14651858:media:CD013594:CD013594-CMP-002.01" target="_blank"><b></b></a></p> </div><img alt="Comparison 2: Early antiretroviral therapy (ART) versus deferred ART, Outcome 1: Immune reconstitution inflammatory syndrome" data-id="CD013594-fig-0006" src="/cdsr/doi/10.1002/14651858.CD013594/media/CDSR/CD013594/image_n/nCD013594-CMP-002.01.svg"/><div> <p><a class="external" href="/cdsr/doi/10.1002/14651858.CD013594/media/CDSR/CD013594/image_t/tCD013594-CMP-002.01.png" target="_blank"><b></b></a></p> </div> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="figure-viewer-caption"> <div class="figure-label">Analysis 2.1</div> <div class="figure-caption"> <p>Comparison 2: Early antiretroviral therapy (ART) versus deferred ART, Outcome 1: Immune reconstitution inflammatory syndrome </p> </div> </div> <div class="tools"><a class="scolaris-systematic-reviews" href="https://training.cochrane.org/essentials/module-4-understanding-using-systematic-reviews" target="_blank">Using systematic reviews (free)</a><a class="figureList" href="/cdsr/doi/10.1002/14651858.CD013594/references#CD013594-fig-0006">Navigate to figure in review</a><button class="print-figure" href="#">Print figure</button><a class="figure-viewer-isolate" href="/cdsr/doi/10.1002/14651858.CD013594/media/CDSR/CD013594/image_n/nCD013594-CMP-002.01.svg" target="_blank">Open in new tab</a></div> </div> </div> <div class="tables-list"> <div class="table"> <table class="summary-of-findings framed" data-id="CD013594-tbl-0001"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Induction: liposomal amphotericin compared with amphotericin deoxycholate</span></div> <tbody> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Liposomal amphotericin compared with amphotericin deoxycholate for induction therapy of progressive disseminated histoplasmosis</b> </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with HIV and progressive disseminated histoplasmosis </p> <p><b>Settings:</b> endemic areas </p> <p><b>Intervention:</b> induction therapy with liposomal amphotericin B </p> <p><b>Comparison:</b> amphotericin B deoxycholate </p> </td> </tr> <tr class="separated"> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell table-tint" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative comparative risks* (95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Number of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="3" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Assumed risk</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Corresponding risk</b> </p> </th> </tr> <tr class="separated"> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>dAmB</b> </p> </th> <th align="" class="headercell table-tint" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>lAmB</b> </p> </th> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Clinical success</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>560 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>818 per 1000</b><br/>(566 to 1000) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 1.46</b><br/>(1.01 to 2.11) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>80<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝<br/><b>Low</b><sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Compared to dAmB, lAmB may have higher clinical success rates.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Death</b> </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>125 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>19 per 1000</b><br/>(3 to 173) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.15</b><br/>(0.02 to 1.38) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊝⊝</p> <p><b>Low</b><sup>b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Treatment with lAmB may result in lower mortality than treatment with dAmB.</p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Safety outcomes:</b> nephrotoxicity </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>375 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>94 per 1000</b><br/>(34 to 251) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.25</b><br/>(0.09 to 0.67) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊕⊕⊕</p> <p><b>High</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Treatment with lAmB resulted in lower rates of nephrotoxicity compared to treatment with dAmB; this was supported by findings of a Cochrane Review which reported moderate‐certainty evidence (<a href="./references#CD013594-bbs2-0064" title="Botero AguirreJP , Restrepo HamidAM . Amphotericin B deoxycholate versus liposomal amphotericin B: effects on kidney function. Cochrane Database of Systematic Reviews2015, Issue 11. [DOI: 10.1002/14651858.CD010481]">Botero Aguirre 2015</a>). </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Safety outcomes:</b> drug discontinuation </p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p>83 per 1000</p> </td> <td align="" class="table-tint table-highlight" colspan="1" rowspan="1" valign="top"> <p><b>19 per 1000</b><br/>(2 to 198) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.23</b><br/>(0.02 to 2.38) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>77<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝<br/><b>Very low</b><sup>c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know if treatment with lAmB leads to fewer treatment discontinuations than dAmB. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>*The basis for the <b>assumed risk</b> (e.g. the median control group risk across studies) is provided in footnotes. The <b>corresponding risk</b> (and its 95% CI) is based on the assumed risk in the comparison group and the <b>relative effect</b> of the intervention (and its 95% CI). </p> <p><b>CI:</b> confidence interval; <b>dAmB:</b> deoxycholate amphotericin B; <b>lAmB:</b> liposomal amphotericin B; <b>RR:</b> risk ratio. </p> </td> </tr> <tr class="separated"> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>GRADE</b> Working Group grades of evidence<br/><b>High certainty:</b> further research is very unlikely to change our confidence in the estimate of effect.<br/><b>Moderate certainty:</b> further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.<br/><b>Low certainty:</b> further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.<br/><b>Very low certainty:</b> we are very uncertain about the estimate. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>Downgraded two levels for very serious imprecision: the CI met the line of no effect and was based on very few events (73 participants, 1 randomized controlled trial).<br/><sup>b</sup>Downgraded two levels for very serious imprecision: the CIs were wide and crossed the line of no effect.<br/><sup>c</sup>Downgraded one level for serious risk of bias (due to unclear reporting criteria) and two levels for very serious imprecision (the CIs were wide and crossed the line of no effect). </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Summary of findings 1.</span> <span class="table-title">Induction: liposomal amphotericin compared with amphotericin deoxycholate</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013594/full#CD013594-tbl-0001">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013594-tbl-0002"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Table of studies at critical risk of bias overall (ROBINS‐I): disease‐related outcomes</span></div> <tbody> <tr> <th align="" class="headercell" colspan="4" rowspan="1" scope="col" valign=""> <p><b>Studies at critical risk of bias outcomes: death, relapse of histoplasmosis</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Review objective</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Domain</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comment</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013594-bbs2-0010" title="McKinseyDS , GuptaMR , RiddlerSA , DriksMR , SmithDL , KurtinPJ . Long-term amphotericin B therapy for disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome (AIDS). Annals of Internal Medicine1989;111(8):655-9. ">McKinsey 1989</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 and 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Confounding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Confounding domains were not controlled for. No report of ART use, CD4 counts, or clinical condition of participants. Rationale for selection of treatment regimen not described. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013594-bbs2-0006" title="CouppiéP , SobeskyM , AznarC , BichatS , ClytiE , BissuelF , et al. Histoplasmosis and acquired immunodeficiency syndrome: a study of prognostic factors. Clinical Infectious Diseases2004;38(1):134-8. ">Couppié 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participant selection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Selection of intervention was made by the treating physician. As more severely ill participants were more likely to get AmB than ITRA selection was strongly related to the outcome. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013594-bbs2-0017" title="RamdialPK , MosamA , DlovaNC , SatarNB , AboobakerJ , SinghSM . Disseminated cutaneous histoplasmosis in patients infected with human immunodeficiency virus. Journal of Cutaneous Pathology2002;29(4):215-25. ">Ramdial 2002</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Confounding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Confounders not addressed with respect to treatment regimens. Descriptive account provided of management of participants without detail on severity of conditions, comedications, or comorbidities. No information provided on time to treatment or duration of treatment. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013594-bbs2-0005" title="BaddleyJW , SankaraIR , RodriquezJM , PappasPG , Many WJ Jr. Histoplasmosis in HIV-infected patients in a southern regional medical center: poor prognosis in the era of highly active antiretroviral therapy. Diagnostic Microbiology and Infectious Disease2008;62(2):151-6. ">Baddley 2008</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Confounding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Logistic regression used to determine association of variables with mortality including potential confounders, age, and race. Antifungal treatment data were not included in regression or reported in detail per participant. Authors reported 32/41 participants received ITRA, 22/41 dAmB, and 7/41 lAmB. Switches between medications were not reported. Authors reported 29 participants received ITRA after AmB. Denominator not reported. 8/13 participants who died were receiving an AmB preparation and 5/13 receiving ITRA. Time of transition from AmB to azole not reported. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013594-bbs2-0013" title="MyintT , AndersonAM , SanchezA , FarabiA , HageC , BaddleyJW , et al. Histoplasmosis in patients with human immunodeficiency virus/acquired immunodeficiency syndrome (HIV/AIDS): multicenter study of outcomes and factors associated with relapse. Medicine (Baltimore)2014;93(1):11-8. ">Myint 2014</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Confounding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Physician determined discontinuation of maintenance therapy may have been influenced by prognostic factors that were not controlled for. Multiple logistic regression used to determine variables associated with relapse; however, assignment to treatment arms were based on clinical assessment and viral load. 'Adherence to therapy' not defined. Unclear if this referred to ART, ITRA, or both. No evidence of adjustment for time‐varying confounding. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013594-bbs2-0014" title="NegroniR , MessinaF , ArechavalaA , SantisoG , BianchiM . Efficacy of the treatment and secondary antifungal prophylaxis in AIDS-related histoplasmosis. Experience at the Francisco J. Muñiz Infectious Diseases Hospital in Buenos Aires. Revista Iberoamericana de Micologia2017;34(2):94-8. ">Negroni 2017</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Confounding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Comorbidity and comedications were not reported or controlled for. Outcome data were not linked to disease severity. Outcomes not reported by drug regimen. Treatment regimens varied by drug and duration. There were drug switches. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013594-bbs2-0015" title="NorrisS , WheatJ , McKinseyD , LancasterD , KatzB , BlackJ , et al. Prevention of relapse of histoplasmosis with fluconazole in patients with the acquired immunodeficiency syndrome. American Journal of Medicine1994;96(6):504-8. ">Norris 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Confounding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Authors reported no specific criteria to select participants for intervention. Criteria included unavailability of ITRA and preference for oral therapy. Intervention group determined by treating physicians who also evaluated clinical evidence of relapse and side effects. Severity of HIV, comorbidities and comedication were not reported. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013594-bbs2-0016" title="PietrobonD , Negro-MarquínezL , KilsteinJ , GalíndezJ , GrecaA , BattagliottiC . Disseminated histoplasmosis and AIDS in an Argentine hospital: clinical manifestations, diagnosis and treatment. Enfermedades Infecciosas y Microbiologia Clinica2004;22(3):156-9. ">Pietrobon 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Confounding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>For outcome 'relapse of histoplasmosis'</b>: follow‐up periods not reported. Duration of ITRA or FCN not reported. Switches between regimens not reported. Concurrent medication not reported. No statistical methods to control for confounding reported. </p> <p><b>For outcome 'death'</b>: this study can be considered to be at 'serious risk of bias'. No use of ART during treatment period. Comorbidities mentioned but unclear whether all relevant co morbidities studied. Severity of PDH not reported. No report of statistical methods to control for confounders. ≥ 1 known important domain was not appropriately measured or controlled for. Given the very small numbers, we have not reported further details in synthesis. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p>For details of risk of bias assessments see <a href="./appendices#CD013594-sec-0084">Appendix 3</a>. </p> <p>AmB: amphotericin B; ART: antiretroviral therapy; dAmB: deoxycholate amphotericin B; FCN: fluconazole; ITRA: itraconazole; lAmB: liposomal amphotericin B. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 1.</span> <span class="table-title">Table of studies at critical risk of bias overall (ROBINS‐I): disease‐related outcomes</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013594/full#CD013594-tbl-0002">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013594-tbl-0003"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Risk of bias Johnson 2002</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Bias</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Authors' judgement</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Support for judgement</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Random sequence generation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Authors reported randomizations in blocks. Details of method of randomization not provided </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Allocation concealment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Closed envelopes</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blinding of participants and personnel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Authors reported that participants received the intervention and comparator by intravenous infusion "in a blinded fashion". It is possible that both participants and personnel were blinded. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blinding of outcome assessment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Clinical and mycological outcomes were predetermined. These included objective components including temperature and laboratory findings. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Incomplete outcome data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reasons reported for missing data. Proportion of data missing from each group was similar. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Selective reporting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low risk</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No protocol cited; however, reported outcomes are consistent with trial aims.</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 2.</span> <span class="table-title">Risk of bias Johnson 2002</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013594/full#CD013594-tbl-0003">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013594-tbl-0004"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Risk of bias ACTG‐A5164, 2009</span></div> <tbody> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Bias</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Authors' judgement</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign=""> <p><b>Support for judgement</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Random sequence generation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Random sequence was generated by central computer using permuted blocks within strata. Neither block size nor treatment assignments to other sites were public. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Allocation concealment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Unclear</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No details provided in protocol or included study.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blinding of participants and personnel</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>High</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Protocol stated that for arm B (deferred ART), no study‐provided drugs were to be provided initially hence blinding of participants and personnel was not possible. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Blinding of outcome assessment</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Primary outcome was a composite endpoint of survival and viral load. Detection bias was unlikely. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Incomplete outcome data</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Equal numbers withdrew without primary endpoint data in each study arm. Details provided for these participants. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Selective reporting</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Low</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Reported outcomes were consistent with protocol.</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 3.</span> <span class="table-title">Risk of bias ACTG‐A5164, 2009</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013594/full#CD013594-tbl-0004">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013594-tbl-0005"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Table of studies at serious risk of bias overall (ROBINS‐I): disease‐related outcomes</span></div> <tbody> <tr> <th align="" class="headercell" colspan="4" rowspan="1" scope="col" valign=""> <p><b>Studies at serious risk of bias outcomes: death, relapse of histoplasmosis</b> </p> </th> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Study</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Review objective</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Domain(s)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comment</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013594-bbs2-0002" title="HechtF , KorzunA , WheatJ , HafnerR . Itraconazole maintenance treatment for histoplasmosis in AIDS: prospective multi-center trial. Abstracts of the Interscience Conference on Antimicrobial Agents and Chemotherapy1995;35:241. HechtFM , WheatJ , KorzunAH , HafnerR , SkahanKJ , LarsenR , et al. Itraconazole maintenance treatment for histoplasmosis in AIDS: a prospective, multicenter trial. Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology1997;16(2):100-7. NCT00000975. A study of itraconazole in the treatment and prevention of histoplasmosis, a fungal infection, in patients with AIDS [Pilot study to determine the feasibility of itraconazole for primary treatment and suppression of relapse of disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome]. clinicaltrials.gov/show/NCT00000975 (first received 31 August 2001). WheatJ , HafnerR , KorzunAH , LimjocoMT , SpencerP , LarsenRA , et al. Itraconazole treatment of disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome. AIDS Clinical Trial Group. American Journal of Medicine1995;98(4):336-42. WheatLJ , ConnollyP , HaddadN , Le MonteA , BrizendineE , HafnerR . Antigen clearance during treatment of disseminated histoplasmosis with itraconazole versus fluconazole in patients with AIDS. Antimicrobial Agents and Chemotherapy2002;46(1):248-50. ">ACTG120, 1992</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 and 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Confounding; participant selection; intervention classification</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severity of HIV; severity of PDH and comorbidities were not controlled for using appropriate statistical methodology. ART use at baseline of an earlier phase of the trial reported: those who responded to the intervention (ITRA) in the induction phase were selected for the intervention in the maintenance phase: participants started intervention at various doses and had reductions in dose made at variable intervals. While this was likely to have been informed by ITRA blood levels that were being monitored, detailed data were not provided per participant. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013594-bbs2-0003" title="NCT00000627. Pilot study to determine the feasibility of fluconazole for induction treatment and suppression of relapse of histoplasmosis in patients with the acquired immunodeficiency syndrome. clinicaltrials.gov/show/NCT00000627 (first received 31 August 2001). WheatJ , MaWhinneyS , HafnerR , McKinseyD , ChenD , KorzunA , et al. Treatment of histoplasmosis with fluconazole in patients with acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Acquired Immunodeficiency Syndrome Clinical Trials Group and Mycoses Study Group. American Journal of Medicine1997;103(3):223-32. WheatLJ , ConnollyP , HaddadN , Le MonteA , BrizendineE , HafnerR . Antigen clearance during treatment of disseminated histoplasmosis with itraconazole versus fluconazole in patients with AIDS. Antimicrobial Agents and Chemotherapy2002;46(1):248-50. WheatLJ , ConnollyP , SmedemaM , BrizendineE , HafnerR . Emergence of resistance to fluconazole as a cause of failure during treatment of histoplasmosis in patients with acquired immunodeficiency disease syndrome. Clinical Infectious Diseases2001;33(11):1910-3. ">ACTG174, 1994</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1 and 2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Confounding; participant selection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>At 3 months, protocol was revised and treatment regimen amended. Analyses were performed on participants who received the revised protocol (higher doses of FCN). Severity and management of HIV was not reported or controlled with appropriate statistical methods: selection into the maintenance arm of the study was related to the effect of the intervention in the induction phase. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013594-bbs2-0009" title="LuckettK , DummerJS , MillerG , HesterS , ThomasL . Histoplasmosis in patients with cell-mediated immunodeficiency: human immunodeficiency virus infection, organ transplantation, and tumor necrosis factor-alpha inhibition. Open Forum Infectious Diseases2015;2(1):ofu116. ">Luckett 2015</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Intervention classification; outcome measurement</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No information about dose, frequency, and timing of interventions. Information was collected retrospectively. Treatment failure outcome was based on clinician judgement only. This was likely to favour switch from azole to amphotericin. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013594-bbs2-0001" title="NCT00000992. A study of itraconazole in preventing the return of histoplasmosis, a fungal infection, in patients with AIDS [Pilot study to determine the feasibility of itraconazole for suppression of relapse of disseminated histoplasmosis in patients with the acquired immunodeficiency syndrome]. clinicaltrials.gov/show/NCT00000992 (first received 1 August 2001). WheatJ , HafnerR , WulfsohnM , SpencerP , SquiresK , PowderlyW , et al. Prevention of relapse of histoplasmosis with itraconazole in patients with the acquired immunodeficiency syndrome. Annals of Internal Medicine1993;118(8):610-6. ">ACTG084, 1992</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Confounding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Severity of HIV infection and ART use were not controlled for with appropriate statistical methods. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013594-bbs2-0007" title="GoldmanM , ZackinR , FichtenbaumCJ , SkiestDJ , KoletarSL , HafnerR , et al. Safety of discontinuation of maintenance therapy for disseminated histoplasmosis after immunologic response to antiretroviral therapy. Clinical Infectious Diseases2004;38(10):1485-9. NCT00006316. Withdrawal of antifungal treatment for histoplasmosis in patients after improved immune response to anti-HIV drugs [Discontinuation of antifungal therapy for histoplasmosis following immunologic response to antiretroviral therapy]. clinicaltrials.gov/show/NCT00006316 (first received 31 August 2001). ">Goldman 2004</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Participant selection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Start of intervention varied – participants enrolled after a range of 14–81 months of antifungal therapy. Unclear how many eligible people were not enrolled. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013594-bbs2-0012" title="MootsikapunP , SrikulbutrS . Histoplasmosis and penicilliosis: comparison of clinical features, laboratory findings and outcome. International Journal of Infectious Diseases2006;10(1):66-71. ">Mootsikapun 2006</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>2</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Confounding; participant selection</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>≥ 1 known important domain was not appropriately measured or controlled for: details of disease severity, comedications and comorbidities not provided for 27 participants discharged from hospital: maintenance therapy was commenced in those who responded to initial treatment on amphotericin B. Timing of start of maintenance therapy was not reported. Selection into this part of the study was related to the intervention. </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><a href="./references#CD013594-bbs2-0011" title="MelzaniA , deReynal de Saint MichelR , NtabB , DjossouF , EpelboinL , NacherM , et al. Incidence and trends in immune reconstitution inflammatory syndrome associated with Histoplasma capsulatum among people living with HIV: a 20-year case series and literature review. Clinical Infectious Diseases2020;70(4):643-52. ">Melzani 2020</a> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>3</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>Confounding</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>ART was discontinued in 2/22 participants at the physician's decision; 2/22 due to patient choice. In unmasking group (14 participants), 10/14 received lAmB and 4/14 received ITRA. Paradoxical group (8 participants) physicians continued ART and ITRA for 6/8. Rationale for treatment choices not reported. Appropriate statistical measures to control for confounding were not reported. ≥ 1 known important domain was not appropriately measured or controlled for. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p>For details of risk of bias assessment see <a href="./appendices#CD013594-sec-0084">Appendix 3</a>. </p> <p>ART: antiretroviral therapy; FCN: fluconazole; ITRA: itraconazole; lAmB: liposomal amphotericin B; PDH: progressive disseminated histoplasmosis. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 4.</span> <span class="table-title">Table of studies at serious risk of bias overall (ROBINS‐I): disease‐related outcomes</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013594/full#CD013594-tbl-0005">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013594-tbl-0006"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Additional summary 1: amphotericin B formulations versus azoles</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>Early ART compared with deferred ART for PDH in HIV</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with HIV and progressive disseminated histoplasmosis </p> <p><b>Settings:</b> endemic areas </p> <p><b>Intervention:</b> induction therapy with triazoles </p> <p><b>Comparison:</b> induction therapy with amphotericin B formulations </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Narrative summary</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>Treatment success</b> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>No RCTs make direct comparisons of amphotericin B and triazoles. Treatment success of triazoles (other than fluconazole) were 83% and 85% in the 2 studies which reported them. </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>a,b</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>—</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="4" rowspan="1" valign=""> <p>ART: antiretroviral therapy; PDH: progressive disseminated histoplasmosis; RCT: randomized controlled trial. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="4"> <div class="table-footnote"> <p><sup>a</sup>Downgraded two levels for serious imprecision. The CIs are wide due to small numbers of participants.<br/><sup>b</sup>Downgraded one level for serious indirectness. No studies report direct comparisons. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 5.</span> <span class="table-title">Additional summary 1: amphotericin B formulations versus azoles</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013594/full#CD013594-tbl-0006">Navigate to table in review</a></div> </div> <div class="table"> <table data-id="CD013594-tbl-0007"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Additional summary 2: early versus deferred ART</span></div> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Early ART compared with deferred ART for PDH in HIV</b> </p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p><b>Patient or population:</b> adults with HIV and progressive disseminated histoplasmosis </p> <p><b>Settings:</b> endemic areas </p> <p><b>Intervention:</b> early ART (&lt; 14 days) </p> <p><b>Comparison:</b> late ART (&gt; 14 days) </p> </td> </tr> <tr> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Outcomes</b> </p> </th> <th align="" class="headercell" colspan="2" rowspan="1" scope="col" valign="bottom"> <p><b>Illustrative risks</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Relative effect<br/>(95% CI)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>No of participants<br/>(studies)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Certainty of the evidence<br/>(GRADE)</b> </p> </th> <th align="" class="headercell" colspan="1" rowspan="1" scope="col" valign="bottom"> <p><b>Comments</b> </p> </th> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>IRIS</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/3 participants<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>1/7 participants<sup>a</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p><b>RR 0.43</b> </p> <p>(0.04 to 4.82)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>10<br/>(1 study) </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>⊕⊝⊝⊝</p> <p><b>Very low</b><sup>b,c</sup> </p> </td> <td align="" bgcolor="#ffffff" colspan="1" rowspan="1" valign="top"> <p>We do not know if early ART increases the risk of IRIS in people with HIV and PDH.</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="7" rowspan="1" valign=""> <p>ART: antiretroviral therapy; IRIS: immune reconstitution inflammatory syndrome; PDH: progressive disseminated histoplasmosis; RCT: randomized controlled trial; RR: risk ratio. </p> </td> </tr> </tbody> <tfoot> <tr> <td colspan="7"> <div class="table-footnote"> <p><sup>a</sup>1/3 people with histoplasmosis in deferred ART arm developed histoplasma IRIS (day 47). 1/7 people with histoplasmosis in early ART arm developed hepatitis C IRIS (day 14).<br/><sup>b</sup>Downgraded two levels for serious imprecision. The CI was wide.<br/><sup>c</sup>Downgraded one level for serious indirectness. The trial only included 10 participants with histoplasmosis and the case definitions were not stated. </p> </div> </td> </tr> </tfoot> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Table 6.</span> <span class="table-title">Additional summary 2: early versus deferred ART</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013594/full#CD013594-tbl-0007">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013594-tbl-0008"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Liposomal amphotericin B (lAmB) versus deoxycholate amphotericin B (dAmB)</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.1 Clinical success <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>80</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>1.46 [1.01, 2.11]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.2 Death <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Random, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.15 [0.02, 1.38]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">1.3 Safety outcomes <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""></td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Subtotals only</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.1 Infusion‐related toxicity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.39 [0.22, 0.69]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.2 Nephrotoxicity</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.25 [0.09, 0.67]</p> </td> </tr> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>1.3.3 Drug discontinuation</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>77</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.23 [0.02, 2.38]</p> </td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 1.</span> <span class="table-title">Liposomal amphotericin B (lAmB) versus deoxycholate amphotericin B (dAmB)</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013594/references#CD013594-tbl-0008">Navigate to table in review</a></div> </div> <div class="table"> <table class="comparison" data-id="CD013594-tbl-0009"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Early antiretroviral therapy (ART) versus deferred ART</span></div> <thead> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p>Outcome or subgroup title</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>No. of studies</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>No. of participants</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Statistical method</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>Effect size</p> </td> </tr> </thead> <tbody> <tr> <td align="" bgcolor="#ffffff" colspan="1" data-title="Outcome or subgroup title" rowspan="1" valign=""> <p class="subgroupTitle">2.1 Immune reconstitution inflammatory syndrome <span class="subgroupLink"><b class="text-toggle-control">Show forest plot</b><i aria-hidden="true" class="fa fa-caret-down"></i></span></p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of studies" rowspan="1" valign=""> <p>1</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="No. of participants" rowspan="1" valign=""> <p>10</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Statistical method" rowspan="1" valign=""> <p>Risk Ratio (M‐H, Fixed, 95% CI)</p> </td> <td align="" bgcolor="#ffffff" colspan="1" data-title="Effect size" rowspan="1" valign=""> <p>0.43 [0.04, 4.82]</p> </td> </tr> <tr class="figure-image"> <td colspan="5"></td> </tr> </tbody> </table> <div class="scolaris-modal-title">Figures and Tables - </div> <div class="table-viewer-caption"> <div class="table-heading"><span class="table-label">Comparison 2.</span> <span class="table-title">Early antiretroviral therapy (ART) versus deferred ART</span></div> </div> <div class="tools"><a class="tableList" href="/cdsr/doi/10.1002/14651858.CD013594/references#CD013594-tbl-0009">Navigate to table in review</a></div> </div> </div> <noscript> <img height="1" src="/scolaris-auth/report/nonjs/fulltexthtmlreg?doi=10.1002%2F14651858.CD013594&amp;rf=&amp;articleType=CDSR" style="display:none" width="1"> </img></noscript> <section class="translation-notes-modal" data-modal-class="translation-notes" data-modal-title="Translation notes" data-ok-btn-selector=".ok-btn" style="display: none"> <div class="translation-notes"> <div class="section-language-toggles"> <nav class="section-languages"> <ul> <li class="section-languages-legend">Available in</li> <li class="section-language"> <a class="" href="es#CD013594-note-0011">Español</a> </li> <li class="section-language"> <a class="" href="fa#CD013594-note-0008">فارسی</a> </li> <li class="section-language"> <a class="" href="fr#CD013594-note-0009">Français</a> </li> <li class="section-language"> <a class="" href="ms#CD013594-note-0010">Bahasa Malaysia</a> </li> </ul> </nav> </div> <section class="translation-notes-content"> </section> <button class="btn primary ok-btn pull-right" type="button">Close</button> </div> </section></article> </div> <div class="citation-modal" style="display: none"> <div class="export-citation-header"> <p class="inset-message" data-load-error="Unable to load citation data" id="citeProcText"></p> </div> <div class="export-citation-body row-fluid"> <div class="span12"> <div class="addthis_toolbox addthis_default_style addthis_16x16_style"> <nav class="inline-nav-list is-bordered"> <li> <h4 class="heading">Save citation to:</h4> </li> <li><a class="citation-btn-refworks at300b btn btn-link" href="#" id="refWorksCitationBtn"><span class="citation-icon refworks"></span>RefWorks</a></li> <li><a class="citation-btn-sciwheel at300b btn btn-link disabled" href="#" id="sciWheelCitationBtn" target="_blank"><span class="citation-icon sciwheel"></span>SciWheel</a></li> </nav> </div> </div> </div> <div class="row-fluid"> <div class="span12"> <div class="citation-format"> <h4>Copy or download citation</h4> <a href="/en/help/exporting-search-results" rel="noopener noreferrer" target="_blank">Export help</a> </div> <nav class="inline-nav-list has-dividers"> <li class="citation-option" data-option="plain"><button class="btn btn-link" type="button">Plain text</button></li> <li class="citation-option" data-option="endnote"><button class="btn btn-link" type="button">EndNote</button></li> <li class="citation-option" data-option="refmanager"><button class="btn btn-link" type="button">Reference Manager</button></li> <li class="citation-option" data-option="procite"><button class="btn btn-link" type="button">ProCite</button></li> <li class="citation-option" data-option="bibtex"><button class="btn btn-link" type="button">BibteX</button></li> <li class="citation-option" data-option="csv"><button class="btn btn-link" type="button">CSV (Excel)</button></li> </nav> <div class="citation-content"> <pre data-load-error="Unable to load citation data" id="citationContent" tabindex="0"></pre> </div> <div class="clearfix"> <form class="download-citation-form" data-citation-citeproc-url="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=citation-citeproc&amp;p_p_cacheability=cacheLevelPage&amp;p_p_col_id=column-1&amp;p_p_col_count=1" method="GET" target="citation-download-iframe"> <input id="siteId" name="siteId" type="hidden" value=""> <input id="downloadType" name="downloadType" type="hidden" value=""> <input id="style" name="style" type="hidden" value=""> <input id="articleId" name="articleId" type="hidden" value=""> <input name="p_p_id" type="hidden" value="scolariscontentdisplay_WAR_scolariscontentdisplay"><input name="p_p_lifecycle" type="hidden" value="2"><input name="p_p_state" type="hidden" value="normal"><input name="p_p_mode" type="hidden" value="view"/><input name="p_p_resource_id" type="hidden" value="citation-download"/><input name="p_p_cacheability" type="hidden" value="cacheLevelPage"/><input name="p_p_col_id" type="hidden" value="column-1"/><input name="p_p_col_count" type="hidden" value="1"/> <button class="btn primary wide pull-right" type="submit">Download</button> <div class="inline-checkbox pull-right"> <label title=" for=" withabstract"=""> <input checked="" class="checkbox" name="withAbstract" type="checkbox"/> <span class="checkbox-label">Include abstract</span> </label> </div> </input></input></input></input></input></input></input></form> <iframe aria-hidden="true" name="citation-download-iframe" src="" style="display: none; visibility: hidden" title="Citation download frame"></iframe> </div> </div> </div> </div> <div class="print-modal" data-modal-title="Print this review" style="display: none;"> <div class="print-options-wrapper"> <p><strong>All sections are selected by default</strong>, please select the sections you do not wish to print or use the select or deselect all button to add or remove sections.</p> <div class="print-options-controls"> <input checked="checked" class="print-options-select-all" title="Select/deselect all" type="checkbox"/> <span class="checkbox-label">Select/deselect all</span> </div> <ul class="print-options checkbox-list"> </ul> <button class="btn primary print-article pull-right"><i aria-hidden="true" class="fa fa-print"></i> Print</button> </div> </div> <div class="download-stats-data-modal" data-modal-title="Download data package" style="display: none;"> <div> <p> The data available are protected by copyright and may only be used in accordance with the <a class="external" href="/about/data-download" target="_blank">Terms and Conditions.</a> </p> <div class="hide-for-zip"> <p> <a class="external" href="https://revman.cochrane.org/#/rm5Converter" target="_blank">RevMan 5 files</a> can be converted to a <a class="external" href="https://links.cochrane.org/review-datapack-userguide" target="_blank">data package.</a> </p> </div> <p> Files in the data package can be imported to <a class="external" href="https://revman.cochrane.org/info" target="_blank">Review Manager software</a> or opened in other tools that support CSV and RIS. </p> <form class="download-stats-data-form" method="GET" target="_blank"> <input name="content-disposition" type="hidden" value="attachment"/> <input name="mime-type" type="hidden" value="application/octet-stream"/> <p class="print-options-controls"> <input aria-label="I agree to these terms and conditions" class="download-stats-data-toc-check-box" type="checkbox"/> <span aria-hidden="true" class="checkbox-label">I agree to these terms and conditions</span> <button class="btn primary download-stats-data pull-right" disabled=""><i aria-hidden="true" class="fa fa-download"></i> Download data</button> </p> </form> </div> </div> <div class="share-modal" data-modal-title="Share this review" style="display:none;"> </div> <div class="viewer-thumbnail-pane-html" style="display:none;"> <div class="figure-viewer-options"> <nav class="inline-nav-list"> <li class="figure-options-btn-container"><button class="btn btn-link" id="figureOptionBtn" type="button">Figures</button></li> <li class="table-options-btn-container"><button class="btn btn-link" id="tableOptionBtn" type="button">Tables</button></li> </nav> </div> <div class="figure-viewer-thumbnails"> <div class="figure-thumbnails is-visible" id="figureThumbnails"></div> <div class="table-thumbnails" id="tableThumbnails"></div> </div> </div> <div class="utilities-html" style="display:none;"> <div class="figure-viewer-utilities"> <a class="figure-viewer-menu-toggle" href="#"> <i class="fa fa-chevron-left"></i><span class="toggle-label" data-figure-hide-text="Hide thumbnails" data-figure-show-text="Show thumbnails" data-table-hide-text="Hide table list" data-table-show-text="Show table list">Hide thumbnails</span> </a> <a class="figure-viewer-navigateback" href="#"> <i class="fa fa-chevron-left"></i> </a> <a class="figure-viewer-rotate" href="#"> <i class="fa fa-undo"></i> </a> <a class="figure-viewer-download" href="#"> <i class="fa fa-download"></i> </a> <a class="figure-viewer-share" href="#"> <i class="fa fa-share-alt"></i> </a> <a class="figure-viewer-zoomin" href="#"> <i class="fa fa-plus"></i><span>zoom in</span> </a> <a class="figure-viewer-zoomout" href="#"> <i class="fa fa-minus"></i><span>zoom out</span> </a> </div> </div> <div class="controls-html" style="display:none;"> <div class="figure-viewer-navigation"> <a class="figure-viewer-nav previous" href="#"> <i class="fa fa-chevron-left"></i><span>left</span> </a> <a class="figure-viewer-nav next" href="#"> <i class="fa fa-chevron-right"></i><span>right</span> </a> </div> </div> <div class="mobile-thumbnail-selector-html" style="display:none;"> <div class="figure-viewer-mobile-thumbnails"> <select class="figure-selection"> <option>Figures</option> </select> <select class="table-selection"> <option>Tables</option> </select> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div>
<div class="portlet-boundary portlet-boundary_1_WAR_kaleodesignerportlet_ portlet-static portlet-static-end kaleo-designer-portlet" id="p_p_id_1_WAR_kaleodesignerportlet_">
<span id="p_1_WAR_kaleodesignerportlet"></span>
</div>
<form action="#" id="hrefFm" method="post" name="hrefFm">
<span></span>
</form>
</div>
<footer class="footer">
<div class="main-footer">
<div class="main-footer-wrapper container">
<div class="brand">
<p class="brand-name">Cochrane</p>
<a href="http://www.cochrane.org/" title="Cochrane logo">
<img alt="Cochrane logo" class="footer-logo logo-part-1" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-1.png"> <img alt="" class="footer-logo logo-part-2" src="https://www.cochranelibrary.com/cochrane-theme/images/footer-logo-part-2.png"> </img></img></a> </div> </div> </div> <div class="aux-footer"> <div class="aux-footer-nav-container container"> <nav class="aux-footer-nav"> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse Publications</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/">Browse by Subject</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/advertisers">Advertisers &amp; Agents</a></li> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Contact Us</a></li> </ul> <ul class="aux-footer-nav-list"> <li><a class="aux-footer-nav-link" href="https://hub.wiley.com/community/support/cochrane-library">Help &amp; Support</a></li> <li><a class="aux-footer-nav-link" href="https://onlinelibrary.wiley.com/terms-and-conditions">Terms &amp; Conditions</a></li> </ul> </nav> </div> <div class="brand"> <div class="brand-container container"> <p class="copyright"> Copyright © 2000 - 2025 by <a class="" href="http://www.wiley.com">John Wiley &amp; Sons, Inc.</a> All Rights Reserved <br> Review our <a href="https://www.wiley.com/privacy"><strong>Privacy Policy</strong></a> <a href="https://www.wiley.com/cookies"><strong>Cookie Policy</strong></a> <a href="#" onclick="Osano.cm.showDrawer('osano-cm-dom-info-dialog-open')"><strong>Cookie Preferences</strong></a> </br></p> <a href="http://eu.wiley.com/"><img alt="Wiley logo" class="logo" src="https://www.cochranelibrary.com/cochrane-theme/images/en-US_wiley-footer-logo.png"/></a> </div> </div> <span class="wiley-semi-circle"></span> </div> <!--BEGIN QUALTRICS WEBSITE FEEDBACK SNIPPET--> <script type="text/javascript"> (function(){var g=function(e,h,f,g){ this.get=function(a){for(var a=a+"=",c=document.cookie.split(";"),b=0,e=c.length;b<e;b++){for(var d=c[b];" "==d.charAt(0);)d=d.substring(1,d.length);if(0==d.indexOf(a))return d.substring(a.length,d.length)}return null}; this.set=function(a,c){var b="",b=new Date;b.setTime(b.getTime()+6048E5);b="; expires="+b.toGMTString();document.cookie=a+"="+c+b+"; path=/; "}; this.check=function(){var a=this.get(f);if(a)a=a.split(":");else if(100!=e)"v"==h&&(e=Math.random()>=e/100?0:100),a=[h,e,0],this.set(f,a.join(":"));else return!0;var c=a[1];if(100==c)return!0;switch(a[0]){case "v":return!1;case "r":return c=a[2]%Math.floor(100/c),a[2]++,this.set(f,a.join(":")),!c}return!0}; this.go=function(){if(this.check()){var a=document.createElement("script");a.type="text/javascript";a.src=g;document.body&&document.body.appendChild(a)}}; this.start=function(){var t=this;"complete"!==document.readyState?window.addEventListener?window.addEventListener("load",function(){t.go()},!1):window.attachEvent&&window.attachEvent("onload",function(){t.go()}):t.go()};}; try{(new g(100,"r","QSI_S_ZN_cGCHHvWNpnJb1zf","https://zncgchhvwnpnjb1zf-wiley.siteintercept.qualtrics.com/SIE/?Q_ZID=ZN_cGCHHvWNpnJb1zf")).start()}catch(i){}})(); </script><div id="ZN_cGCHHvWNpnJb1zf"><!--DO NOT REMOVE-CONTENTS PLACED HERE--></div> <!--END WEBSITE FEEDBACK SNIPPET--> </footer> <div class="scolaris-modal-overlay"></div> <div class="scolaris-modal"> <div class="scolaris-modal-titlebar clearfix"> <p class="scolaris-modal-title"></p> <a class="scolaris-modal-close" href="#"><span>close</span><span class="icon fa fa-times"></span></a> <div class="scolaris-modal-ui"></div> </div> <!-- Static injection of addtoAny as dynamic injection not working properly--> <div class="scolaris-share-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"> <div class="a2a_kit a2a_kit_size_32 a2a_default_style"> <a class="a2a_button_facebook share-button">  Facebook</a> <a class="a2a_button_x share-button">  X(Twitter)</a> <a class="a2a_button_whatsapp share-button">  WhatsApp</a> <a class="a2a_dd share-button">  View more</a> </div> </div> </div> <div class="scolaris-modal-content clearfix"> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="scolaris-modal-ui clearfix"></div> </div> <div class="english-only-modal-wrapper" data-modal-class="english-only-modal" data-modal-title="Feature in English only" style="display: none"> <div class="english-only-modal"> <p class="message"></p> <button class="btn primary ok-btn pull-right" type="button">OK</button> <button class="btn primary border-only cancel-btn pull-right" type="button">Cancel</button> </div> </div> <!--[if gte IE 9]><!--> <script src="/cochrane-theme/vendor/ie9.js?t=1738734064000" type="text/javascript"></script> <!--<![endif]--> <script src="https://www.cochranelibrary.com/cochrane-theme/js/theme.js?t=1738734064000" type="text/javascript"></script> <script src="https://content.readcube.com/cochrane/checkout.js"></script> <script src="https://content.readcube.com/cochrane/epdf_linker.js" type="text/javascript"></script> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js" type="text/javascript"></script> <script src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/hit-highlighting.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/topics-lookup.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/institution.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/api-manager.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/pico.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/reference-linking.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/rightsLink.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.submit.failed.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.comment.form.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/safety-alerts.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/ui.translation-notes-modal.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-content-display/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772750000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/notifications-portlet/notifications/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772751000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-search/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-topics/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772894000" type="text/javascript"></script> <script src="https://www.cochranelibrary.com/scolaris-language-portlet/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1739772746000" type="text/javascript"></script> <script type="text/javascript">Liferay.Util.addInputFocus();</script> <script type="text/javascript">Liferay.Portlet.register("scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header_",portletId:"scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_header\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013594\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013594\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013594\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013594"});Liferay.Portlet.register("scolariscontentdisplay_WAR_scolariscontentdisplay");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_",portletId:"scolariscontentdisplay_WAR_scolariscontentdisplay",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentdisplay_WAR_scolariscontentdisplay\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dcolumn-1\x26p_p_col_pos\x3d0\x26p_p_col_count\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013594\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013594\x2526type\x253Dcdsr\x2526contentLanguage\x253D"});Liferay.provide(Liferay.Util,"openKaleoDesignerPortlet",function(c){var b=AUI();var e=Liferay.PortletURL.createURL("https://www.cochranelibrary.com/en/content?p_p_id=2_WAR_kaleodesignerportlet&p_p_lifecycle=0");e.setParameter("mvcPath","/designer/edit_kaleo_draft_definition.jsp");e.setParameter("availableFields",c.availableFields);e.setParameter("availablePropertyModels",c.availablePropertyModels);e.setParameter("ddmStructureId",c.ddmStructureId);e.setParameter("draftVersion",c.draftVersion);e.setParameter("kaleoProcessId",c.kaleoProcessId);e.setParameter("name",c.name);e.setParameter("openerWindowName",c.openerWindowName);e.setParameter("portletResourceNamespace",c.portletResourceNamespace);e.setParameter("propertiesSaveCallback",c.propertiesSaveCallback);e.setParameter("refreshOpenerOnClose",c.refreshOpenerOnClose);e.setParameter("saveCallback",c.saveCallback);e.setParameter("version",c.version);e.setWindowState("pop_up");c.uri=e.toString();var d=c.dialog;if(!d){var f=b.one(Liferay.Util.getOpener()).get("region");d={destroyOnHide:true};c.dialog=d}if(!("align" in d)){d.align=Liferay.Util.Window.ALIGN_CENTER}var a=c.dialogIframe;if(!a){a={closeOnEscape:false};c.dialogIframe=a}Liferay.Util.openWindow(c)},["liferay-portlet-url"]);Liferay.Portlet.register("1_WAR_kaleodesignerportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_1_WAR_kaleodesignerportlet_",portletId:"1_WAR_kaleodesignerportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3d1_WAR_kaleodesignerportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013594\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013594\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013594\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013594"});Liferay.Portlet.register("scolarissearchportlet_WAR_scolarissearch");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolarissearchportlet_WAR_scolarissearch_",portletId:"scolarissearchportlet_WAR_scolarissearch",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolarissearchportlet_WAR_scolarissearch\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013594\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013594\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013594\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013594"});Liferay.Portlet.register("scolariscontentlanguagebanner_WAR_scolarislanguageportlet");Liferay.Portlet.onLoad({canEditTitle:false,columnPos:0,isStatic:"end",namespacedId:"p_p_id_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_",portletId:"scolariscontentlanguagebanner_WAR_scolarislanguageportlet",refreshURL:"\x2fen\x2fc\x2fportal\x2frender_portlet\x3fp_l_id\x3d20757\x26p_p_id\x3dscolariscontentlanguagebanner_WAR_scolarislanguageportlet\x26p_p_lifecycle\x3d0\x26p_t_lifecycle\x3d0\x26p_p_state\x3dnormal\x26p_p_mode\x3dview\x26p_p_col_id\x3dnull\x26p_p_col_pos\x3dnull\x26p_p_col_count\x3dnull\x26p_p_static\x3d1\x26p_p_isolated\x3d1\x26currentURL\x3d\x252Fweb\x252Fcochrane\x252Fcontent\x253FtemplateType\x253Dfull\x2526urlTitle\x253D\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013594\x2526doi\x253D10\x2e1002\x252F14651858\x2eCD013594\x2526type\x253Dcdsr\x2526contentLanguage\x253D\x26templateType\x3dfull\x26urlTitle\x3d\x252Fcdsr\x252Fdoi\x252F10\x2e1002\x252F14651858\x2eCD013594\x26contentLanguage\x3d\x26type\x3dcdsr\x26doi\x3d10\x2e1002\x252F14651858\x2eCD013594"});AUI().use("aui-base","liferay-menu","liferay-notice","liferay-poller","liferay-session",function(a){(function(){Liferay.Util.addInputType();Liferay.Portlet.ready(function(b,c){Liferay.Util.addInputType(c)});if(a.UA.mobile){Liferay.Util.addInputCancel()}})();(function(){new Liferay.Menu();var b=Liferay.Data.notices;for(var c=1;c<b.length;c++){new Liferay.Notice(b[c])}})();(function(){Liferay.Session=new Liferay.SessionBase({autoExtend:true,sessionLength:1800,redirectOnExpire:false,redirectUrl:"https\x3a\x2f\x2fwww\x2ecochranelibrary\x2ecom\x2fweb\x2fcochrane",warningLength:0})})()});</script> <script src="https://www.cochranelibrary.com/cochrane-theme/js/main.js?browserId=other&amp;minifierType=js&amp;languageId=en_US&amp;b=6210&amp;t=1738734064000" type="text/javascript"></script> <script type="text/javascript"></script> <div class="mobile-righthand-nav"> <a class="rh-nav-close-btn" href="#"> <span>Close</span> <span class="fa fa-chevron-down"></span> </a> <div class="wrapper"> </div> <a class="rh-nav-open-btn" href="#"> <span>Review tools &amp; navigation</span> </a> </div> <iframe aria-hidden="true" id="printframe" name="printframe" style="position: absolute; left: -2000px; top: 0;" title="Print frame"></iframe> <iframe aria-hidden="true" id="citationExportFrame" name="citationExportFrame" style="position: absolute; left: -2000px; top: 0;" title="scolaris.citation.export.frame"></iframe> <nav> <div class="mobile-navigation"> <div class="close-container"> <a aria-label="Navigate back" class="main-nav-back-btn" href="#"><i class="fa fa-chevron-left"></i></a> <a class="main-nav-close-btn" href="#" title="Close menu">Close menu <i class="fa fa-times"></i></a> </div> <div class="mobile-search basic-search-container"> <div class="portlet-boundary portlet-boundary_scolarissearchportlet_WAR_scolarissearch_ portlet-static portlet-static-end" id="p_p_id_scolarissearchportlet_WAR_scolarissearch_"> <span id="p_scolarissearchportlet_WAR_scolarissearch"></span> <section class="portlet" id="portlet_scolarissearchportlet_WAR_scolarissearch"> <header class="portlet-topper"> <h1 class="portlet-title"> <span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Search\x20Portlet')"> <img alt="" id="ymag__null__null" src="/scolaris-search/icon.png"> <span class="taglib-text hide-accessible">Scolaris Search Portlet</span> </img></span> <span class="portlet-title-text">Scolaris Search Portlet</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarissearchportlet_WAR_scolarissearch" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="header-search"> <form action="https://www.cochranelibrary.com/en/content?p_auth=9nGOjNGw&amp;p_p_id=scolarissearchportlet_WAR_scolarissearch&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolarissearchportlet_WAR_scolarissearch_scolarisAction=redirectSearchResult" method="post"> <input name="searchType" type="hidden" value="basic"> <input name="facetDisplayName" type="hidden" value=""> <input name="facetQueryTerm" type="hidden" value=""/> <input name="facetQueryField" type="hidden" value=""/> <input name="facetCategory" type="hidden" value=""/> <fieldset class="fieldset"> <legend class="sr-only">Basic Search</legend> <div class="select search-by"> <select aria-label="Search by options" class="custom-select-enabled search-type" name="searchBy" title="Search by options"> <option value="1">Title Abstract Keyword</option> <option value="2">Record Title</option> <option value="3">Abstract</option> <option value="4">Author</option> <option value="5">Keyword</option> <option value="6">All Text</option> <option value="7">Publication Type</option> <option value="8">Source</option> <option value="9">DOI</option> <option value="14">Language</option> <option value="10">Accession Number</option> <option value="11">Trial Registry Number</option> <option value="12">Cochrane Group</option> <option value="13">Cochrane Topic</option> </select> </div> <div class="search-select-crg-container select" style="display: none;"> <select class="search-select-crg-list"></select> </div> <div class="search-select-topic-container select" data-topic-list-url="https://www.cochranelibrary.com/en/content?p_p_id=scolaristopics_WAR_scolaristopics&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=topics-list&amp;p_p_cacheability=cacheLevelPage" style="display: none;"> <select class="search-select-topic-list"></select> </div> <div class="search-select-cl-container select" style="display: none;"> <select class="search-select-cl-list"></select> </div> <div class="search-text-container"> <div class="control-group control-group-inline search-input-wrapper"> <input aria-label="Enter search term" class="field browser-search search-text ui-autocomplete-input" id="searchText" name="searchText" placeholder="Search" size="30" type="text" value=""/>
<div id="autocomplete-results"></div>
</div>
<div class="control-group control-group-inline search-button-wrapper">
<button aria-label="Search" class="searchByBtn" type="submit">
<i aria-hidden="true" class="fa fa-search"></i>
</button>
</div>
</div>
</fieldset>
</input></input></form>
</div>
<script>
    window.displayResultURL = 'https://www.cochranelibrary.com/en/content?p_p_id=scolarissearchportlet_WAR_scolarissearch&p_p_lifecycle=2&p_p_state=normal&p_p_mode=view&p_p_resource_id=getSuggestions&p_p_cacheability=cacheLevelPage&_scolarissearchportlet_WAR_scolarissearch_templateType=full&_scolarissearchportlet_WAR_scolarissearch_urlTitle=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013594&_scolarissearchportlet_WAR_scolarissearch_contentLanguage=&_scolarissearchportlet_WAR_scolarissearch_type=cdsr&_scolarissearchportlet_WAR_scolarissearch_doi=10.1002%2F14651858.CD013594';
    window.searchByOption = '';
</script>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<a class="btn secondary" href="/en/browse-by-topic">Browse </a>
<a class="btn secondary advanced-search-button" href="/en/advanced-search">Advanced search</a>
</div>
<div class="menu-items parent">
<div>
<div class="nav-root-item parent">
<a class="language-selection-title-link" href="#" title="Select language">
<span class="mobile-nav-language-title">Select your preferred language </span></a> <span class="icon fa fa-caret-down"></span>
<div class="mob-child">
<div class="portlet-boundary portlet-boundary_scolarislanguageselector_WAR_scolarislanguageportlet_ portlet-static portlet-static-end" id="p_p_id_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav_">
<span id="p_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav"></span>
<section class="portlet" id="portlet_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Language\x20Selector')">
<img alt="" id="fdkn__null__null" src="/scolaris-language-portlet/icon.png"> <span class="taglib-text hide-accessible">Scolaris Language Selector</span> </img></span> <span class="portlet-title-text">Scolaris Language Selector</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolarislanguageselector_WAR_scolarislanguageportlet_INSTANCE_mobilenav" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="language-display" data-content-languages="[de, en, es, fa, fr, hi, hr, id, ja, ko, hu, ms, nl, pl, pt, ru, ro, ta, th, zh_HANT, zh_HANS]"> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-file-text"></i> English </a> <a class="language-select-mobile" href="#" title="Select your preferred language"> <i class="fa fa-globe"></i> English </a> </div> <div class="form-content language-selector-modal child"> <div class="row-fluid"> <h3><i class="fa fa-file-text"></i> Cochrane review language</h3> <p>Select your preferred language for Cochrane reviews and other content. Sections without translation will be in English.</p> <div class="dropdown-trigger" id="active-content-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="content-language-selector" data-languagecode="de" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=de">Deutsch</a> <a class="content-language-selector is-active" data-languagecode="en" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=en">English</a> <a class="content-language-selector" data-languagecode="es" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=es">Español</a> <a class="content-language-selector" data-languagecode="fa" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fa">فارسی</a> <a class="content-language-selector" data-languagecode="fr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=fr">Français</a> <a class="content-language-selector" data-languagecode="hi" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hi">हिन्दी</a> <a class="content-language-selector" data-languagecode="hr" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hr">Hrvatski</a> <a class="content-language-selector" data-languagecode="id" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=id">Bahasa Indonesia</a> <a class="content-language-selector" data-languagecode="ja" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ja">日本語</a> <a class="content-language-selector" data-languagecode="ko" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ko">한국어</a> <a class="content-language-selector" data-languagecode="hu" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=hu">Magyar</a> <a class="content-language-selector" data-languagecode="ms" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ms">Bahasa Malaysia</a> <a class="content-language-selector" data-languagecode="nl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=nl">Nederlands</a> <a class="content-language-selector" data-languagecode="pl" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pl">Polski</a> <a class="content-language-selector" data-languagecode="pt" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=pt">Português</a> <a class="content-language-selector" data-languagecode="ru" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ru">Русский</a> <a class="content-language-selector" data-languagecode="ro" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ro">Română</a> <a class="content-language-selector" data-languagecode="ta" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=ta">தமிழ்</a> <a class="content-language-selector" data-languagecode="th" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=th">ภาษาไทย</a> <a class="content-language-selector" data-languagecode="zh_HANT" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANT">繁體中文</a> <a class="content-language-selector" data-languagecode="zh_HANS" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage&amp;_scolariscontentlanguagebanner_WAR_scolarislanguageportlet_contentLanguage=zh_HANS">简体中文</a> </div> </div> <div class="row-fluid"> <h3 class="portal-language-header"><i class="fa fa-globe"></i> Website language</h3> <p>Select your preferred language for the Cochrane Library website.</p> <div class="dropdown-trigger" id="active-portal-language"> <span>English</span> <i aria-hidden="true" class="fa fa-caret-down"></i> </div> <div class="language-selector-dropdown"> <a class="portal-language-selector is-active" data-portallanguage="en" href="/en/cdsr/doi/10.1002/14651858.CD013594/full/en">English</a> <a class="portal-language-selector" data-portallanguage="es" href="/es/cdsr/doi/10.1002/14651858.CD013594/full/es">Español</a> </div> </div> <a class="btn secondary ok-btn pull-right" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentlanguagebanner_WAR_scolarislanguageportlet&amp;p_p_lifecycle=2&amp;p_p_state=normal&amp;p_p_mode=view&amp;p_p_resource_id=set-content-language&amp;p_p_cacheability=cacheLevelPage">Save</a> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
<div class="parent">
<a class="mobile-link signin" data-redirect="false" href="https://www.cochranelibrary.com/c/portal/login?p_l_id=20757&amp;redirect=%2Fcdsr%2Fdoi%2F10.1002%2F14651858.CD013594%2Ffull" rel="nofollow">
                        Sign In
                    </a>
</div>
</div>
<div class="menu-items-footer">
<div class="utility-links">
<a class="cochrane-link" href="http://www.cochrane.org/" target="_blank">Visit Cochrane.org</a>
</div>
</div>
</div>
<div class="menu-items child"></div>
</div>
</nav><div class="basic-login-form-content" data-modal-title="Sign in" style="display: none;">
<div class="form-content">
<div class="row-fluid">
<div class="span12">
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_MODAL_">
<span id="p_58_INSTANCE_MODAL"></span>
<section class="portlet" id="portlet_58_INSTANCE_MODAL">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="dbam__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"> <span class="taglib-text hide-accessible">Sign In</span> </img></span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_MODAL" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_MODAL&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_MODAL_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_MODAL_fm" method="post" name="_58_INSTANCE_MODAL_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_MODAL_formDate" type="hidden" value="1740724855454"> <input class="field" id="_58_INSTANCE_MODAL_saveLastPath" name="_58_INSTANCE_MODAL_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_MODAL_redirect" name="_58_INSTANCE_MODAL_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013594/full"> <input class="field" id="_58_INSTANCE_MODAL_doActionAfterLogin" name="_58_INSTANCE_MODAL_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_login"> Email Address </label> <input class="field clearable" id="_58_INSTANCE_MODAL_login" name="_58_INSTANCE_MODAL_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_MODAL_password"> Password </label> <input class="field" id="_58_INSTANCE_MODAL_password" name="_58_INSTANCE_MODAL_password" type="password" value=""/> </div> <span id="_58_INSTANCE_MODAL_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="clearfix"> <div class="checkbox-list pull-left"> <div class="checkbox-list-item"> <div class="control-group form-inline input-checkbox-wrapper"> <label for="_58_INSTANCE_MODAL_rememberMeCheckbox"> <input id="_58_INSTANCE_MODAL_rememberMe" name="_58_INSTANCE_MODAL_rememberMe" type="hidden" value="true"/> <input checked="" class="field" id="_58_INSTANCE_MODAL_rememberMeCheckbox" name="_58_INSTANCE_MODAL_rememberMeCheckbox" onclick="Liferay.Util.updateCheckboxValue(this); " type="checkbox" value="true"/> Remember Me </label> </div> </div> </div> <div class="pull-right"> <a href="https://onlinelibrary.wiley.com/user/forgottenpassword" target="_blank">Forgotten password?</a> </div> </div> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> <a class="btn secondary" href="https://onlinelibrary.wiley.com/user-registration" target="_blank">Register</a> </div> <div class="pull-right"> <a class="institutional-login-form-button" href="https://www.cochranelibrary.com/en/content?p_p_id=scolariscontentdisplay_WAR_scolariscontentdisplay&amp;p_p_lifecycle=0&amp;p_p_state=normal&amp;p_p_mode=view&amp;_scolariscontentdisplay_WAR_scolariscontentdisplay_action=institution-access">Institutional login</a> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div></div>
<div class="institution-login-form-content" data-modal-title="Institutional login" style="display: none;">
<div class="form-content">
<div class="row-fluid access-content-wrapper">
<div class="span12">
<div class="section">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="obft__null__null" src="/scolaris-content-display/icon.png"> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </img></span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_combinedloginform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="access-content-section"> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/>
</div>
<button class="btn primary" name="button" type="submit">Go</button>
</div>
<div class="message error" id="institutionLookupErrorDiv" style="display:none">
                        '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access.
                    </div>
</div>
<input id="entityId" name="entityId" type="hidden" value=""/>
</form>
<h4>Previously accessed institutions</h4>
<ul class="plain" id="previousInstitutions">
<li>(none)</li>
</ul>
</div>
<div class="section-content">
<div class="open-athens-login">
                Login using <a href="/openathens">OpenAthens</a>
</div>
</div>
</div>
</div>
</div>
</div>
<div style="display:none">
<input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
<div class="portlet-boundary portlet-boundary_58_ portlet-static portlet-static-end portlet-login" id="p_p_id_58_INSTANCE_4_">
<span id="p_58_INSTANCE_4"></span>
<section class="portlet" id="portlet_58_INSTANCE_4">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Sign\x20In')">
<img alt="" id="joiu__null__null" src="https://www.cochranelibrary.com/cochrane-theme/images/spacer.png" style="background-image: url('https://www.cochranelibrary.com/sprite/html/icons/_sprite.png'); background-position: 50% -592px; background-repeat: no-repeat; height: 16px; width: 16px;"/> <span class="taglib-text hide-accessible">Sign In</span> </span> <span class="portlet-title-text">Sign In</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_58_INSTANCE_4" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <p>If you have a <strong>Wiley Online Library</strong> institutional username and password, enter them here.</p> <form action="https://www.cochranelibrary.com/en/content?p_p_id=58_INSTANCE_4&amp;p_p_lifecycle=1&amp;p_p_state=normal&amp;p_p_mode=view&amp;_58_INSTANCE_4_struts_action=%2Flogin%2Flogin" autocomplete="on" class="form sign-in-form" id="_58_INSTANCE_4_fm" method="post" name="_58_INSTANCE_4_fm"> <fieldset class="input-container" disabled="disabled"> <legend class="sr-only">Cochrane Login</legend> <input name="_58_INSTANCE_4_formDate" type="hidden" value="1740724855458"> <input class="field" id="_58_INSTANCE_4_saveLastPath" name="_58_INSTANCE_4_saveLastPath" type="hidden" value="false"> <input class="field" id="_58_INSTANCE_4_redirect" name="_58_INSTANCE_4_redirect" type="hidden" value="/cdsr/doi/10.1002/14651858.CD013594/full"> <input class="field" id="_58_INSTANCE_4_doActionAfterLogin" name="_58_INSTANCE_4_doActionAfterLogin" type="hidden" value="false"> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_login"> Username </label> <input class="field clearable" id="_58_INSTANCE_4_login" name="_58_INSTANCE_4_login" type="text" value=""> </input></div> <div class="control-group input-text-wrapper"> <label class="control-label" for="_58_INSTANCE_4_password"> Password </label> <input class="field" id="_58_INSTANCE_4_password" name="_58_INSTANCE_4_password" type="password" value=""> </input></div> <input class="field" id="_58_INSTANCE_4_institutionalLogin" name="_58_INSTANCE_4_institutionalLogin" type="hidden" value="true"/> <span id="_58_INSTANCE_4_passwordCapsLockSpan" style="display: none;"> Caps Lock is on. </span> <div class="login-form-footer clearfix"> <div class="pull-left"> <button class="btn primary" type="submit">Sign in</button> </div> </div> </input></input></input></input></fieldset> </form> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/>
<input id="openlabel" name="openlabel" type="hidden" value="Open access"/>
</div>
</section>
</div>
</div>
</div>
</div>
</div></div>
<div class="get-access-form-content" data-modal-title="Unlock gold-standard Cochrane evidence" style="display: none;">
<div class="portlet-boundary portlet-boundary_scolariscontentdisplay_WAR_scolariscontentdisplay_ portlet-static portlet-static-end scolaris-content-display-portlet" id="p_p_id_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform_">
<span id="p_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform"></span>
<section class="portlet" id="portlet_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform">
<header class="portlet-topper">
<h1 class="portlet-title">
<span class="" onmouseover="Liferay.Portal.ToolTip.show(this, 'Scolaris\x20Content\x20Display')">
<img alt="" id="wpdq__null__null" src="/scolaris-content-display/icon.png"/> <span class="taglib-text hide-accessible">Scolaris Content Display</span> </span> <span class="portlet-title-text">Scolaris Content Display</span> </h1> <menu class="portlet-topper-toolbar" id="portlet-topper-toolbar_scolariscontentdisplay_WAR_scolariscontentdisplay_INSTANCE_getaccessform" type="toolbar"> </menu> </header> <div class="portlet-content"> <div class="portlet-content-container"> <div class="portlet-body"> <div class="readcube-checkout-container-outer"> <div class="row-fluid access-content-wrapper"> <div class="span6 access-left-content"> <div class="section"> <div class="section-content"> <p>Improve your health decisions with access to trusted, independent evidence from the Cochrane Library. Unlock this review for uninterrupted access.</p> <p>Still deciding? <a href="https://m.info.wiley.com/webApp/cochranenewsletter"> Sign up to our newsletter to learn more </a> </p> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title">Institutional users</h3> <div class="section-content"> <p>Search for your institution's name below to login via Shibboleth</p> <form action="/shibboleth" id="institutionLoginForm" method="post"> <div class="fieldset"> <div class="form-group access-input-wrapper"> <div class="ui-widget ui-front"> <label class="sr-only" for="institutionName">Institution name</label> <input class="field" id="institutionName" name="institutionName" type="text" value=""/> </div> <button class="btn primary" name="button" type="submit">Go</button> </div> <div class="message error" id="institutionLookupErrorDiv" style="display:none"> '<span id="enteredInstitionNameSpan"></span>' is not set up for this type of access on Wiley Online Library. Please contact your institution's administrator to ask about access. </div> </div> <input id="entityId" name="entityId" type="hidden" value=""/> </form> <h4>Previously accessed institutions</h4> <ul class="plain" id="previousInstitutions"> <li>(none)</li> </ul> </div> <div class="section-content"> <div class="open-athens-login"> Login using <a href="/openathens">OpenAthens</a> </div> </div> </div> </div> <div class="section"> <div class="access-content-section"> <h3 class="title"> Other access options </h3> <div class="section-content"> <ul class="plain"> <li> <a class="get-access-individual-login-button" href="/c/portal/login"> Individual access - via Wiley Online Library </a> </li> </ul> </div> </div> </div> </div> <div class="span6 access-right-content readcube-checkout-container"> <div class="section"> </div> </div> </div> </div> </div> </div> </div> <div style="display:none"> <input id="freelabel" name="freelabel" type="hidden" value="Free access"/> <input id="openlabel" name="openlabel" type="hidden" value="Open access"/> </div> </section> </div> </div> <!-- Scolaris Version: --> <script type="text/javascript">if(window._satellite){_satellite.pageBottom()};</script> </div> <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'918e6d03493af4ca',t:'MTc0MDcyNDg1NS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script></body> </html> 